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Abstract 
      The search for novel and effective drugs is a priority goal for treatment of cancer, due to 
the rapid development of resistance to chemotherapeutic drugs. Moreover, high toxicity 
usually associated with some cancer chemotherapy drugs and their undesirable side-effects 
increase the demand for novel anti-tumor drugs active against untreatable tumors, with fewer 
side-effects and/or greater therapeutic efficiency. Natural products play an important role in 
the development of anti-cancer drugs. 30 % of anti-tumor compounds used in medicine are 
natural products or close relatives of them. However, the number of natural products is 
limited; millions of hybrids can be prepared as combinations of or parts of different natural 
products. This new approach seems to be very promising in the development of lead 
compounds for medicinal use, as the biological activity of many new hybrids is superior to 
their parent compounds. This concept offers an advantage of high diversity and the inherent 
biological properties of the hybrids over a combinatorial chemistry.  
      By taking the advantage of hybrid concept, in this thesis different series of new 
podophyllotoxin, phenanthrene and pyrazole based hybrids were synthesized with a view to 
produce promising anticancer agents. All the synthesized hybrid molecules were investigated 
for their anticancer activity on different cancer cells. Some of the synthesized hybrid 
molecules displayed either improved cytotoxicity or higher binding affinity to the target in 
comparison to their individual parent compounds.  
      Based on the results from the biological studies; it is evident that some of the synthesized 
compounds have the potential to be developed as leads and their further structural 
modifications may produce promising anticancer agents. 
Keywords: Hybrid; anticancer; podophyllotoxin; phenanthrene; pyrazole. 
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1. Introduction 
      Cancer is a worldwide health problem, representing the leading cause of mortality and 
morbidity worldwide which accounts for 13% (8.2 millions) of all human deaths in 2012. 
Improvements in treatment and prevention have led to a decrease in cancer deaths, but the 
number of new diagnoses is expected to rise by 70 % from 14 million to 22 million over the 
next twenty years. Among men, the five most common types of cancers diagnosed in 2012 
are lung, prostate, colorectal, stomach, and liver cancer, while breast, colorectal, lung, cervix 
and stomach cancers are most commonly diagnosed in women.
1
 Cancer is a large group of 
diseases sharing the common characteristic of abnormal cellular division that is not subject to 
normal growth controls.
2
 All organs of the body are made up of cells. Normally, cells divide 
to produce more cells only when the body needs them. If cells divide when new ones are not 
needed, they form a mass of excess tissue, called a tumor. 
      Tumors can be benign or malignant. Benign tumors are not cancer. They do not spread to 
the other parts of the body and they are seldom a threat to life. Often, benign tumors can be 
removed by surgery, and they are not likely to return. Malignant tumors are cancer. They 
have tendency to spread, invade and destroy nearby tissues and organs. Cancer cells can also 
break away from a malignant tumor and travel through the bloodstream (leukaemia) or the 
lymphatic system (lymphoma) to form new tumors in other parts of the body. This spreading 
of cancer to other locations via lymph or blood is called metastasis. It is one of the most 
feared diseases due to a general perception that it is an indiscriminate and incurable affliction 
that insidiously attacks people of all cultures and ages. Prognosis of cancer has improved 
greatly in modern times owing to treatment advances and early detection programs. However, 
survival rates have improved; cancer still remains the second leading cause of deaths. The 
rate of its induction throughout the world is increasing every year, making it a challenging 
area for major focus for both physicians as well as scientists. 
 Chapter-I 
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1.1 Factors responsible for cancer 
      Cancer arises from single cell. The transformation of normal cell to a tumor cell is a 
multistage process; progression from a pre-cancerous lesion to malignant tumors. These 
changes are due to the interaction of a person's genetic factors and 3 categories of external 
agents such as physical, chemical and biological carcinogens
3
 
Physical carcinogens include hard and soft X-rays Ultraviolet light, Ionizing radiation and 
many other external agents.  
Chemical carcinogens such as asbestos, arsenic (a drinking water contaminant), components 
of tobacco smoke, aflatoxin (a food contaminant) and many other. These chemical 
carcinogens are believed to be the greatest cause of cancer. Among these, tobacco use is 
responsible for over 20% of global cancer deaths and about 70% of global lung cancer deaths. 
They interact with DNA either directly or indirectly and cause changes in the genetic code. 
Biological carcinogens were previously considered not to cause cancer but later it was found 
that Burkett's lymphoma, nasopharyngeal carcinoma in South East China has been caused by 
the Epstein-Barr virus. Cervical cancer is also believed to be caused by the Herpes Simplex 
Virus Human T-cell Leukaemia virus causes certain leukaemia and lymphomas. Cancer 
causing viral infections are believed to be responsible for up to 20% of cancer deaths. 
1.2 Types of treatment 
      The main goal of the cancer treatment is to cure cancer or to prolong life of the patient. 
Improving the patient's quality of life is also an important goal. Early diagnosis and proper 
treatment of some of the cancers, such as breast cancer, oral cancer and colorectal cancer, 
cervical cancer have high cure rates. Early diagnosis of cancer is essential for the safe and 
effective treatment because every cancer type requires a specific treatment regimen which 
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constitutes one or more treatment procedures such as surgery, and/or radiotherapy, and/or 
chemotherapy.
4
 
Chemotherapy- Treatment with drugs or chemical substances that kill cancer cells. Currently, 
50% of patients are undergoing chemotherapy, to remove micro metastasis. However, 
chemotherapy is able to cure about 10-15% of all cancers. 
Radiation therapy- involves treatment with the use of high-energy radiation from x-rays, 
gamma rays, neutrons, to kill cancer cells and shrink tumors. Approximately 50% of cancer 
could be cured with the radiation therapy, if diagnosed at an early stage. 
Surgery- A procedure to remove or repair a part of the body or to find out whether disease is 
present. 30% of the patients without metastasis respond to surgery and radiation. 
Biological therapy (immunotherapy) - It helps the body's natural ability (immune system) to 
fight against disease or protects the body from some of the side effects of cancer treatment. 
Hormone therapy- To slow or stop the growth of certain cancers (such as prostate and breast 
cancer), synthetic hormones or other drugs may be given to block the body’s natural 
hormones. 
1.3 Chemotherapy 
      The word chemotherapy means the use of any chemical or drug substance to treat any 
disease, but to most people refers chemotherapeutic drugs as drugs used for cancer 
treatment.
5 
Chemotherapy is a distinctively different approach than surgery and radiation 
therapy. They are considered as local treatments and act only in one area of the body such as 
lung, prostate or breast and target the cancers directly whereas chemotherapy always used as 
systemic treatment. Thus chemotherapeutic drugs travel throughout the body to reach cancer 
cells which is different from physically removing a tumor or a part of it. Chemotherapy uses 
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chemical agents (anti-cancer or cytotoxic drugs) to interact with cancer cells to eradicate or 
control the growth of cancer. 
       Currently, cancer chemotherapy can be curative in certain forms of neoplasms such as 
testicular cancer, non-Hodgkin's lymphoma, and choriocarcinoma as well as childhood 
cancers such as acute lymphoblastic leukaemia, Wilma' tumor, Burkitt's lymphoma, and 
embryonal rhabdomyosarcoma.  Chemotherapy combined with initial surgery is used to 
improve the cure rate in locally advanced early-stage breast cancer, rectal cancer, 
oesophageal cancer and osteogenic sarcoma. For many other types of cancer, chemotherapy 
provides palliative rather than curative therapy at present. Effective palliative therapy results 
in improvement of the symptoms and signs of cancer and enhancement in the overall quality 
of life.
6-8
 
      In order to understand mechanism of chemotherapeutic drugs, it is necessary to 
understand the normal life cycle of a cell, or the cell cycle. All the living tissues and/or 
organs are made up of cells. Cells continue to grow and reproduce through a process of cell 
cycle to replace the lost cells that undergo injury or normal apoptosis. The cell cycle is an 
ordered set of events that both normal cells and cancer cells go through into form two new 
cells from a single cell. The resulting two new cells are identical and each of these two cells 
can go through this cell cycle again when new cells are needed. Normal cells grow and die in 
a precisely controlled way while cancer occurs when the process becomes abnormal with 
cells dividing and forming more cells without control and order.
9-11
 
      The cell cycle has been divided to 5 phases through which reproduction of cells occur 
over and over. All these phases lead back to the resting phase (G0), which is the starting 
point. 
G0 phase (resting stage): The cell has not yet started to divide. The G0 cells have 
proliferation ability but do not divide. Cells spend much of their time in this phase. 
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Depending on the cell type, this phase can last from a few hours to a few years. When the cell 
receives a signal to divide, it moves into the G1 phase. 
G1 phase: In this growth phase, the cells increases in size and synthesizes cellular 
components that are needed for DNA synthesis. This phase lasts about 18 to 30 hours. 
S phase: the chromosomes that contain genetic code (DNA) are copied or duplicated so that 
the formed new cells will have matching strands of DNA. In this phase, cells last about 18 to 
20 hours. 
G2 phase:  the cell synthesizes cellular components that are required for mitosis and gets 
ready to start divide into two cells. This phase lasts from 2 to 10 hours. 
M phase (mitosis): this phase lasts only 30 to 60 minutes, where the chromosome separates 
and the cell splits into 2 new cells. 
      The growth rate of tumor depends on proportion of actively dividing cells (cycling cells), 
length of the cell cycle (doubling time) and rate of cell loss. Tumor cells characteristically 
exhibit sigmoid shape growth curve in which doubling time varies with size. Tumors grow 
rapidly when they are small. However, as they become larger growth slows down and this 
depends on cell loss, tumor blood and oxygen supply. The cell cycle kinetics plays an 
important role in cancer treatment because many of the chemotherapeutic drugs act only on 
rapidly dividing cells (not the cells that are in G0 phase).
12
 Many of the anticancer drugs 
exert their action on cells that are in specific phase of the cell cycle and are called cell cycle-
specific drugs. These drugs kill only the proliferating cells during specific phase of the cell 
cycle. For example vinca alkaloids and paclitaxel arrest the cells in meta phase whereas drugs 
like methotrexate are active against S-phase cells. They have a dose-related plateau in their 
ability to kill cells because only a subset of actively proliferating cells is to be sensitive to the 
drug-induced toxicity at any one time. Therefore, to increase the cell killing, duration of 
exposure should be increased rather than increasing the drug dose. The other group of drugs 
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called as cell cycle-nonspecific drugs that can kill the tumor cells irrespective of their phase 
including the cells that are in resting G0 phase although cycling cells are more sensitive. For 
instance, camptothecin and irinotecan are cell cycle nonspecific drugs. These drugs have a 
linear dose–response curve thus killing greater number of cells with increasing dose 
concentration. Understanding how these drugs work on cancer cells helps to predict which 
drugs are likely to work well together or in combination for the safe and effective treatment 
of the cancers.
13
 
      In general, the passage of cell from G1 to S phase regulates the fate of division cycle. 
This progression of the cell through the cell cycle is regulated by a group of kinases called 
cyclin-dependent kinases (CDKs). CDKs phosphorylate the cellular substrates which are 
required for progression into each of the phases in the cell cycle. CDKs are activated by 
associating with proteins called cyclins. Thus activation of each CDK is controlled by 
availability of cyclins. Among the cyclins, D-type cyclins are activated by the external 
cellular factors. Their levels decrease during G1 and increase towards the G1/S phase. It 
regulates the activation of CDK4 and CDK6 whereas cyclin E regulates CDK2 and CDK3 
which is expressed during the G1 /S transition. The levels of cyclin A increases in S phase 
which in turn activates CDK2. The cyclin A/CDK2 complex also plays an important role in 
DNA replication. The progression through metaphase (G2/M) is regulated by cyclin B levels. 
During mitosis cyclin B is degraded and its degradation appears to regulate the cell’s 
progression out of mitosis and into G1 phase. Abnormal or mis-regulated CDK expression 
leads to cell cycle defects which induce unscheduled proliferation as well as genomic and 
chromosomal instability. As important cell cycle regulators, the mis-regulated cyclin-
dependent kinase family proteins have been associated with many human tumors 
development through different mechanisms. Therefore, CDK inhibition may provide 
therapeutic benefit against certain tumors.
14-15
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      The balance between cell proliferation and apoptosis is important for maintaining normal 
tissue homeostasis and development. Apoptosis and cell proliferation are linked by cell cycle 
regulators and apoptotic stimuli.
16
 Apoptosis, or programmed cell death results in controlled 
self-destruction. Three types of changes can be observed mainly during the apoptosis; 1) 
caspases activation, cysteine protease family proteins which have a property to cleave after 
aspartic acid residues. These activated caspases cleave many important cellular proteins and 
nuclear DNA. 2) DNA and protein breakdown, inter nucleosomal cleavage of DNA in 
multiples of 180-200 base pairs by endonucleases. 3) Membrane changes such as plasma 
membrane blebbing and recognition by phagocytic cells. Thus, Chromatin condensation and 
nuclear fragmentation are the morphological hall marks of apoptosis which are accompanied 
by rounding up of the cell and reduction in cell volume (size).
17-18
 
      Previous literature suggests that defects in apoptotic signalling pathways play a crucial 
role in development, progression and metastasis of many cancers.
19-21
Thus, understanding the 
mechanisms of apoptotic pathways is crucial and helps in the development of drugs that 
target apoptotic genes or pathways. Caspases play an important role in inducing apoptosis as 
they are both initiators and executioners. Caspases can be activated mainly by two pathways 
such as intrinsic (mitochondrial) and extrinsic (death receptor).  
The extrinsic death receptor mediated pathway 
      The extrinsic pathway involves binding of death ligands (TNF and Fas ligand) to the 
death receptors (TNFR1, FAS9CD95)) which results in formation of a binding site for an 
adaptor protein and the formed receptor-ligand-adaptor protein complex is called as death 
inducing receptor complex (DISC). This complex initiates the activation of procaspase-8 and 
then caspase-8 and caspase-3, which cleaves other target proteins and nuclear DNA leading 
to apoptosis.
22 
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The intrinsic mitochondria mediated pathway 
      The intrinsic pathway is initiated within the cell. The intrinsic stimuli such as irreparable 
DNA damage, high concentrations of cytosolic Ca2+and severe oxidative stress are some of 
the initiators of the intrinsic mitochondrial pathway. These stimuli increase the mitochondrial 
permeability by inducing the release of pro apoptotic proteins such as cytochrome C into 
cytoplasm. The cytoplasmic release of cytochrome C activates the Caspase-3 through the 
formation of apoptosome complex composed of cytochrome-C, Apaf-1 and caspase-9. The 
activated caspase-3 cleaves the nuclear DNA which results in apoptosis. This pathway is 
largely regulated by the group of proteins called Bcl-2 family proteins. The Bcl-2 family 
proteins are classified mainly into two types namely pro apoptotic (Bax, Bak, Bad, Bcl-Xs, 
Bid) and the anti-apoptotic (Bcl-2, Bcl-Xl, Mcl-1). The proapoptotic proteins promote the 
apoptosis by inducing the cytochrome C release into the cytoplasm while the anti-apoptotic 
proteins regulate the apoptosis by inhibiting such release. Therefore, the balance between pro 
and anti-apoptotic proteins determines whether apoptosis would be initiated.
23
 
      The apoptosis resistance of tumor cells is responsible for to the failure of chemotherapy 
and radiotherapy. Therefore targeting apoptotic pathways against cancer cells through natural 
or synthetic compounds is considered as an efficiency anti-cancer therapy. Recently, many 
molecules that target apoptotic signalling pathways enter various stages of clinical trials. 
Some of these include inhibitors of the Bcl family of proteins and some pan-IAP inhibitors.
24-
26
 
Types of chemotherapy 
      Sometimes, chemotherapy alone is used for the treatment of cancers. In other cases, 
chemotherapeutic drugs may be used along with other treatments.
27 
It may be used as 
adjuvant therapy or neo adjuvant therapy. 
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Adjuvant therapy- After surgery or radiation treatment to remove cancer, there may still 
some cancer cells that are not removed. Adjuvant therapy includes killing those cancer cells 
with chemotherapeutic drugs. For instance, adjuvant hormone therapy after radiation for 
prostate cancer. 
Neo adjuvant therapy- Chemotherapy can be given as first step to shrink tumor before the 
main treatment such as radiation or surgery. Neo adjuvant therapy with chemotherapeutic 
drugs also kills some small deposits of cancer cells that cannot be seen on scans or x-rays. 
1.3.1 Classification of chemotherapeutic drugs 
         Chemotherapeutic drugs can be divided into several groups based on their mechanism 
of action. These include alkylating agents, anti-metabolites, mitotic inhibitors, topoisomerase 
Inhibitors, antitumor antibiotics, and miscellaneous drugs.
 28-29 
Alkylating agents 
      Alkylating agents were among the first anti-cancer drugs and the most commonly used 
agents in chemotherapy. Alkylating agents are so named because of their ability to add alkyl 
groups to many electronegative groups under conditions present in cells. They stop tumor 
growth by cross-linking guanine nucleobases in DNA double-helix strands-directly attacking 
DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA 
replication, the cells can no longer divide. These agents are generally considered to be cell 
cycle phase non-specific and kills the cells in multiple phases of the cell cycle. Although 
alkylating agents may be used for most types of cancer, they are generally of greatest value in 
treating slow-growing cancers. These are not as effective on rapidly growing cells. Examples 
of alkylating agents include cisplatin (1), nitrogen-mustards (chlorambucil (2), 
mechlorethamine (3)) and cyclophosphamide (4) 
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Anti-metabolites 
      Anti-metabolites were another major group of anti-cancer agents that prevents the 
biosynthesis of nucleotides and their incorporation into DNA. They prevent the biosynthesis 
of normal cellular metabolites. These compounds bear the structural similarity with the 
naturally occurring compounds such as vitamins, nucleosides and amino acids. Some of these 
compounds directly block the specific enzyme activity or prevent a single biosynthetic step. 
These agents are cell cycle specific and damage cells during the S phase. They are commonly 
used to treat various leukaemias, tumors of the breast, ovary, and the gastrointestinal tract, as 
well as other cancers. The examples include methotrexate (5) and 5-fluorouracil (6). 
 
Topoisomerase inhibitors 
      These drugs interfere with enzymes called topoisomerases, which are important in DNA 
replication and repair. They are used to treat certain leukaemia’s, as well as lung, ovarian, 
gastrointestinal, and other cancers. Topoisomerases (type I, type II) are the enzymes that act 
on the topology of DNA. Both type I and type II topoisomerases change the supercoiling of 
DNA. Type I topoisomerases function by nicking one of the strands of the DNA double helix, 
twisting it around the other strand, and relegating the nicked strand whereas topoisomerasesII 
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cuts the both strands of the DNA helix simultaneously. Once cut, the ends of the DNA are 
separated, and a second DNA duplex is passed through the break. Following passage, the cut 
DNA is resealed. This reaction allows type II topoisomerases to increase or decrease the 
linking number of a DNA loop by 2 units. Many chemotherapeutic drugs works by 
interfering with the topoisomerase.
12
 For instance, ironotecan (7),topotecan (8) 
(Topoisomerase-I inhibitors), etoposide (9), teniposide (10) and etopophos (11) 
(Topoisomerase-II inhibitors). 
 
Tubulin polymerization inhibitors 
      Microtubules (MTs), rigid and hollow cylindrical structures composed of α- and β-tubulin 
dimers. They determine cell shape and play important roles in cell division, cell motility and 
migration, intra cellular organelle transport, and signal transduction. Mitotic inhibitors stop 
mitosis and work during the M phase of the cell cycle through binding to the tubulin protein. 
Disruption of microtubule leads to G2/M phase cell cycle arrest followed by apoptotic cell 
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death. Examples of this category are often plant alkaloids and other compounds derived from 
natural products. 
      Anti-mitotic agents can be further divided into two classes such as stabilizers and de 
stabilizers depending on their binding site on tubulin and disruption of tubulin dynamics. 
Stabilizers include compounds that bind to the taxane binding site (e.g., paclitaxel (12) and 
epothilone (13)) and prevent the depolymerisation of tubulin. Destabilisers include 
compounds that bind to the vinca alkaloid domain (e.g., Vinca alkaloids such as vinblastine 
(14)) and colchicine binding site (e.g., colchicines, combretastatins (15), podophyllotoxin 
(16), nocodazole (17)) which inhibit the polymerization of tubulin. A large number of natural, 
semi synthetic or synthetic tubulin inhibitors are currently in clinical development. For 
instance azaepothilone is in advanced phase III clinical studies.
15
Epothilones are the more 
potent microtubule stabilizers than the taxanes and they induce the regression of taxane-
resistant human tumors. 
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Anti tumor antibiotics 
      Many of these antitumor antibiotics interfere with the synthesis of RNA, DNA or both. 
These agents considered as cell cycle nonspecific and works on cells that are in different 
phases. Thus, they are widely used for a variety of cancers. A major drawback of these drugs 
is they can permanently damage the heart cells if given in high doses. Examples include 
doxorubicin (18). 
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Corticosteroid hormones 
      Since the growth of some cancers is hormone dependent as stimulation, control of 
proliferation of certain tissues including prostate and mammary glands. Cancers from such 
tissues can be inhibited by administration of hormone or anti-hormones by maintaining the 
hormonal balance. Breast and prostate cancers can be effectively treated with sex  hormone  
like oestrogen antagonists ( tamoxifen ) for breast cancer and oestrogen for prostate cancer.
 
      In chemotherapy, drugs that interfere primarily with DNA synthesis and mitosis (the S 
and M phases of the cell cycle) are used to destroy cancer cells. Since chemotherapeutic 
drugs cannot distinguish between normal cells and cancer cells, both types of cells are 
affected by these drugs and causes toxicity even to the normal cells. However, the value of 
chemotherapy lies in the fact that chemotherapeutic agents have a definite selectivity for 
cancer cells over normal cells. The known side effects of chemotherapy are caused by the cell 
killing effect of anti-cancer drugs. Cancer cells typically grow and divide more rapidly than 
normal cells. The fast-growing normal cells most likely to be affected by chemotherapy are 
blood cells forming in the bone marrow, cells in the digestive tract, reproductive system and 
hair follicles. Thus the common side effects observed with many of the chemotherapy drugs 
include fatigue, nausea, diarrhoea, mouth sores, hair loss and anaemia. Each patient reacts to 
chemotherapy in a unique way. Some people have very few side effects, while others may 
experience more. Factors such as the type of drug, the amount of drug, and the condition of 
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the cancer patient may determine the kind and the degree of adverse effects that a cancer 
patient experiences. 
 
1.4. Podophyllotoxin 
      Podophyllotoxin (16) is the naturally occurring aryl tetralinlignan isolated from 
podophyllin, a resin produced by species of the genera Podophyllum 
(Berberidaceae).
30
Lignans are a family of natural products obtained as secondary metabolites 
through the shikimic acid pathway and are formed by the union of two phenyl propane units. 
All the derivatives of podophyllotoxin belong to the class of lignans, which contains the 2, 3-
dibenzylbutane skeleton, which can be further classified as aryltetrallin lactone and aryl 
naphthalene lactone lignans
31
 
 
      Linnaeus first described and gave the modern botanical name for podophyllotoxin in 
1753.
32
 Podwyssotzki 
33
 carried out first serious chemical investigation in 1880 and empirical 
formula was advanced by Borsche and Niemann 
34
 which was further confirmed with total 
synthesis and crystal structure by Gensler et al.
35
 Podpophyllotoxin is a bioactive lignan 
isolated from the plant sources and this compound has been the focus of extensive chemical 
modification leading to clinically useful anticancer drugs eg., etoposide.
36
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1.4.1. Biological activity of Podophyllotoxin 
      Podophyllumpeltatum, also referred as American mandrake or May apple, and the related 
Indian species Podophyllum emodi Wall has been used medicinally for centuries as folk 
medicine for treatment of tuberculosis, gonorrhoea, syphilis, gout, cough, psoriasis, venereal 
warts and certain types of tumors in many diverse cultures especially in Chinese, Japanese 
and Eastern world.
37-39
 In 1942, Kaplan introduced topical podophylltoxin for the curative 
effect on tumorous growth (condylomaaccuminata).
40
 It still continues to be the drug of 
choice in the treatment of venereal wart Condylomaacuminatum. Moreover, the podophyllum 
species which grow in the Himalayan region have long been known to possess medicinal 
properties and their extract has been used as an emetic, cathartic, mortal poison, antidote for 
snake venom, anthelmintic and expectorant.
41-42
Podophyllotoxin exhibits significant antiviral 
activity and have been found to be the most active component against herpes simplex type I 
virus.
43
Podophyllotoxin derivatives also known to exhibit insecticidal, phyto growth 
inhibition activity, ichthytoxic, anti-rheumatic, and anti-malarialactivities.
44-45
 
      Podophyllotoxin and many of its derivatives have attracted considerable interest as 
human cancer chemotherapeutic agents. The clinical utility of podophyllotoxin as an 
anticancer agent was restricted due to its toxic side effects such as nausea, vomiting and 
severe gastrointestinal disturbances. However, the remarkable cytotoxic activity and 
extensive use in traditional medicine make podophyllotoxin an important lead compound in 
the anti-cancer drug development. Extensive structural modifications on podophyllotoxin 
lead to the discovery of two clinically useful anti-tumor drugs; etoposide and teniposide.
46
 
1.4.2. Mechanism of action 
      Majority of the lignans primarily act by inhibiting the polymerization of tubulin or DNA 
topoisomerase-II enzyme. Previous structure-activity relationship (SAR) studies have shown 
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that podophyllotoxin like compounds preferentially inhibit tubulin polymerization which 
further leads to arrest of the cell cycle at in the metaphase and clumping of chromosome (c-
mitosis) followed by apoptotic cell death. At the subcellular level, podophyllotoxin binds to 
the colchicine binding site of tubulin, and prevents the polymerisation of these tubulin 
macromolecules to form microtubules, which constitute the fibres of the mitotic spindle.
47-
48In contrast, etoposide like compounds doesn’t act on tubulin assembly and are reported to 
act as potent irreversible inhibitors of DNA topoisomerase-II. Their action is based on the 
arrest of cells in either the late S or early G2 phase of the cell cycle and formation of nucleic 
acid-drug-enzyme complex, which induces single- and double-stranded DNA breaks as the 
initial step in a series of biochemical transformations that eventually lead to cell death.
49-50
 
1.4.3. Etoposide and Teniposide 
      The renewed medicinal interest in podophyllotoxin derivatives as an anticancer agents 
started in 1950s and much work has been done by Sandoz Laboratories in Basel, Switzerland. 
First, they investigated the possibility of the podophyllum lignans that might occur naturally 
as glycoside and obtained podophyllotoxin-ß-D-glucopyranoside as the main component and 
its 4'-demethyl derivative from the Indian podophyllum species. Further, the research was 
focussed on a modification of both the glucosides and aglucones of a wide range of 
podophyllotoxin derivatives which lead to discovery of two clinically important anticancer 
drugs etoposide (9) and teniposide (10).
51-52
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      These semi synthetic derivatives of podophyllotoxin, etoposide (VP-16), teniposide (VM-
26)  are widely used as anticancer drugs against several types of neoplasm’s including 
testicular and small-cell lung cancers, lymphoma, leukaemia, Kaposi’s sarcoma, etc. 
However, etoposide is widely used in the treatment of cancers, several limitations such as 
poor water solubility, moderate potency, myelosuppression, development of drug resistance 
and cytotoxicity towards normal cells, still exist.
53-54
Therefore in order to obtain better anti-
cancer agents with potent activity and minimum toxicity, extensive structural modifications 
have been devoted to overcome these problems which give rise to a development of a water-
soluble phosphate ester prodrug of etoposide, etopophos (11) with improved in vivo 
bioavailability from 0.04% (etoposide) to 50% (etopophos). This pro drug readily converts 
into active drug by endogenous phosphatises exhibited similar pharmacological and 
pharmacokinetic profiles to those of etoposide.
55 
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      Recent developments on podophyllotoxins showed that some non-sugar substituted 
analogues, in particular N-linked derivative, such as NK-611 (19), NPF (20), GL-331 (21)as 
well as C-linked derivatives, TOP-53 (22) exhibited superior pharmacological properties 
compared to etoposide derivatives. They have reached phase I and phase II clinical trials as 
antitumor agents. However, they did not proceed further because of the side effects 
associated with the use of these agents include myelosuppression, neutropenia, and nausea.
56
 
      Based on these therapeutic applications of podophyllotoxin-related compounds, many 
investigators have focused their research on podophyllotoxin and extensive structural 
modifications have been made to improve the water solubility and reduce the cytotoxicity. 
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1.4.4.Structure activity relationship studies 
A-Ring modification 
      This includes derivatives in which the methylenedioxy group has been cleaved to produce 
two free phenolic groups. These have been transformed into other groups or oxygenated rings 
with or without substituent’s. In 1964, Schreier first synthesized methylenedioxy cleaved A-
ring opened podophyllotoxin analogues to produce the 6,7-dihydroxy derivative 23and 6,7-
dimethoxy derivatives 24.
57
 Later Lee et al reported modified derivatives of 23 and 24 by 
introducing C4-βsubstituted aryl amino group into the molecules (25) and their biological 
assays results showed that the compounds were less active in inhibiting the cell growth 
inhibition and topoisomerase inhibition.
58
 Claude Monneret et al prepared the A-ring 
pyridazine derivatives of podophyllotoxin (26) and pyradazine analogues of etoposide and 
studied their antitubulin activity. The results showed that the compounds displayed no tubulin 
inhibition which indicates the importance of methylenedioxy A ring for binding to tubulin.
59
 
Overall these results indicate that maintenance of an intact methylenedioxy A ring is essential 
for retaining cytotoxicity, topoisomerase inhibition as well as tubulin polymerisation 
inhibition. 
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B-Ring modifications 
      There are very few reports on the B-ring modifications. The compounds α-peltatin (27) 
and β-peltatin (28) are the naturally occurring lignin as that exhibited remarkable antitumor 
and antiviral activity through antimitotic mechanisms. Thurston et al
60
 and Lee et 
al
61
synthesized α–peltatin (29) and β-peltatin (30) esters and ethers including its 
glycosidicethylidene and ethenylidene cyclic acetals. All these compounds were found to be 
less cytotoxic than etoposide against DNA topoisomerase-II inhibition.  
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      Nishimura et al synthesized glycosidic substituents of 1-β-hydroxy-α-peltatin (31) and1-
β-hydroxy-5-methyl-α-peltatin (32). These compounds exhibited weak cytotoxicity towards 
leukaemiaL1210 in comparison to etoposide and podophyllotoxin.
62 
These results indicate 
that 5-oxygenation of B ring of the podophyllotoxin nucleus may lead to derivatives with 
decrease biological activity 
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C-Ring modifications 
 Among podophyllotoxin modifications, C-ring modification has gained much 
attention. Hsiung Lee et al synthesized several ring C aromatized analogues of 
podophyllotoxin and tested their ability to inhibit cancer cell proliferation and human DNA 
topoisomerase-II.
63
 All the compounds showed dramatic loss of topoisomerase inhibition 
activity in comparison to etoposide which indicated that non aromatized C ring is essential 
for the inhibition of topoisomerase–II enzyme and this loss of activity might be due to loss of 
axial E-ring configuration. 
 
 Laatsch et al
64
 prepared some epipodophyllotoxin derivatives (35) with a un 
saturation side chain. The C-ring expansion products of podophyllotoxin are obtained from 
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the appropriate azide via a photochemical nitrene rearrangement and all these compounds 
were less cytotoxic than podophyllotoxin (36, 37). 
 
      Hitatsuyanagico et al synthesized 4-oxa-2-azapodophyllotoxin (38) and 4-thia-2-
azapodophyllotoxin (39) and tested for their biological activity. This compound displayed 
significant activity against Adriamycin-resistant P-388 leukaemia cells.
 65-66 
 
      2,4-Diazapodophyllotoxins (40 and 41) have been synthesized by Yamagami et al and 
tested for its biological activity. Their cytotoxicity evaluated on L1210 leukaemia cells.
67
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In order to obtain potent topoisomerase-II inhibitors, podophyllotoxin analogues with 
various C-4β alkyl, amidomethyl, and amino ethyl groups were synthesized by Taiho 
pharmaceutical co. ltd company which contain carbon rather than oxygen at the C-4 position. 
These new compounds are evaluated for their anticancer activity against P388 mouse 
leukaemia cells. C4β-alkyl derivatives exhibited cytotoxicity comparable to that of etoposide; 
however they didn’t show inhibitory effect on Topoisomerase-II. Compounds with 4-amido 
methyl group displayed dramatic loss of cytotoxic activity and moderate topo inhibition. 
Interestingly, 4β- amino ethyl derivatives such as TOP-53 (22) exhibited remarkable growth 
inhibition against P-388 cells with IC50 values ranging from 0.001 to 0.0043 µM with potent 
topoisomerase inhibition similar to the etoposide. Among these compounds, TOP-53 
proceeded to the Phase II clinical trial although failed to reach clinical use.
68-70 
            A large number of substituted 4β-anilino side chains were introduced into the 
podophyllotoxin structure with various substituted aryl amines through nucleophilic 
substitution reaction of 4β-bromo-4′-demethyl-4-desoxy podophyllotoxin. These 
modifications resulted in compounds with increased cytotoxicity and topoisomerase 
inhibition. Some of the 4β-arylamino-podophyllotoxins were as or more potent than 
etoposide in topo-II inhibition.
71-72
In most cases, para substituted on phenyl ring resulted in 
the potent activity than etoposide. For instance, GL-331 (21) is a para substituted aryl amino 
derivative of podophyllotoxin functions as a highly potent topoisomerase-II inhibitor that 
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causes DNA double-strand breakage and G2 phase of cell cycle arrest. It could also induce 
cell death by inducing apoptosis. GL-331 was also displayed potent cytotoxicity against 
different MDR cancer cell lines. It successfully reached clinical trials against different 
tumors, especially etoposide resistant malignancies, but has not reached clinical status. 
Recently, C-4-N-substituted analogues of podophyllotoxin have occupied a significant 
position design and development of podophyllotoxin based anti-cancer agents. Lee et al 
synthesized large libraries of C4-N-substituted congeners of podophyllotoxin such as C-4α 
and C-4β–aliphatic amino derivatives (42) via nucleophilic substitution of 4-bromo-4-
desoxy-podophyllotoxin with appropriate alkyl and aryl amines.  The compounds displayed 
potent inhibition of DNA topoisomerase-II, as well as strong ability to cause cellular protein-
linked DNA strand breakage.
73
Among these, The C-4β isomers showed more potent activity 
than the C-4α isomers, which indicated that the C-4β stereochemistry is quite important to 
retain topoisomerase inhibitory activity as well as cytotoxicity. 
 
      Kamal et al have been synthesized six different series of 4β-N substituted 
podophyllotoxin derivatives such as 4β-N-polyarylamino congeners, 4β-anilino-
benzothiazolo, 4β-acrylamido, 4β-cinnamido, 4β-sulfonamide and 4β-[(4′-
sulfonamido)benzamide] derivatives of podophyllotoxin and evaluated for their cytotoxicity 
against different cancer cell lines.
74-80
 Some of these synthesized compounds exhibited potent 
cytotoxicity towards HCT-15, HEP-2, IMR-32, A-549, DU-145, and PC-3. Most of the 
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synthesized compounds displayed significant cytotoxic activity with IC50 values in sub micro 
molar levels and some of them are more potent than etoposide. Among these, some of the 
compounds caused similar inhibition of DNA topoisomerase-II activity that is comparable 
with etoposide. 
      Extensive structure-activity relationship study on various podophyllotoxin derivatives 
indicated that modification of C-4 position on the podophyllotoxin has resulted in a discovery 
of structurally diverse and number of promising candidates, suggesting that C-4 position of 
podophyllotoxin play an important role in cytotoxic activity and topoisomerase inhibitory 
activity of etoposide-related compounds. 
D-Ring modifications 
      Previous reports have suggested that the transfused γ-lactone D ring in podophyllotoxin 
and its analogues is the essential structural requirement for maintaining their anticancer 
activity. The metabolism of podophyllotoxin and etoposide result in epimerization of trans 
lactone ring to the less active cis derivatives. In order to minimize or avoid the metabolic 
inactivation and C-2 epimerization, several different approaches have been proposed by 
different researchers. Gensler et al synthesized a series of D-ring modified cyclopentane, 
cyclopentanone, ester, sulfide, sulphoxide and sulphone derivatives along with some 
delactonised derivatives. These derivatives showed weak tubulin inhibition in compared to 
their parent compounds.
81 
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      There is a limited number  reports for the podophyllotoxin analogues having  lactone D 
ring opened  because the trans fused γ-lactone was considered as essential structural features 
for anticancer activity of podophyllotoxin-type compounds. However, ethyl hydrazide 
derivative of podophyllic acid 46 (SP-I) exhibited potent anti-mitotic activity and its clinical 
efficacy was discontinued due to severe side effects.
82
This indicates the importance of the D 
ring opened compounds. Based on these reports, several D-ring opened analogues (47, 48) 
were synthesized by Subrahmanyam et al.  These compounds showed potent anticancer 
activity, particularly, against ovarian, renal and lung cancer cells.
83
 
 
      Gordaliza et al prepared podophyllotoxin derivatives lacking the lactone ring such as 
podophyllic aldehyde (49) and its analogues (50).
84-85
 These compounds not only retained the 
cytotoxicity but also exhibited selective potency against the HT-29 colon carcinoma. These 
results prompted many researchers in preparing new podophyllotoxin derivatives by reaction 
of podophyllic aldehyde with different aliphatic, aromatic, and hetero aromatic amines. Most 
of the resulting imines displayed a remarkable anticancer activity with significant selectivity 
towards human colon carcinoma cells, even higher than that of the starting aldehyde. 
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      Bertounesque et al synthesized some non-epimerizable cis and trans D-lactone analogues 
of podophyllotoxin (51,52). These compounds were screened for their in vitro cytotoxicity 
against L1210 cell lines. The results showed that most of the compounds displayed dramatic 
loss of activity.
86
 
 
      Wen-guang et al synthesized a series of spin labelled derivatives of podophyllotoxin, N'-
podophyllic acid-[4-(2,2,6,6,-tetramethyl-1-piperidyloxy)] hydrazone (GP-1, 53) and its 
congeners (GP-1-OH (54), GP-1-H (55)). Some of these spin labelled derivatives exhibited 
remarkable growth inhibition and are comparable to that of their parent podophyllotoxin.
87
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 Gordaliza et al
 
synthesized a series of fused pyrazole derivatives of cyclolignans 56 
through simple chemical routes and evaluated for their anticancer activities against P-388 
murine leukaemia, A-549 lung carcinoma and HT-29 colon carcinoma. Despite the lack of 
the lactone D ring in their structures, these compounds retain the cytotoxic activity and 
showed IC50 values at M levels.
88
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E-Ring modifications 
 Previous reports have suggested that E-ring of the podophyllotoxin is related to 
metabolism and its inactivation. There are very few reports on E-ring modification, for 
instance; demethylations, introduction of nitrogen radicals and oxidation to the o-quinone are 
some of the modifications have been made on this part. Saulnier
89
et al synthesized E-ring 
deoxy analogues of podophyllotoxin. The results from in vivo data revealed that these 
analogues were less potent than VP-16 against P-388 leukaemia.  Berkowitz
90
et al prepared 
podophyllotoxin derivatives, in which one, two or all three methoxy groups on the phenyl E 
ring were replaced by hydrogen atoms or an alkyl group (57, 58). Results from cytotoxic 
assays showed that some of these compounds were as potent as parent compound in 
inhibiting the cancer cell proliferation suggesting the presence of three methoxy groups in the 
E-ring of the podophyllotoxin may not be a strong determinant for cytotoxicity. 
 
     Recently Lee et al,
91
 synthesized a series of 3', 4'-Odidemethylepipodophyllotoxins (59) 
and 3', 4'-O-didemethoxy-3',4'-dioxoepipodophyllotoxins (60) with various C-4ß-aniline 
moieties and screened them for their anticancer activity as well as DNA topoisomerase  
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inhibition activity. The results showed that most of the 3', 4'-O-didemethoxy-3',4'-
dioxoepipodophyllotoxins (the ortho-quinone compounds) less potent than  3', 4'-O-
didemethylepipodophyllotoxins. 
 
      Moreover, E-ring modifications also have been focused on the design and synthesis of 
prodrug of etoposide and podophyllotoxins. Several synthetic modifications of 4'-position 
have been made by Bristol-Myers Company. For instance, the compounds 4'-acyl derivatives 
and phosphorus- containing derivatives.
92-93
 Many of these E-ring modified derivatives 
retained significant in vivo antitumor activity against P388 leukaemia and some of them were 
even more active than etoposide. As a result of this, a water- soluble etoposide prodrug, 
etoposide phosphate 61 (BMY-404811), was developed. When it is administered 
intravenously, the plasma phosphatases rapidly convert this pro drug into the parent drug and 
thus constituted an improved formulation of etoposide. 
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1.5 Phenanthrene based tylophorine derivatives 
1.5.1 History and isolation 
      The phenanthroindolizidine alkaloids tylophorine (62), tylocerebrine (63), antofine (64) 
and phenanthroquinolizine alkaloids cryptopleurine (65) are a family of plant-derived 
alkaloids Fig. (1).
94
 They have been isolated from the Cynanchum, Pergularia, Tylophora, 
and some genera of the Asclepiadaceae and Moraceae families primarily from India and 
Japan.
95
 One of these plants, Tylophoraindica, was included as an official drug in the Bengal 
pharmacopeia of 1884.
96
 The leaves of this plant have been used for the treatment of asthma 
as well as bronchitis, rheumatism and dysentery in India. The medicinal properties of these 
plants spurred the isolation and characterization of the individual alkaloid constituents. The 
isolation of the major alkaloid from Tylophoraindica, tylophorine, was first reported in 
1935
97
 and its structure and stereochemistry were reported in 1960.
98
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1.5.2 Pharmacological activities 
      The biological properties of these tylophora alkaloids range from cancer cell growth 
inhibition (in vitro and in vivo) 
99-103
 and anti-inflammatory 
104
 activities to anti-
ameobicidal
105
 andanti-viral
13)106activities. In the early 1960’s tylocrebrine, a positional 
isomer of tylophorine was advanced to clinical trials but failed due to CNS toxicity, 
manifested as disorientation and ataxia. Suffness proposed that more polar analogues, which 
cannot cross the blood brain barrier, could have less side effects.
107 
These analogues act by 
the same mechanism of action and behave as functional analogues of the tylophora alkaloids. 
Medicinal interest in the phenanthroindolizidines was revived in the 1990’s when it was 
shown that a number of these compounds are highly potent (10
−8
-10
−12
µM) growth inhibitors 
in the NCI’s 60 cell line assay and that their mode of action appears to be different than other 
known anti-cancer compounds based on their COMPARE analysis.
108
 Both drug-sensitive 
and multidrug-resistant cancer cells demonstrate growth inhibition in the low nano molar 
range with this class of compounds. 
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      Xiaoguang Chen et al synthesized a series thirty four new deoxytylophorinine derivatives 
(66) and studied their anticancer activity against seven human tumor cell lines. These 
compounds showed potent growth inhibition on lung cancer cells (A549). These compounds 
inhibit the A549 cell proliferation by interfering with PI3K and MAPK signalling 
transduction pathways and the cell cycle progression.
109
 
 
      Sanghee Kim et al synthesized a series of antofine analogues (67) with different 
substituents on the phenanthrene ring and evaluated for their anticancer activity on three 
cancer cells.
110
 
 
      Kuo-Hsiung Lee et al synthesized series of polar phenanthrene-based tylophorine 
derivatives (PBTs) and evaluated their cytotoxic activity against A549 human cancer cell 
line. Among them, 68 and 69 showed potent growth inhibition with IC50 values of 0.16 and 
0.27 µM, respectively, which are comparable to those of currently used antitumor drugs such 
as etoposide.
111
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      Kuo-Hsiung Lee et al also synthesized novel 9-substituted 2,3-methylenedioxy-6-
methoxy-PBTs. Some of the synthesized compounds exhibited potent cytotoxic activity 
against diverse panel of human tumor cell lines, including a multidrug-resistant variant and is 
comparable with the activity of the two frontline anti-neoplastic drugs which are used as 
positive controls. The IC50 values for these compounds on different cell lines were in the sub 
micro molar range, for instance the compound 70 had IC50 value less than 100 nM against the 
A549 cells.
112
They also explored the mechanisms of cell growth inhibition of these 
compounds in A549 cells. The compounds inhibit the cell proliferation through cell cycle 
arrest at G2/M phase and induction of apoptosis by inactivating Akt and by inhibiting the NF-
κB signalling pathway.113 
 
      Takashi Ikeda et al reported asymmetric total synthesis of the highly potent 
phenanthroindolizidine alkaloid 3 and its derivatives. Evaluation of in vitro anticancer 
activity of these compounds showed that the substituents on the phenanthrene ring and 
configuration strongly affected the anticancer activity. Among them the compound 71 
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showed moderate in vivo antitumor efficacy, but almost all other compounds exhibited 
inherent toxicity
.114
 
 
      Gunda I. Georg et al synthesized a library of N-substituted phenanthropiperidines to 
explore the effects of N-substitution at the phenanthropiperidine core. The compounds, in 
general, had reduced anti-cancer activity relative to tylophorine. But, among the series the 
compound with 2-substituted N-benzyl analogues (72, 73) displayed GI50 values in the range 
of 600-800 nM against MCF-7 breast cancer cells. These results indicate that the E ring of 
tylophorine is essential for the anti-cancer activity of the 6,7,10,11-tetramethoxy-1,2,3,4-
tetrahydrodibenzo[f,h]isoquinoline core scaffold.
115 
 
       Shiow-Ju Lee et al synthesized a series of tylophorine-derived dibenzoquinolines and 
tested for anticancer, anti-inflammatory and anti-corona virus activity. The most potent 
compound from the series (74) showed improved solubility compared to tylophorine, in vivo 
efficacies in a lung A549 xenografted tumor mouse model and a murine paw edema model, 
good bioavailability, and no measurable neurotoxicity.
116 
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       Xiaoming Yang et al synthesized a series of novel heteroatom-incorporated antofine and 
cryptopleurine analogues and tested their anti-cancer activity against a panel of five cancer 
cell lines. Two compounds (75 and 76) exhibited potent inhibition of cell proliferation in 
vitro (GI50: 9 nM and 20 nM). These compounds inhibit the cell proliferation by 
dysregulation of DNA replication during early S phase.
117 
 
      Various E-ring hydroxylatedantofine and cryptopleurine analogues were designed, and 
synthesized by Xiaoming Yang et al. The compound 77 showed the most potent anticancer 
activity among the series which inhibit the cell proliferation through down regulation of 
HSP90 and β- catenin in A549 lung cancer cells in a dose dependent manner.118 
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1.5.3 Mechanism of action        
      The specific cellular target of the phenanthroindolizidines and quinolizidines is unknown, 
but a significant amount of cellular activity of these compounds is known. It was determined 
in the 1970’s that tylocrebrine, tylophorine and cryptopleurine inhibit protein synthesis, and 
to a lesser extent RNA and DNA synthesis.
119
 Inhibition of protein synthesis in Ehrlich 
ascitestumor cells by  tylophorine, tylocrebrine and cryptopleurine was reported in.
99
 It was 
observed that tylocrebrine and cryptopleurine prevent the breakdown of polyribosomes and 
release of nascent peptides and it was inferred that they inhibit peptide chain elongation.
120
 
The 40S ribosomal subunit has been postulated to house the binding site of these drugs.
121
 
      Recently, Inhibition of NF-κB mediated transcription by (S)-tylophorine and analogues 
was also reported.
101-102
 The transcription factor NF-κB (nuclear factor kappa B) mediates the 
expression of a number of pro-inflammatory cytokines, adhesion molecules, growth factors, 
and anti-apoptosis survival proteins.
122-123
 NF-κB transcriptional activity is normally 
suppressed in the cytosol via complexation with its natural inhibitor molecule IkB. Various 
cellular stress and pro-inflammatory stimuli can result in the translocation (and hence 
activation) of NF-κB into the nucleus via the degradation of IkB. The proteolytic destruction 
of IkB via the ubiquitin-proteasome pathway is triggered by phosphorylation of IkB at Ser32 
and Ser36 by the IkB kinase complex (IKK). As such, inhibitors of IKK may be useful in the 
treatment of inflammatory diseases as well as in cancer. These recent discoveries emphasize 
that tylophorine derivatives merit development as a new antitumor drug class distinctly 
different from current cancer chemotherapeutic agents. Nuclear Factor-κB, a transcription 
factor, has been suggested to be a mechanism of drug resistance because of its anti-apoptotic 
role.
124-125
 Thus, inhibition of NF-κB may account for the cytostatic activity of these drugs in 
multi-drug resistant cancer cell lines. To date, the specific cellular target protein or nucleic 
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acid has not been identified. It would be advantageous to drug development to understand 
how these drugs interact with specific cellular targets. 
1.5.4 Structure activity relationship of PBTs:  
      The potent medicinal properties and interesting structures of the phenanthroindolizidines 
and phenanthroquinolizidines have attracted synthetic organic chemists and medicinal 
chemists for several decades. According to previous reports,
126-128
favourable modifications 
for the phenanthrene based tylophorines are as follows.  
 A planar phenanthrene system is required, but not sufficient for cytotoxic activity. 
 A N-hydrophilic substituent at the C-9 position is essential for the enhanced 
cytotoxicity and should be linked through a methylene rather than a carbonyl group. 
 This C-9 N-hydrophilic substituent is ideal for the introduction of a polar moiety. 
Analogs containing terminal carboxylic acid or hydroxyl methyl groups are more 
favorable than those with methyl esters.  
 On the phenanthrene skeleton, a methoxy substituent best fits both the steric and 
electronic requirements at the C-6 position and is preferred over benzyloxy and 
hydroxy groups.  
 Adding a methylenedioxy ring at the 2, 3 position of the planar phenanthrene system 
can dramatically enhance the cytotoxic activity and led to the most potent derivative. 
1.6 Pyrazoles 
1.6.1 Structure 
      Pyrazole (78) belongs to the class of nitrogen containing five membered heterocycles 
with two double bonds and two nitrogen atoms at adjacent positions. Pyrazole, a structural 
isomer of imidazole, is an aromatic molecule. It possesses pyrrole and pyridine like nitrogen 
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aromatic 1- and 2-position, unlike imidazole having nitrogen aromatic 1- and 3-position. 
Pyrazole is, therefore, also identified by the name “1, 2-diazole”. 
 
1.6.2 Biological activities 
      First synthesis of pyrazole is reported by Knorr in 1883, which led to discovery of 
antipyrine and its derivatives. Antipyrine is the first pyrazolone derivative was used in the 
treatment of pain, inflammation and fever in 1884.129As a result, large numbers of pyrazoles 
have been obtained and some of these pyrazole derivatives are in clinic. The pyrazole 
scaffold has drawn a great attention due to its extensive range of biological and 
pharmacological effects regardless of scarcity in nature. These pyrazole derivatives are rarely 
found in nature probably due to difficulty in the formation of N-N bond by living 
organisms.
130
 Structural changes of pyrazoles have offered a high degree diverse compounds 
that has been useful for the development of novel molecules in the medicinal chemistry with 
improved potency and less toxicity. Moreover, pyrazole derivative serves as starting 
materials for the synthesis of condensed heterocyclic systems and represent as interesting 
template for combinatorialchemistry.
131
 
      Some of the drugs, possessing pyrazole as basic moiety, like celecoxib,
132
 deracoxib
133 
etoricoxib and atorivodine
134 
are in the clinical use. Pyrazole derivatives possess an extensive 
range of pharmacological activities such as anti-inflammatory, antipyretic, analgesic,
135
 
antimicrobial,
136
 sodium channel blocker,
137
antitubercular,
138
 antiviral,
139
 antihypertensive,
140
 
antiglaucoma,
141
 antioxidant,
142
 antidepressant, anxiolytic, neuroprotective,
143 
antidiabetic
144 
activity and anticancer.
145 
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1.6.3 Pyrazoles as anti-cancer agents  
             The search for anticancer drugs led to the discovery of several pyrazoles derivatives, 
having potent anti-cancer activity. Some of the pyrazole derivatives with anti-cancer activity 
in the market are Ruxolitinib (79)
146 
a Janus kinase 2 (JK2) inhibitor for the treatment of 
myelo proliferative neoplasm and Crizotinib (80)
147 
a dual cMet/ALK inhibitor (proto-
oncogene/anaplastic lymphoma kinase) for the treatment of non-small cell lung carcinoma. 
Moreover, the discovery of the natural antibiotic pyrazofurin (81), 4-hydroxy-3-β-D-
ribofuranosyl-1H-pyrazoles-5-carboxamide, having a potent antitumor efficacy in some 
cancers, led to extensive investigation of several pyrazoles containing different functional 
groups for their anticancer activity.
148
 
 
      Pyrazole molecules exhibit their anticancer activity through inhibition of different types 
of enzymes, proteins, receptors which play an important role in cell division such ascyclin 
dependent kinase (CDK), Heat shock protein, aurora kinase, BCR-ABL kinase, tumor growth 
factor, epidermal growth factor receptor (EGFR) besides their capability to induce apoptosis 
in different cancer cell lines.
149 
      Krystofet al synthesized a series of thirty-five 3,5-diamino-1H-pyrazole derivatives (82) 
substituted with different aryl azo groups at position 4. Some of the synthesized compounds 
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showed potent growth inhibition on HT-29 cancer cells. These compounds also exhibit 
remarkable CDK2 inhibition activity.
150 
 
      Brasca et al synthesized a series of pyrazole derivatives and evaluated their anticancer 
activity against A278 cells. The compound 83 showed highly potent growth inhibition and 
dose dependent inhibition of A2780 tumor growth up to 91%. The compound also showed 
good CDK2/CyclinA inhibition. It also effects the cell cycle progression and DNA synthesis 
of A2780 cells and underwent Phase I and II clinical trials.
151
 
 
      Manetti et al synthesized a series of pyrazolo[3,4-d]pyrimidines derivatives and 
investigated their Abl enzyme inhibitory activity in a cell free assay and their anti-
proliferative activity in cellular assays on human leukaemia cell lines. Among them, the 
compound 84 showed highest cell growth inhibition with selectivity towards Bcr-Abl positive 
human leukaemia cells.
152
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      A series of 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamide derivatives was 
synthesized by Brough et al and evaluated for their anti-cancer activity against HCT-116 
(human colon cancer cells) and for heat shock protein 90 (HSP90) inhibition. Most of the 
synthesized compounds inhibit the HSP90 in the low micro molar range and compounds 85 
was most potent among the series.
153
 
 
      Fancelli et al synthesized series of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives as 
potent aurora kinase inhibitors. The most potent compound 86 had an IC50 of 0.027 μM for 
Aur-A inhibition and IC50 values in the range of   0.05 μM - 0.5 μM for the inhibition of 
proliferation of different tumor cell lines.
154 
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      Lv et al synthesized a series of pyrazole containing thiourea derivatives, 3(3, 4-dimethyl 
phenyl)-5(4-methoxyphenyl)-4,5dihydro-1H-pyrazole-1-carbothiamide 87 and studied their 
EGFR inhibitory activity and anti-cancer activity.
155
 
 
      A series of 1,3,4-trisubstituted pyrazole-benzohydrazide derivatives were synthesized by 
Abadi et al. Compound 88 proved to be the most active among the series. These compounds 
exhibited antiangiogenic properties against HUVEC cells.
156
 
 
1.6.4 Pyrazole derivatives as inducers of apoptosis 
      Li-Chen Chou et al synthesized the benzopyrazole analogue 1-benzyl-3-(5-
hydroxymethyl-2-furyl)indazole (YC-1, 89) and furopyrazole analogue (90) of YC-1 and 
evaluated for their anticancer activity. These compounds exhibited potent anticancer activity 
against U937 leukaemia cells and via an intrinsic mitochondrial-dependent apoptosis 
pathway.
157
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      3-Aryl-1-(4-tert-butylbenzyl)-1H-pyrazole-5-carbohydrazide hydrazone derivatives were 
synthesized by Liang-Wen Zheng et al and investigated their anticancer activity on A549 
cancer cells. Among them, compound (E)-1-(4-tert-butylbenzyl)-N’-(1-(5-chloro-2-
hydroxyphenyl)ethylidene)-3-(4-chlorophenyl)-1H-pyrazole-5-carbohydrazide (91) exhibited 
the potent growth inhibitory effect and induced apoptosis of A549 lung cancer cells.
158
 
 
      3,5-diaryl-1H-pyrazole derivatives (92) were reported  by the Y. Shaw Arthur et al, which 
showed   potent activity against OVCAR, SW620, H460 and AGS cells with GI50 values of 
0.67, 0.89, 0.73 and 0.79 μM, respectively. These compounds induce apoptosis in OVCAR 
cells by the mitochondrial apoptotic pathway through the activation of caspase-9, caspase-3, 
as well as the cleavage of protein poly(ADP-ribose) polymerase (PARP) and DNA 
fragmentation.
159 
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      Lee et al synthesized several 3-aryl-1-arylmethyl-1H-pyrazole-5-carboxamide derivatives 
and evaluated their anti-proliferative activity against A549 lung cancer cell line. These 
compounds in particular, compounds 93 and 94 showed significant A549 cell growth 
inhibition by inducing apoptosis which is confirmed by DNA fragmentation.
160 
 
      Balbi et al synthesized novel substituted pyrazole derivatives (95) and screened their 
anticancer potency in human lung carcinoma A549, human ovarian adenocarcinoma A2780 
and murine P388 leukaemia cell lines. Some of the synthesized compounds exhibited good 
anti-proliferative and apoptotic inducing activity.
161 
 
      BangoluErden et al synthesized a series of novel 1,5-diarylpyrazole-3-carboxamide 
derivatives and tested their anti-proliferative activities against Huh7 (human liver), MCF7 
(breast) and HCT116 (colon carcinoma cell lines). Among these, compound 96 with 2-
chloro-4-pyridinyl group in the amide part showed significant anticancer activity against all  
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cell lines with IC50 values in the range of 1.6- 3.3 μM, and produced dramatic cell cycle arrest 
at Sub G1 phase as an indicator of apoptotic cell death induction.
162 
 
      Despite the synthesis and testing of untold numbers of pyrazole analogues, it is clear that 
we still do not have an ideal set of congeners to properly define the structure–activity 
relationship although many different biological tests have been devised to assess their 
activity. Even if pyrazole derivatives have achieved significant clinical benefit for many solid 
tumors, their effectiveness has been limited by toxic side effects. This drug discovery story 
has taught us that pyrazole compounds could have an important role in chemotherapy. 
1.7 Natural products in anticancer drug discovery 
      The search for novel and effective drugs is still a priority goal for cancer therapy, due to 
the development of resistance to chemotherapeutic drugs. In addition, the toxicity and 
undesirable side effects associated with some chemotherapeutic drugs increases the demand 
for new anti-tumor drugs with fewer adverse effects and/or with improved therapeutic 
efficacy. Natural products are the most important anti-cancer agents and play an important 
role in the development of anti-cancer drugs. Half of the drugs currently in clinical use are of 
natural-product origin and three quarters of anti-tumor compounds used in medicine are 
natural products or their derivatives. Of the 140 anti-cancer agents approved since 1940 and 
available for use, over 60% can be related to a natural product.
163-164 
Among these, 6% are 
natural products, 27% are derivatives of natural products, 5% are synthetic with natural 
product pharmacophores, and 23% are synthetic mimics of natural products.   
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      Natural-product chemistry has recently been revisited and will continue to be a powerful 
source of drug candidates. It is now generally accepted that collections of natural products 
have a higher probability of delivering hits than typical libraries of molecules generated by 
combinatorial chemistry.
165
 These natural products could be optimized for desirable drug 
properties by combinatorial biosynthesis. Natural products offer a great opportunity to 
evaluate not only totally new chemical classes of anticancer molecules, but also new lead 
compound with potentially relevant mechanisms of actions. 
Microbial anti-cancer agents 
      Microorganisms are the source of large number of anti-tumor compounds or their 
derivatives. In particular, actinomycetes produce a large number of products with anti-tumor 
properties, many of which also act as antimicrobial agents. Many of the important 
compounds currently used in chemotherapy of tumors are microbially produced antibiotics or 
their derivatives. Actinomycin D was one of the microbial products used for Wilm’s tumor in 
children.
166 
Doxorubicin, daunorubicin, bleomycin, phleomycin, mitomycin C are some of the 
microbial derived anti-tumor products.
167
 
Marine based anti-cancer agents 
      Marine microorganisms consists a complex and diverse assembly of microscopic life 
forms and it is estimated that only 1% of them have been cultured or identified. Marine 
resources for applications in biotechnological use, particularly in drug discovery, are a 
relatively recent activity. Approximately 68 % of the clinically useful marine natural products 
are with anti-cancer activity and the remaining used for pain, inflammation, asthma and 
Alzheimer’s.168Cytarabine (Cytostar) is a chemotherapeutic drug used for non-Hodgkin’s 
lymphoma which was originally derived from a marine sponge.
169
 Some the compounds 
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derived from the marine products were Cytarabine (Cyto star), Ecteinascidin 743 (ET743) 
Theopederins, Annamides, Trabectedin (Yondelis), Aplidine. 
Plant based anti-cancer agents 
      Plants have been a useful source of many approved anti-cancer agents.
170 
The history of 
plant as source of anti-cancer agents started in early 1950s with the discovery and 
development of the vinca alkaloids (vinblastine and vincristine) and the isolation of the 
cytotoxic podophyllotoxins. Since 1961, nine plant derived compounds have been approved 
for use as anticancer drugs. These includes, Vinblastine (Velban), Vincristine (Oncovin), 
Etoposide, Teniposide, Taxol (paclitaxel), Navelbine (Vinorelbine), Taxotere (Docetaxel), 
Camptothecin (Camptosar, Campto), Topotecan (Hycamtin) and Irinotecan.Other plants 
natural products such as indole-3-carbinol (I3C), isoflavonegenistine, 3,3′- diindolemethane, 
(-)-epigallocatechin-3-gallate, curcumin, resveratrol and lycopene are known to inhibit the 
various cancer cells proliferation. These compounds appear to act by interfering with multiple 
cellular signalling pathways, and inducing apoptosis incancer cells without affecting the 
normal cells.
171 
     New strategies have been developed in recent years to expand the use of “biological 
drugs” besides the use of small drug molecules, like (a) gene expression modulation with 
small DNA or RNA fragments or interference RNAi as therapeutics, (b) anticancer vaccines 
(c) cell therapy with human embryonic stem cells. The extremely high cost of developing 
these “biological drugs” will contribute toward leaving an open space for drugs based on 
small molecules, as their development is cheaper. 
      Modern combinatorial chemistry allows the synthesis of large no. of new compounds in a 
short time. The synthesised libraries can be screened for their biological activity using high-
throughput screening (HTS) techniques. However, the success of these random approaches 
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not very pronounced, which may be due to the lack of high diverse new chemical entities 
(NCEs). Recently, Medicinal chemists have made considerable efforts to advance the 
druggability of hit molecules via more elaborated and “rational” designs of drugs. Molecular 
hybridization is a new concept in drug design which is based on the combination of two or 
more pharmacophoric moieties of various bioactive substances to produce a new hybrid 
compound with improved affinity and efficacy compared to the parent drugs 
 
1.8 Hybrid molecules 
         Hybrid molecules are defined as chemical entities with two or more structural 
components having similar or different biological functions, indicating that a hybrid molecule 
acts as two distinct pharmacophores. Both entities of the hybrid molecule are not necessarily 
acting on the same biological target. The molecular hybridization strategy is different from 
the fragment based lead discovery.
172
 The fragment-based approach in drug design is the 
improvement of the biological activity of a molecule fragment by the addition of chemical 
functions able to bind to adjacent regions of the active site when the protein target is known.
 
Moreover, this hybridisation strategy can result in compounds with modified selectivity 
profile, different and/or dual modes of action and reduced side effects.
173-175
 This 
pharmacophore hybridization is similar to conventional combination therapy, with the 
exception that the two molecules are covalently linked as a single entity. The selection of the 
two scaffolds/pharmacophores in the hybrid molecule is usually based on their synergistic or 
additive pharmacological activities to enable the identification of highly active novel 
molecules.
176-177
 
1.8.1 Classification of Hybrids 
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          Hybrid molecules can be classified in three different categories based on their 
mechanism of action.
178
 
The category Aconcerns a single target and both pharmacophores of the hybrid molecule are 
able to interact with the same target and considered as double edge sword. For example, 
trioxaquines interact with heme via their amino quinolone moiety which can also alkylate 
heme after a reductive activation. 
In the second category B concerns two non-related targets; these hybrid molecules have a 
dual mode of action on the two different and non-related targets. Hybrid anticancer drugs 
based on the conjugation of taxol (Paclitaxel) to camptothecin, epipodophylotoxin, or 
colchicine via an amide containing linker fall in this subcategory.
179
 
Category C concerns two related targets both of which interact with two related targets. For 
instance hybrid antiprion molecules prepared by linking acridines to imino-dibenzyl entities 
fall in this category.
180
 
Hybrid molecule can also classified on the basis of types of linkers connecting the two 
pharmacophores
181
 
Directly linked hybrids, Pharmacophores are joined through a functional group of each 
molecule that has been designed to be metabolized in the biological system to release the two 
pharmacophoric units. Notable examples of this category are estramustine, lactandrate and 
lactestoxate.
182, 183
 
Conjugate hybrids or Spacer linked hybrids: These hybrids can be classified as cleavable 
and non-cleavable. In General, most of the reported cleavable conjugate hybrids contain ester 
linker that is cleaved by esterase’s two release two individual drugs.Examples of cleavable or 
conjugate hybrids are Taxol-linker-CPT and 5-fluorouracil-cytarabine. In Non-cleavable 
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hybrids, pharmacophores or drugs are connected through a metabolically stable linker which 
is not a part of either of the individual pharmacophores. Examples for these category hybrids 
are Estrogen-Platinum, androgen ligand-aniline mustard. 
Mergedor Overlapped hybrids: These types of hybrids have their frameworks merged by 
overlapping structural motifs or pharmacophores of two drugs which give rise to smaller and 
simpler molecules. These hybrids may retain the properties of either or both of the merged 
drugs. The examples for this type of hybrid is Azatoxin.
184
 
      Hybrid drugs can be designed using different approaches such as ‘post hoc’ and ‘ad 
hoc’.The ‘post hoc’ approach, involves the use of drugs that are in clinical use. For instance 
estramustine belongs to this class of hybrid agents.
182,185
 Whereas ‘ad hoc’ approach involves 
the use of lead molecules that are suffering from some drawback such as in vivo instability or 
lack of drug-like properties. In general, Molecular hybridization approach could be useful for 
lead optimization and should be implemented at the early stages of drug discovery and 
development process.
178 
Limitation and challenges 
     Although hybrid molecules are blend of known drugs or leads which are ‘privileged’ drug-
like structures, they still warrant incorporating drug likeness. The chemical structures of most 
of the hybrid drugs have high molecular mass and high lipophilicity (CLogP) which indicates 
violation of Lipinski’s rule. This represents a significant challenge for oral bioavailability and 
poor aqueous solubility, making. The synthesis of most of the hybrid drugs involve 
complicated chemistry due to use of linkers and labile bond to link two molecules. Moreover, 
it should be noted that regulatory requirements for hybrid drugs would be more challenging, 
because of the current strict regulatory requirements for the approval of single molecule 
anticancer drugs, 
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1.8.2 Hybrid drugs as anticancer agents 
      Cancer is a complex disease, and it is unlikely that drugs that act on single target will be 
effective for treating the most advanced carcinomas.
186,187 
Combinations of drugs that act on 
multiple targets simultaneously are better for controlling complex diseases such as cancer, 
and are less prone to drug resistance.
188 
Hybrid drug strategy is one of the approach that is 
designed to improve the efficacy of the such drug combinations. There are many reports 
which showed that that in vitro growth inhibitory activity and in vivo antitumor efficacy can 
be greatly potentiated by using this hybridisation strategy. Many of the hybrid anticancer 
agents possess enhanced efficacies compared to the parent drugs or their combinations.
178, 189
 
Some of the examples of the hybrid anticancer agents are estramustine, paclitaxel-
epipodophyllotoxine taxol-camptothecin, and 5-fluorouracil-cytarabine. 
Estramustine 
         Estramustine (97) is probably the first clinically used hybrid drug. It is a hybrid of 
estradiol and nitrogen mustard which is designed to bind to the steroid receptors in prostate 
cancer cells and there by releasing the toxic nitrogen mustard selectively to the cancer 
cells.
190
 However, estramustine is used for prostate cancer and it doesn’t bind to the steroid 
receptors. Its anticancer activity is mainly due to its antimitotic activity. Currently, many of 
the estramustine and its combination with other anticancer drugs are in clinical trials for 
different types of tumors.
 191-193 
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Paclitaxel–epipodophyllotoxine and camptothecin 
      Paclitaxel (TXL) is a plant based anticancer agent used in clinic against ovarian and 
breast cancers. It inhibits the cancer cell proliferation by binding to and stabilizing the 
microtubules and thereby promoting the irreversible assembly of tubulin into microtubules. 
Other natural products camptothecin (CPT), etoposide (EP) are also approved anticancer 
agents for clinical use which act by different mechanisms. Lee et al synthesised a different 
paclitaxel hybrids with other naturally derived anticancer agents such as TXL-CPT (98), 
TXL-EP (99) to improve the potency of the both compounds or reduce side effects and drug 
resistance.
194-196
 These hybrids were synthesized by taking various linkers at the TXL-C-20 
and C-7-positions and the two components were joined by an ester, imine, and amine or 
amide linkages. Some of these synthesized molecules showed significant in vitro cytotoxicity 
against human prostate cancer cells such as LNCaP and PC-3 without affecting the normal 
cells. 
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5-Fluorouracil–cytarabine 
      The thymilidate synthetase inhibitor, 5-Fluorouracil (5-FU) is a standard 
chemotherapeutic drug which has been in use against cancer for about 40 years. It inhibits the 
cancer cell growth by different mechanisms, but primarily acts on thymilidate synthetase. 
Cytarabine (ara-C) is an anti-metabolite anticancer agent which converts into cytosine 
arabinoside and thereby causes the DNA damage when the cells are in S phase. Menger and 
Rourk have designed, synthesized a hybrid of 5-Fluorouracil–cytarabine (100) using acyloxy 
alkyl carbamate linker to prevent the cytarabine susceptibility to deactivation by cytidine de 
aminase.
197 
 
         Therefore, the design of hybrid molecules with a dual mode of action is a niche in the 
field of anticancer drug discovery. The advantage of designing hybrid molecules over 
multicomponent drugs is that of the reduced risk of drug–drug adverse interactions compared 
to multicomponent drugs. The hybrid strategy will definitely leave a mark in the market of 
very few truly safe and effective anti-cancer agents. 
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 1.9 Objectives of the present work 
       The objectives of the present study involve the design and synthesis of novel 
podophyllotoxin, phenanthrene and pyrazole based hybrids with a view to produce promising 
anti-cancer agents. The work carried in the research tenure has been compiled in the form of 
a thesis entitled “Design and synthesis of podophyllotoxin, phenanthrene and pyrazole 
based hybrids as potential anticancer agents”. The thesis has been divided into seven 
chapters as shown below. 
CHAPTER I: This chapter gives the general introduction about cancer chemotherapy, role of 
natural products and hybrid molecules in anticancer drug design as well as the objectives of 
the present work. 
CHAPTER II: This chapter describes the synthesis of a series of 4-aza-2,3-
Dihydropyridophenanthroline derivatives through one step multi component reaction and 
these conjugates have been evaluated for their anticancer activity. 
CHAPTER III: This chapter deals with the synthesis of new podophyllotoxin derivatives by 
linking benzimidazole moiety through the C8-position of the C- ring of the podophyllotoxin 
scaffold. This chapter is more focused on tubulin polymerization inhibition, molecular 
docking and anticancer activity of the newly synthesized podophyllotoxin hybrids.  
CHAPTER IV: In this chapter a new class of phenanthrene based tylophorine derivatives 
containing triazole nucleus has been synthesized and evaluated for their anticancer activity. 
Further these derivatives were evaluated for their NF-кB inhibitory effects and apoptosis 
inducing effects on MCF-7 cell lines. 
CHAPTER V: This chapter deals with the synthesis of pyrazole containing benzimidazole 
hybrids and their anti-proliferative activity. Further, we investigated the mechanism of cell 
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growth inhibition such as morphology, cell migration, colonogenic survival, cell cycle 
analysis and apoptotic inducing effect of the potent compounds in human breast cancer cell 
line MCF-7.  
CHAPTER VI: A new series of pyrazolo-triazole hybrids were designed and synthesized in 
this chapter. All the synthesized compounds were evaluated for their in vitro anticancer 
activity against human tumor cell lines. The most potent compounds in the series were further 
evaluated for their cell growth inhibition studies and apoptosis inducing effects. 
CHAPTER VII: This chapter providers the summary of the research undertaken in this PhD 
candidature and also scope for the future work that could be carried out in this area. 
The overall objectives of the thesis has been divided as 
 To develop new hybrid molecules by merging two molecular fragments which are 
known for their individual anticancer activity to achieve improved activity, selectivity 
and toxicity of anticancer agents. 
 To establish structure activity relationship studies based on their cytotoxicity data 
which could be used in further development of molecules with improved anti-cancer 
activities 
 To investigate the mechanism of cell growth inhibition of most potent compounds 
from each series using various cell based assays. 
      The strategy for the design of these hybrid anticancer molecules is straightforward which 
involves blending or simply linking a known anticancer agent to a carrier molecule (or 
another anticancer drug) that inhibit cancer cells more efficiently. 
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Chapter-II   
Synthesis and biological evaluation of 4-aza-2,3-
dihydropyridophenanthrolines as tubulin polymerization 
inhibitors 
      
Abstract 
 A series of new 4-aza-2,3-dihydropyridophenanthrolines 12-31 were synthesized by a one-
step three component condensation of 1,10-phenanthroline amine, tetronic acid and various 
aromatic aldehydes. These were evaluated for their antiproliferative activity against three 
human cancer cell lines (MIAPaCa-2, MCF-7 and HeLa) using SRB assay. Majority of the 
tested compounds exhibited significant anticancer activity on these cell lines and interestingly 
compounds 19 and 20 were more potent than etoposide and podophyllotoxin against all three 
tested cancer cell lines with GI50 values in the range of 0.01-0.5 µM. Furthermore, these 
compounds showed significant inhibition of tubulin polymerization which is comparable to 
that of podophyllotoxin and disrupted microtubule network by accumulating tubulin in the 
soluble fraction. The flow cytometry analysis confirmed that the synthesized compounds led 
to cell cycle arrest at the G2/M phase. Moreover, the structure activity relationship studies in 
this series are also discussed.  
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2.1 Introduction 
       Podophyllotoxin (1), is the main component of podophyllum resin, a naturally occurring 
antimitotic cyclolignan which shows strong anticancer activity against various cancer cell 
lines.
1-2
 Interest in podophyllotoxin has been heightened by its potent antimitotic activity and 
it inhibits the assembly of tubulin protein into microtubules through tubulin binding at the 
colchicine site.
3
 Attempts to use podophyllotoxin for the treatment of cancer were mostly 
unsuccessful and complicated by severe gastrointestinal side effects.
4
 However, its use as a 
lead in anticancer drug design has resulted in several clinically useful compounds like 
etoposide (2), teniposide (3) and etopophos (4).
5-7
 These compounds inhibit DNA 
topoisomerase-II by stabilizing the covalent topoisomerase-II DNA cleavable complex
8
 and 
are used against different types of cancers, including small-cell lung cancer, non-Hodgkin’s 
lymphoma, leukemia, neuroblastoma, kaposi’s sarcoma and soft tissue sarcoma.9 In spite of 
their wide clinical applications, they have several limitations, such as development of drug 
resistance, poor water solubility, metabolic inactivation, and toxic effects like 
myelosupression.
10
  Extensive structural modifications have been carried out by a number of 
researchers to overcome such limitations, which led to the development of NK-611 (5)
11 
and 
GL-331 (6),
12
 which are in different stages of clinical studies and exhibit improved 
cytotoxicity as well as DNA topoisomerase-II inhibition, compared to etoposide.  
       The presence of four stereo genic carbons in ring C is responsible for the structural 
complexity of podophyllotoxin (Figure 2.1), thus preventing the generation of its analogues 
from commercially available materials.
13
 Furthermore, stereo chemical complexity of 
podophyllotoxin can be simplified by the removal of the stereo centers at C-2 and C-3, which 
also solves the problem of epimerization at C-2 that afflicts the clinical usage 
Chapter-II 
 
87 | P a g e  
 
podophyllotoxin, because the rapidly formed cis-lactone metabolite (in vivo) is significantly 
less potent.
14
  In this connection, many researchers made an important contribution for the 
synthesis of 4-azapodophyllotoxin (7) and its derivatives (7a,7b) which retains cytotoxicity 
as well as inhibition of tubulin polymerization comparable to that of podophyllotoxin.
15-16
 
 
Figure 2.1. Structures of podophyllotoxin (1), etoposide (2), teniposide (3), etopophos (4), 
NK-611 (5), GL-331 (6) and 4-azapodophyllotoxin (7). 
       1,10-Phenanthroline (8) and their derivatives have recently attracted much attention, 
because of their potential activity against cancer
 
as well as viral, bacterial and fungal 
infections.
17-20
 1,10-phenanthroline (8) itself shows potential activity towards neoplastic cell 
lines.
21
 Based on the promising anticancer activity of 4-azapodophyllotoxins and 1,10-
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phenanthrolines, we have designed some new analogues by replacing A and B rings of 4-
azapodophyllotoxin scaffold with 1,10-phenanthroline moiety with a view to combine the 
pharmacological characteristics of both these chromophores. 
 
Figure 2.2. Selected structures of 4-azapodophyllotoxin analogues (7a, 7b) and 1,10-
phenanthroline (8) as well as proposed dihydropyridophenanthrolines (12-31). 
       Multicomponent reactions (MCRs) carry a privileged position because they provide a 
powerful tool towards the one-pot synthesis of diverse and complex compounds as well as 
small and drug-like heterocycles required for drug discovery programmes.
22,23 
Such processes 
avoid time consuming protection/deprotection steps, as well as purification processes, and 
allows eco-friendly synthesis of molecules.
24-26
  
      Recently, there has been a growing interest in the design and synthesis of new analogs of 
podophyllotoxin aimed at structural simplification by designing mimetic scaffolds that can be 
constructed using one-step multicomponent reactions (MCRs).
 27-29
  Magedove et al reported 
a synthesis of dihydropyridopyrazole scaffold based on 4-aza podophyllotoxin which are 
readily prepared by combining an aminopyrazole, tetronic acid, and an aromatic or 
heteroaromatic aldehyde in a one-pot condensation process.
16
 Thus, the utilization of 
requisite aldehyde, amine and tetronic acid starting materials leads directly to the synthesis of 
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large no. of libraries to expand the scope of possible A, B, C and E ring system substitutions 
in these potent anticancer podophyllotoxin mimetic scaffolds. 
In continuation, to the structural modifications of the podophyllotoxin (1), a series of new 4-
azapopdophyllotoxin analogs were designed  
 To allows a drastic reduction of the structural complexity of the podophyllotoxin  
 To yield new 4-azapodophyllotoxin analogs  (12-31) containing phenanthroline 
skeleton via one step three-component reactions of 1,10-phenanthroline amine (9), 
tetronic acid (10) and different aromatic aldehydes (11 a-t) 
 To produce potent podophyllotoxin mimetic scaffold as an additional option in the 
search of tubulin-targeting anticancer agents. 
2.2 Results and discussion 
2.2.1 Chemistry 
        The 4-aza-2,3-dihydropyridophenanthroline congeners (12-31) were synthesized by 
three component one-step synthesis involving the condensation of 1,10-phenanthroline amine 
(9), tetronic acid (10), and various substituted aromatic aldehydes (11 a-t) that proceeds 
smoothly via the formation of chalcone intermediate in refluxing ethanol (Scheme 2.1).
16
 In 
all cases, the resulting compounds were precipitated as the reaction mixtures were allowed to 
cool to room temperature and were isolated by simple filtration followed by recrystallization 
from ethanol to afford the pure compounds. All the synthesized compounds were 
characterized by 
1
H NMR, 
13
C NMR as well as HRMS. 
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Scheme 2.1 Synthesis of 4-aza-2,3-dihydropyridophenanthrolines (12-31) 
 
 
Scheme 2.2 Probable reaction mechanism of MCR involving 1,10-phenanthroline amine (9), 
tetronic acid (10) and different aromatic aldehydes (11 a-t) 
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2.2.2 In vitro anticancer activity 
         All the synthesized 4-aza-2,3-dihydropyridophenanthroline derivatives (12-31) were 
evaluated for their anti-proliferative activity in three human cancer cell lines of pancreatic 
(MIA PaCa-2), breast (MCF-7) and cervical (HeLa) origin by using sulforhodamine B (SRB) 
method.
30
 Podophyllotoxin and etoposide were used as the positive controls and the results 
are summarized in Table 2.1. It is observed that all the synthesized compounds showed 
significant anti-proliferative activity with GI50 values ranging from <0.01 to 13.6 μM, while 
the positive controls, etoposide and podophyllotoxin demonstrated the GI50 in the range of 
0.23 to 0.71 μM and 0.25 to 1.3 μM, respectively. The majority of the tested compounds 
displayed potent growth inhibition on cervical (HeLa) and pancreatic (MIA PaCa-2) cancer 
cell lines as compared to the breast cancer cell lines (MCF-7). Some of the compounds like 
15, 16, 17, 19, 20, 21, 22 and 31 were distinctly more potent than podophyllotoxin and 
etoposide, with GI50 concentrations in the submicromolar level on certain cell lines. 
However, compounds 19 and 20 were the only compounds that were more active than 
etoposide and podophyllotoxin against all the three tested cancer cell lines with GI50 values in 
the range of 0.01- 0.5 µM.  
Table 2.1. Anti-proliferative activity (
a
GI50-µM) of 4-aza-2,3-dihydropyridophenanthrolines 
compounds (12-31) 
Compound MIA PaCa-2
b
 MCF-7
c
 HeLa
d
 
12                   NA NA 0.15±0.1 
13 13.6±1.9 NA NA 
14 3.4±1.0 4.6±1.1 4.2±0.5 
15 0.7±0.3 0.06±0.02 2.6±0.43 
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16 5.9±2.1 4.6±0.6 0.04±0.04 
17 0.1±0.04 8.4±0.7 0.0091 
18 1.2±0.7 6.4±0.6 0.8±0.6 
19 0.02±0.01 0.01 0.0097 
20 0.5±0.04 0.0097 0.03±0.01 
21 0.9±0.07 7.7±1.3 0.3±0.02 
22 2.0±0.18 7.6±1.2 0.0089 
23 NA NA 0.3±0.1 
24 5.4±1.5 9.2±2.2 1.76±0.6 
25 1.9±1.6 NA 0.6±0.09 
26 0.5±0.4 10.3±2.4 0.2±0.1 
27 9.8±1.3 9.7±1.9 7.0±1.6 
28 3.7±0.9 8.2±0.2 0.16±0.01 
29 2.8±0.5 1.7±0.2 0.1±0.03 
30 NA NA 2.5±0.2 
31 0.1±0.03 2.1±0.5 1.7±0.3 
1 0.5±0.1 0.23±0.09 0.71±0.2 
2 1.3±0.03 0.25±0.1 0.64±0.4 
a
50 Growth inhibition and the values are mean of three independent experiments;  
b
pancreatic cancer,
 c
breast cancer, 
d
cervix cancer, 
1
podophyllotoxin, 
2
etoposide,  NA = not 
active
 
          Based on the cytotoxicity data, the structure activity relationship (SAR) for these new 
4-aza-2,3-didehydropodophyllotoxin derivatives (12-31) was examined. It is interesting to 
observe that the compounds with electron withdrawing groups such as fluoro substitution at 
para-position (12) and 3,4,5-trifluoro substitution (30) on the phenyl ring showed similar or 
slightly reduced activity on HeLa cancer cell line in comparison to the 3,4-difluoro 
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substitution (20), which displayed potent cytotoxic activity against all the tested cell lines. 
Similarly, electron donating groups such as methoxy substitution on the phenyl ring also 
plays an important role in the activity, and this preference remains unchanged whether there 
are other substituents on ring E in combination with methoxy substitution. For instance, 3,4-
dimethoxy (16), 2,5-dimethoxy (17), 3-fluoro-4-methoxy (18), 2-fluoro-5-methoxy (19) 
groups are well tolerated and showed significant growth inhibition on certain cell lines, while 
compounds having 4-methoxy (14) 2-hydroxy-4-methoxy (27) substituents, displayed 
moderate to low activity. Moreover, the compounds having substitution of 3,4,5-trimethoxy 
phenyl E ring (29) as in case of podophyllotoxin and 3,5-dimethoxy-4-hydroxy (31) 
substitution as in case of etoposide, maintained cytotoxicity similar or equal to the 
podophyllotoxin. The combination of hydroxyl group at 2 or 4 position of E ring with 
methoxy, methyl, bromo and chloro produces compounds 21-27, showed selective inhibition 
on HeLa cancer cells with GI50 values in the range of 0.01-1.76 µM. In view of the promising 
anti-proliferative activity of some leads like 17, 19 and 20, it was considered of interest to 
pursue detailed biological studies on these compounds. 
2.2.3 Effect of compounds on in vitro tubulin polymerization     
           Since these new compounds have structural resemblance to podophyllotoxin, it was 
considered of pertinent to investigate their effect on the inhibition of tubulin polymerization. 
To examine this, varying concentrations of 17, 19 and 20 were incubated with the tubulin 
protein along with podophyllotoxin as a positive control. Table 2.2 shows that the compounds 
19 and 20 significantly decreased tubulin assembly with IC50 values of 0.83 µM and 0.92 
µM, which are comparable to that of podophyllotoxin. In contrast, compound 17 showed 
moderate inhibition of tubulin polymerization with IC50 values 2.0 µM. These results are in 
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correlation to the corresponding cytotoxicity values and the order of inhibition of tubulin 
polymerization is 1 > 19> 20> 17. 
Table 2.2 Inhibition of tubulin polymerization of 17, 19 and 20. 
S.No Compound IC50 (M) 
1 17 2.0±0.09 
2 19 0.83±0.06 
3 20 0.92± 
4 1 0.81±0.12 
 
2.2.4 Effect of compounds on cell cycle arrest     
             The inhibition of tubulin assembly is often associated G2/M-phase arrest of cell cycle 
in various cancer cell lines.
31
 Therefore effect of these compounds (17, 19 and 20) were 
determined on the cell cycle progression in HeLa cells by employing at 5 µM concentration 
for 24 h duration. It was observed that, these compounds markedly arrested the progression of 
cell cycle at G2/M. Among them, 19 exhibited 82% of cells in G2/M phase, whereas 20 and 
17 accumulated cells to 76.44% and 73.77% respectively in G2/M phase. Thus these results 
suggest that compounds induce cytotoxicity in HeLa cells through cell cycle arrest at the 
mitosis phase (Figure 2.3). 
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Figure 2.3 Induction of cell cycle G2/M arrest in HeLa cells treated with 5 μM of the 
compounds 17, 19 and 20. The percentage of cells in each phase of cell cycle was quantified 
by flow cytometry. 
2.2.5 Effect of compounds on microtubule network   
              Microtubule depolymerizing agents prevent the organization of the mitotic spindle 
and result in improper chromosome separation.
32
 As 19 and 20 significantly inhibit the 
tubulin assembly, we analyzed their effect on the cellular microtubule network by 
immunocytochemistry. Human cervical cancer cells were treated with the compounds at 5 
µM concentrations for 24 h and the cells were stained with antitubulin antibody.  As 
expected, treatment by these compounds disrupted microtubule organization and cells 
exemplify a typical rounded phenotype, which is a hallmark of arrest at mitosis (Figure 2.4).  
G2/M:33.25
G2/M:76.44
%
G2/M:73.77
G2/M:82.04
Control 
 20 
17 
19 
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Figure 2.4 Effect of 19 and 20 on microtubules and nuclear condensation of HeLa cells 
treated with 19 and 20 at 5 μM concentrations.  
2.2.6 Effect of compounds on polymerized vs soluble tubulin in cells 
                 Microtubule depolymerization agents disrupt the cellular tubulin protein levels by 
increasing the fraction of free tubulin.
33-34
 Since the compounds (19 and 20) efficiently arrest 
cells at G2/M phase and inhibit tubulin polymerization, it was considered of interest to 
analyze the effect of these compounds on intracellular tubulin. To examine this, HeLa cells 
were treated with compounds 19 and 20 at 5 µM concentrations for 24 h. Subsequently, cells 
were permeabilized, soluble and polymerized fractions of tubulin were collected. The DMSO 
treated cells showed equal amounts of tubulin in both the fractions indicating normal 
equilibrium among free and polymerized tubulin. In contrast, podophyllotoxin, 19 and 20 
treated cells showed tubulin in the soluble fraction. In comparison, paclitaxel a microtubule 
polymerization agent showed more amount of tubulin in the polymerized fraction. Therefore, 
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these results suggest that 19 and 20 robustly inhibit tubulin polymerization (in vitro) by 
increasing the soluble fraction of cellular tubulin (Figure 2.5). 
 
Figure 2.5. Distribution of tubulin in polymerized vs soluble fractions as analyzed by 
immunobloting in 19 and 20 treated HeLa cells. 
2.3 Conclusion  
 In summary, a library of new heterocyclic compounds, 4-aza-2,3-
dihydropyridophenanthroline derivatives (12-31) were synthesized by a straightforward one-
step multicomponent synthesis, which involves simple isolation of the products by filtration 
and requires no further purification. These new compounds exhibited remarkable anti-
proliferative activities on different cancer cell lines, which are comparable to that of 
podophyllotoxin and etoposide. Compounds 19 and 20 showed potent inhibition of the 
tubulin polymerization and arrested the cells at G2/M phase of the cell cycle in HeLa treated 
cancer cells. Moreover, these compounds cause disruption of microtubule network and 
accumulated tubulin in the soluble fraction in a manner similar to podophyllotoxin. The ease 
of synthesis and encouraging biological activities make these dihydropyridophenanthroline 
derivatives as promising leads in the development of anticancer agents. 
2.4 Experimental section 
All aldehydes, tetronic acid and 1,10 phenanthroline amine were purchased from commercial 
sources and used without purification. Reactions were monitored by TLC, performed on 
silica gel glass plates containing 60 F-254, and visualization on TLC was accomplished with 
P S 
Paclitaxel 
P P P P S S S S 
Control 1 19 20 
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UV light or iodine indicator. 
1
H and 
13
C NMR spectra were recorded on INOVA (400 MHz) 
or Gemini Varian-VXR-unity (200 MHz) or Bruker UXNMR/XWIN-NMR (300 MHz) 
instruments, Chemical shifts (δ) are reported in ppm downfield from internal TMS standard. 
ESI spectra were recorded on Micro mass, Quattro LC using ESI+ software with capillary 
voltage 3.98 kV and ESI mode positive ion trap detector. High-resolution mass spectra 
(HRMS) were recorded on QSTAR XL Hybrid MS/MS mass spectrometer. Melting points 
were determined with an electro thermal melting point apparatus, and are uncorrected. All the 
synthesized compounds were obtained as racemic mixtures. All the compounds were 
synthesized following the reported protocol.
16
 
13-(4-Flurophenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-12(9H)-one  
(12)  
A mixture of 1, 10 phenanthroline amine (9, 98 mg, 0.5 mmol), tetronic acid (10, 50 mg, 0.5 
mmol) and 4-flurobenzaldehyde (11a, 62 mg, 0.5 mmol) in EtOH (10 mL) was refluxed for 3 
h. After the completion of the reaction, the reaction mixture was allowed to cool to room 
temperature and the precipitated product was collected by vacuum filtration and washed with 
EtOH (3 mL), then recrystallized from ethanol to afford pure compound 12 as a white solid in 
161 mg, 84.7% yield. Mp: 224–226 oC.; 1H NMR (300 MHz, CDCl3+DMSO-d6) δ 9.1 (d, 
1H, J = 3.3 Hz), 8.88 (d,1H, J = 7.9 Hz), 8.71 (d, 1H, J = 3.1 Hz), 7.83 (dd, 1H, J = 8.4, 4.2 
Hz), 7.55– 7.46 (m, 2H), 6.81–6.74 (m, 2H), 6.31–6.24 (m, 2H), 5.16 (s, 1H), 4.55 (d, 1H, J = 
8.2 Hz), 4.24 (d, 1H, J = 8.3 Hz). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) δ 174.6, 149.9, 
145.5, 145.1, 140.7, 139.6, 136.1, 131.5, 130.1, 129.5, 128.9, 125.3, 123.7, 122.9, 120.7, 
116.8, 103.5, 81.7, 74.8, 34.3.; MS (ESI): 384 [M+H]
+
; HRMS (ESI) calcd for C23H15FN3O2 
[M+H]
+
 384.11428; found: 384.11636. 
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13-(3-Chlorophenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-12(9H)-
one (13) 
This compound 13 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) with 3-chlorobenzaldehyde (11b, 70 mg, 0.5 mmol) to afford pure 
compound 13 as a brown solid in 173 mg, 87% yield. Mp: 257–261 oC.; 1H NMR (300 MHz, 
DMSO-d6) δ 9.10 (d, 1H, J = 3.99 Hz), 8.90 (d, 1H, J = 8.99 Hz), 8.70 (d, 1H, J = 3.99 Hz), 
7.93 (d, 1H, J = 8.99 Hz), 7.83 (dd, 1H, J = 7.99, 3.99 Hz), 7.57 (s, 1H), 7.51 (s, 1H), 7.34-
7.21 (m, 3H), 5.02 (s, 1H), 4.54 (d, 1H, J = 7.99 Hz), 4.19 (d, 1H, J = 7.99 Hz). 
13
C NMR (75 
MHz, DMSO-d6) δ 175.1, 153.4, 151.1, 149.8, 144.3, 142.2, 141.7, 136.9, 135.5, 132.1, 
131.7, 130.3, 127.8, 126.4, 124.0, 123.4, 122.2, 118.9, 117.2, 116.3, 101.3, 68.3, 31.2. MS 
(ESI): 418 [M+H+NH4]
+
; HRMS (ESI) calcd for C23H19O2N4Cl [M+H+NH4]
+
 418.11911; 
found: 418.09508 
13-(4-Methoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-12(9H)-
one (14)  
This compound 14 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 4-methoxybenzaldehyde (11c, 68 mg, 0.5 mmol) to afford pure 
compound 14 as a white solid in 179 mg, 90.6% yield. Mp: 255 – 258 oC.; 1H NMR (500 
MHz, DMSO-d6) δ 9.08 (d, 1H, J = 3.4 Hz), 8.89 (d, 1H, J = 8.3 Hz), 8.70 (d, 1H, J = 3.0 
Hz), 7.84 (dd, 1H, J = 8.4, 4.2 Hz), 7.64 (d, 1H, J = 7.6 Hz), 7.52 (t, J = 6.2 Hz, 1H), 6.98 (d, 
2H, J = 8.9 Hz), 6.70 (d, 2H, J = 8.9 Hz), 5.25 (s, 1H), 4.54 (d, J = 8.3 Hz, 1H), 4.20 (d, J = 
8.3 Hz, 1H), 3.93 (s, 3H). 
13
C NMR (75 MHz, DMSO) δ 175.2, 153.3, 150.7, 146.2, 145.4, 
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141.5, 136.5, 131.2, 130.8, 129.6, 128.7, 124.0, 123.2, 121.6, 117.7, 112.4, 104.8, 82.7, 75.4, 
56.0, 31.2. MS (ESI): 396 [M+H]+; HRMS (ESI) calcd for C24H18N3O3 [M+H]
+
 396.13624; 
found: 396.13427 
13-(4-Trifluromethylphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-
12(9H)-one  (15)  
This compound 15 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 4-trifluromethyl benzaldehyde (11d, 87 mg, 0.5 mmol) to afford 
pure compound 15 as a brown solid in 169 mg, 78% yield. Mp: 278–281 oC.; 1H NMR (300 
MHz, CDCl3) δ 8.75 (s, 1H), 8.63 (s, 1H), 8.00 (s, 1H), 7.92 (s, 1H), 7.52–7.46 (m, 2H), 
7.45–7.40 (m, 2H), 7.29 (d, J = 11.3 Hz, 2H), 5.21–5.12 (m, 2H), 4.85 (s, 1H). MS (ESI): 434 
[M+H]+ & 452 [M+H2O+H]
+
; HRMS (ESI) calcd for C24H17O3N3F3 [M+H2O+H]
+
 
452.12165; found: 452.12089 
13-(3-4-Dimethoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-
12(9H)-one (16)  
This compound 16 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 3,4-methoxybenzaldehyde (11e, 83 mg, 0.5 mmol) to afford pure 
compound 16 as a light brown solid in 181 mg, 85% yield. Mp: 254–258 oC.; 1H NMR (300 
MHz, CDCl3+DMSO-d6) δ 9.12 (d, 1H, J = 3.39 Hz, 1H), 8.9 (d, 1H, J = 8.26 Hz), 8.73 (d, 
1H, J = 3.2 Hz), 7.86 (d, J = 8.41 Hz), 7.59-7.45 (m, 2H), 7.24 (s, 1H), 6.85 - 6.74 (m, 2H), 
5.26 (s, 1H), 4.57 (d, J = 8.24 Hz, 1H), 4.26 (d, J = 8.24 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H). 
13C NMR (75 MHz, DMSO) δ 175.5, 153.6, 151.2, 150.5, 147.1, 145.9, 141.1, 136.5, 131.6, 
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130.8, 130.3, 128.9, 124.1, 123.4, 121.6, 117.6, 112.2, 111.5, 104.3, 82.5, 75.3, 56.4, 55.5, 
30.4. MS (ESI): 426 [M+H]+ & 444 [M+H2O+H]
+
; HRMS (ESI) calcd for C25H22O5N3 
[M+H2O+H]
+
 444.15540; found: 444.15542 
13-(2,5-Dimethoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-
12(9H)-one (17)  
This compound 17 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2,5-dimethoxybenzaldehyde (11e, 83 mg, 0.5 mmol) to afford 
pure compound 17 as a brown solid in 176 mg, 82.8% yield. Mp: 257–259 oC.; 1H NMR (300 
MHz, CDCl3+DMSO-d6) δ 9.08 (d, 1H, J = 3.4 Hz), 8.89 (d, 1H, J = 8.3 Hz), 8.70 (d, 1H, J = 
3.0 Hz), 7.84 (dd, 1H, J = 8.4, 4.2 Hz), 7.57-7.46 (m, 2H), 7.12 (s, 1H), 6.80 - 6.70 (m, 2H), 
5.25 (s, 1H), 4.54 (d, 1H, J = 8.3 Hz), 4.20 (t, 1H, J = 8.3 Hz), 3.93 (s, 3H), 3.87 (s, 3H). 
13
C 
NMR (75 MHz, DMSO) δ 175.0, 153.0, 150.6, 150.0, 145.9, 145.6, 141.4, 136.3, 131.0, 
130.5, 129.9, 128.8, 123.9, 123.1, 121.0, 117.4, 111.7, 111.1, 104.4, 82.3, 75.0, 56.5, 55.3, 
30.4. MS (ESI): 426 [M+H]
+
  HRMS (ESI) calcd for C25H20O4N3 [M+H]
+
 426.14483; found: 
426.14560. 
13-(3-Fluro-4-methoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-
f][1,7]phenanthrolin-12(9H)-one (18)  
This compound 18 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 3-flouro-4-methoxybenzaldehyde (11g, 77 mg, 0.5 mmol) to 
afford pure compound 18 as a brown solid in 166 mg, 80% yield. Mp: 265–269 oC.; 1H NMR 
(500 MHz, DMSO-d6) δ 9.1 (d, 1H,  J = 3.2 Hz), 8.88 (d, 1H,  J = 8.12 Hz), 8.71 (d, 1H, J = 
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3.1 Hz), 7.83 (d, 1H, J = 7.92 Hz), 7.55–7.48 (m, 2H), 7.19 (s 1H), 6.92 (d, 1H, J = 7.98 Hz), 
6.81 (d, 1H, J = 7.9 Hz), 5.16 (s, 1H), 4.55 (d, 1H, J = 8.2 Hz), 4.24 (d, 1H, J = 8.3 Hz), 3.87 
(s, 3H).
13
C NMR (75 MHz, DMSO-d6) δ 175.1, 156.4, 155.5, 153.1, 150.3, 146.7, 145.9, 
141.4, 136.7, 130.6, 129.5, 128.8, 124.2, 123.3, 121.9, 117.5, 116.7, 116.2, 112.7, 103.4, 
74.8, 56.0, 31.1. MS (ESI): 414 [M+H]
+
 & 432 [M+NH4+H]
+
; HRMS (ESI) calcd for 
C24H21O3N4F [M+NH4+H]
+
 432.15922; found: 432.13576. 
13-(2-Fluro-5-methoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-
f][1,7]phenanthrolin- 12(9H)-one  (19)  
This compound 19 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2-fluoro-5-methoxybenzaldehyde (11h, 77 mg, 0.5 mmol) to 
afford pure compound 19 as a brown solid in 177 mg, 85% yield. Mp: 269–272 oC.; 1H NMR 
(300 MHz, CDCl3+DMSO-d6) δ 9.1 (d, 1H,  J = 3.3 Hz), 8.88 (d,1H,  J = 7.9 Hz), 8.71 (d, 
1H, J = 3.1 Hz), 7.83 (dd, 1H, J = 8.4, 4.2 Hz), 7.46–7.55 (m, 2H), 7.21 (s 1H), 6.88–6.79 (m, 
2H), 5.16 (s, 1H), 4.55 (d, 1H, J = 8.2 Hz), 4.24 (d, 1H, J = 8.3 Hz), 3.87 (s, 3H). 
13
C NMR 
(75 MHz, DMSO-d6) δ 174.7, 156.1, 155.4, 153.0, 150.2, 146.2, 145.8, 141.6, 136.5, 130.5, 
129.4, 128.5, 124.0, 123.1, 120.9, 117.2, 116.3, 116.0, 112.5, 102.8, 74.9, 55.6, 48.8, 30.0. 
MS (ESI): 414 [M+H]
+
 & 432 [M+H2O+H]
+
; HRMS (ESI) calcd for C24H19O4N3F 
[M+H2O+H]+ 432.13541; found: 432.13482 
13-(3,4-Diflurophenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-12 
(9H)-one (20)  
This compound 20 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
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(10, 50 mg, 0.5 mmol) and 3,4-diflourobenzaldehyde (11i, 71 mg, 0.5 mmol) to afford pure 
compound 20 as a white solid in 180 mg, 89.7% yield. Mp: 263–266 oC.; 1H NMR (300 
MHz, CDCl3+DMSO-d6) δ 9.11 (d, 1H, J = 4.15 Hz), 8.91 (d, 1H, J = 8.12 Hz), 8.73 (d, 1H, 
J = 3.39 Hz) 7.98 (d, 1H, J = 7.74 Hz), 7.59 (m, 1H), 7.52 (t, 1H, J = 8.49 Hz), 7.21-7.30 (m, 
2H), 6.19 (s, 1H), 5.06 (s, 1H), 4.61 (d, 1H, J = 8.49 Hz), 4.21 (d, 1H, J = 8.49 Hz). 
13
C NMR 
(75 MHz, CDCl3+DMSO-d6) δ 174.2, 149.7, 145.3, 144.9, 140.5, 139.8, 135.7, 131.3, 130.3, 
128.4, 125.2, 123.5, 122.8, 120.6, 117.6, 117.4, 117.1, 116.9, 103.5, 81.9, 74.5, 35.5. MS 
(ESI): 402 [M+H]+HRMS (ESI) calcd for C23H14O2N3F2 [M+H]
+
 402.10486; found: 
402.10516 
13-(3-Chloro-4-hydroxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin-12 (9H)-one (21)  
This compound 21 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 3-chloro-4-hydroxybenzaldehyde (11j, 78 mg, 0.5 mmol) to 
afford pure compound 21 as a white solid in 188 mg, 89.7% yield. Mp: 296–298 oC.; 1H 
NMR (300 MHz, CDCl3+DMSO-d6) δ 10.2 (s, 1H), 9.08 (d, 1H, J = 3.3 Hz), 8.9 (d, 1H, J = 
8.4 Hz), 8.71 (d, 1H, J = 3.1 Hz), 7.81 (d, 1H, J = 8.4 Hz), 7.49–7.54 (m, 2H), 6.93 - 7.01 (m, 
2H),  6.12 (s, 1H), 5.21 (s, 1H), 4.57 (d, 1H, J = 8.49 Hz), 4.26 (d, 1H, J = 8.30 Hz). 
13
C 
NMR (75 MHz, DMSO-d6) δ 190.4, 158.7, 150.7, 149.6, 144.1, 142.4, 141.6, 136.8, 135.2, 
131.9, 131.6, 130.0, 127.6, 126.2, 123.9, 123.5, 122.1, 118.8, 116.8, 116.2, 100.6, 67.7, 
31.40. MS (ESI): 416 [M+H]
+
 HRMS (ESI) calcd for C23H15O3N3Cl [M+H]
+
 416.07965; 
found: 416.08025 
Chapter-II 
 
104 | P a g e  
 
13-(3-Bromo-4-hydroxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin-12(9H)-one (22)  
This compound 22 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 3-bromo-4-hydroxybenzaldehyde (11k, 100 mg, 0.5 mmol) to 
afford pure compound 22 as a white solid in 206 mg, 90% yield. Mp: 305-308 
o
C.; 
1
H NMR 
(300 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.09 (d, 1H, J = 3.3 Hz), 8.77 (m, 1H), 8.70 (d, 1H, J 
= 8.49 Hz), 7.74 - 7.83 (m, 1H), 7.57-7.47 (m, 2H), 7.11 (d, 1H, J = 8.3 Hz), 6. 91 (s, 1H), 
6.85 (d, 1H, J = 8.4 Hz), 5.19 (s, 1H), 4.52 (d, 1H, J = 8.26 Hz), 4.26 (d, 1H, J = 8.26 Hz). 
13
C NMR (75 MHz, DMSO-d6) δ 190.1, 159.6, 158.5, 158.0, 149.8, 145.7, 140.9, 138.7, 
138.1, 134.8, 133.2, 132.2, 130.4, 129.9, 129.5, 124.9, 122.4, 116.4, 109.9, 99.4, 74.5, 30.1. 
MS (ESI): 460 [M+H]
+
; HRMS (ESI) calcd for C23H15O3N3Br [M+H]
+
 460.02915; found: 
460.03062 
13-(2-Hydroxy-5-chlorophenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-
f][1,7]phenanthrolin  -12(9H)-one (23)  
This compound 23 was prepared following the method described for the preparation of the 
compound 12a, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2-hydroxy-5-chlorobenzaldehyde (11l, 78 mg, 0.5 mmol) to 
afford pure compound 23 as a brown solid in 179 mg, 86% yield. Mp: 294–296 oC.; 1H NMR 
(300 MHz, CDCl3+DMSO-d6) δ 10.3 (s, 1H), 9.07 (d, 1H, J = 3.4 Hz), 8.88 (d, 1H, J = 8.4 
Hz), 8.69 (d, 1H, J = 3.0 Hz), 7.81 (dd, 1H, J = 8.4, 4.2 Hz), 7.50 – 7.46 (m, 2H), 7.00 (dd, 
1H, J = 8.49, 2.45 Hz), 6.92 (d, 1H, J = 8.6 Hz),  6.12 (s, 1H), 5.2 (s, 1H), 4.54 (d, 1H, J = 
8.3 Hz), 4.2 (d, 1H, J = 8.3 Hz).
 13
C NMR (75 MHz, DMSO-d6) δ 174.4, 153.1, 149.6, 145.7, 
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145.3, 141.1, 135.8, 130.0, 129.0, 128.2, 127.2, 123.5, 122.6, 122.1, 120.5, 116.5, 103.6, 
81.9, 74.5, 47.5, 29.9. MS (ESI): 416 [M+H]+ & 434 [M+H2O+H]
+
HRMS (ESI) calcd for 
C23H17O4N3Cl [M+H2O+H]
+
 434.09021; found: 434.09047  
13-(2-Hydroxy-5-bromophenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin -12(9H)-one (24)  
This compound 24 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2-hydroxy-5-bromobenzaldehyde (11m, 100 mg, 0.5 mmol) to 
afford pure compound 24 as a white solid in 198 mg, 86% yield. Mp: 295–298 oC.; 1H NMR 
(500 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.09 (dd, 1H, J = 4.3, 1.3 Hz), 8.88 (dd, 1H, J = 8.4, 
1.3 Hz ), 8.70 (dd, 1H, J = 4.3, 1.3 Hz), 7.83 (q, 1H, J = 4.3, 4.1 Hz), 7.55-7.48 (m, 2H),  
7.14 (dd, 1H, J = 8.4, 2.6 Hz), 6.95 (s, 1H), 6.88 (d, 1H, J = 8.6 Hz), 5.20 (s, 1H), 4.55 (d, 
1H, J = 8.3 Hz), 4.27 (d, 1H, J = 8.3 Hz). 
13
C NMR (75 MHz, DMSO-d6) δ 174.9, 154.1, 
150.1, 146.1, 145.7, 141.5, 136.3, 132.2, 130.9, 130.6, 130.5, 129.6, 128.7, 124.0, 123.1, 
120.9, 117.6, 110.3, 104.0, 82.3, 74.9, 47.9, 30.3. MS (ESI): 460 [M+H]
+
. 
13-(2-Hydroxy-5-methylphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin-12(9H)-one (25)  
This compound 25 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2-hydroxy-5-methylbenzaldehyde (11n, 68 mg, 0.5 mmol) to 
afford pure compound 25 as a brown solid in 166 mg, 84% yield. Mp: 266–269 oC.; 1H NMR 
(300 MHz, DMSO-d6) δ 10.29 (s, 1H), 9.12 (d, 1H, J = 3.3 Hz), 8.95 (d, 1H, J = 8.83 Hz), 
8.71 (d, 1H, J = 4.4 Hz), 7.82-7.76 (m, 1H), 7.51–7.46 (m, 2H), 7.31 (s, 1H), 6.94–6.82 (m, 
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2H), 5.34 (s, 1H), 4.56 (d, 1H, J = 8.83 Hz), 4.14 (d, 1H, J = 8.83 Hz), 2.49 (s, 3H). MS 
(ESI): 396 [M+H]
+
 HRMS (ESI) calcd for C24H18O3N3 [M+H]
+
 396.13427; found: 
396.13429. 
13-(2-Hydroxy-3-methylphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin-12(9H)-one (26)  
This compound 26 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2-hydroxy-3-methylbenzaldehyde (11o, 68 mg, 0.5 mmol) to 
afford pure compound 26 as a brown solid in 174 mg, 88% yield. Mp: 261–264 oC.; 1H NMR 
(300 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.11 (d, 1H, J = 3.42 Hz), 8.92 (d, 1H, J = 8.79 Hz), 
8.70 (d, 1H, J = 4.2 Hz), 7.83 (d, 1H, J = 8.46 Hz), 7.56–7.48 (m, 2H), 7.30 (t, 1H, J = 6.8 
Hz), 7.04–6.91 (m, 3H), 5.34 (s, 1H), 4.58 (d, 1H, J = 8.24 Hz), 4.19 (d, 1H, J = 8.24 Hz), 
2.51 (s, 3H). MS (ESI): 396 [M+H]
+
.  
13-(2-Hydroxy-4-methoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin-12(9H)-one (27)  
This compound 27 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2-hydroxy-4-methoxybenzaldehyde (11p, 76 mg, 0.5 mmol) to 
afford pure compound 27 as a white solid in 177 mg, 89% yield. Mp: 258–263 oC.; 1H NMR 
(300 MHz, CDCl3+DMSO-d6) δ 10.29 (s, 1H), 9.10 (d, 1H, J = 3.39 Hz), 8.89 (d, 1H, J = 
8.23 Hz), 8.71 (d, 1H, J = 3.21 Hz), 7.83 (dd, 1H, J = 8.4, 4.2 Hz), 7.59–7.48 (m, 2H), 6.71–
6.59 (m, 3H), 5.19 (s, 1H), 4.56 (d, 1H, J = 8.3 Hz), 4.21 (d, 1H, J = 8.3 Hz). 
13
C NMR (75 
MHz, DMSO-d6) δ 188.9, 158.4, 153.2, 151.1, 149.7, 146.8, 143.6, 138.9, 132.3, 131.5, 
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127.4, 123.2, 121.1, 119.3, 113.7, 111.2, 105.9, 101.8, 77.4, 56.0, 31.3. MS (ESI): 412 
[M+H]
+ 
HRMS (ESI) calcd for C24H18N3O4 [M+H]
+
 412.12996; found: 412.13102. 
13-(2,3,4-Trimethoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-
12(9H)-one (28)  
This compound 28 was prepared following the method described for the preparation of the 
compound 12a, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 2,3,4-trimethoxybenzaldehyde (11q, 98 mg, 0.5 mmol) to afford 
pure compound 28 as a brown in 183 mg, 80% yield. Mp: 249–251 oC.; 1H NMR (300 MHz, 
CDCl3+DMSO-d6) δ 9.06 (d, J = 3.4 Hz, 1H), 8.87 (d, J = 8.0 Hz, 1H), 8.67 (d, J = 3.0 Hz, 
1H), 7.81 (dd, J = 8.4, 4.3 Hz, 1H), 7.55–7.39 (m, 2H), 6.44 (s, 1H), 6.04 (s, 1H), 5.19 (s, 
1H), 4.54 (d, J = 8.3 Hz, 1H), 4.24 (d, J = 8.3 Hz, 1H), 4.05 (s, 3H), 3.80 (s, 3H), 3.64 (s, 
3H). 
13
C NMR (75 MHz, DMSO-d6) δ 175.1, 152.6, 150.7, 150.0, 146.1, 145.6, 141.6, 136.1, 
130.4, 129.8, 128.9, 127.8, 124.5, 123.8, 123.0, 121.0, 107.6, 104.8, 82.3, 75.0, 61.5, 60.8, 
56.0, 49.4, 30.4. MS (ESI): 456 [M+H]
+
 & 474 [M+H2O+H]
+
 HRMS (ESI) calcd for 
C26H24O6N3 [M+H2O+H]
+
 474.16596; found: 474.16506. 
13-(3-4-5-Trimethoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-
12(9H)-one (29)  
This compound 29 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 3,4,5-trimethoxybenzaldehyde (11r, 98 mg, 0.5 mmol) to afford 
pure compound 29 as a brown solid in 196 mg, 86% yield. Mp: 255–258 oC.; 1H NMR (300 
MHz, CDCl3+DMSO-d6) δ 9.13 (d, 1H, J = 3.39 Hz), 8.94 (d, 1H, J = 7.55 Hz), 8.74 (d, 1H, 
J = 3.21 Hz), 8.08 (d, 1H, J = 8.49 Hz), 7.58-7.50 (m, 2H), 6.6 (s, 2H), 5.10 (s, 1H), 4.54 (d, 
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J = 8.3 Hz, 1H), 4.24 (d, J = 8.24 Hz, 1H), 3.97 (s, 3H), 3.89 (s, 6H). 
13
C NMR (75 MHz, 
DMSO-d6) δ 175.4, 153.1, 152.7, 150.3, 146.8, 145.7, 141.9, 136.8, 130.5, 129.9, 128.4, 
127.9, 124.9, 123.9, 123.3, 121.1, 108.2, 103.9, 82.3, 75.0, 60.8, 56.0, 31.2. MS (ESI): 456 
[M+H]
+
 HRMS (ESI) calcd for C26H22O5N3 [M+H]
+
 456.15540; found: 456.15587. 
13-(3,4,5-Trifluorophenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7]phenanthrolin-
12(9H)-one (30)  
This compound 30 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 3,4,5-triflourobenzaldehyde (11s, 80 mg, 0.5 mmol) to afford pure 
compound 30 as a white solid in 189 mg, 90% yield. Mp: 257–262 oC.; 1H NMR (300 MHz, 
CDCl3+DMSO-d6) δ 9.09 (d, 1H, J = 4.18 Hz ), 8.90 (d, 1H, J = 8.23 Hz), 8.76 (d,  1H, J = 
3.41 Hz) 7.96–7.85 (m, 1H), 7.59–7.48 (m, 2H), 6.88 (s, 2H), 4.98 (s, 1H), 4.72 (d, 1H, J = 
8.3 Hz), 4.30 (d, 1H, J = 8.3 Hz). MS (ESI): 420 [M+H]
+
; HRMS (ESI) calcd for 
C23H13F3N3O2 [M+H]
+
 420.09598; found: 420.09632. 
13-(4-Hydroxy-3,5-dimethoxyphenyl)-10,13-dihydrofuro[3,4-b]pyrido[3,2-f][1,7] 
phenanthrolin-12(9H)-one (31)   
This compound 31 was prepared following the method described for the preparation of the 
compound 12, employing 1,10-Phenanthroline amine (9,  98 mg, 0.5 mmol), tetronic acid 
(10, 50 mg, 0.5 mmol) and 4-hydroxy-3,5-dimethoxybenzaldehyde (11t, 91 mg, 0.5 mmol) to 
afford pure compound 31 as a brown solid in 193 mg, 87.5% yield. Mp: 253–255 oC.; 1H 
NMR (300 MHz, CDCl3+DMSO-d6) δ 9.11 (d, J = 3.37 Hz, 1H), 8.90 (d, J = 7.55 Hz, 1H), 
8.67–8.57 (m, 2H), 7.53-7.46 (m, 2H), 6.34 (s, 2H), 4.91 (s, 1H), 4.71 (s, 1H), 4.50 (d, J = 
8.24 Hz, 1H), 4.27 (d, J = 8.3 Hz, 1H),  3.87 (s, 6H). 
13
C NMR (75 MHz, DMSO-d6) δ 188.4, 
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159.1, 150.2, 149.3, 147.0, 143.2, 139.1, 132.1, 131.0, 127.1, 123.5, 120.4, 113.7, 110.4, 
105.8, 101.6, 78.3, 56.0, 55.3, 31.4. MS (ESI): 442 [M+H]
+ 
HRMS (ESI) calcd for 
C25H20O5N3 [M+H]
+
 442.13975; found: 442.14020. 
Cell cultures, maintenance and anti-proliferative evaluation 
     The cell lines, MIA PaCa-2 (pancreatic), MCF-7 (breast), HeLa (cervical) which were 
used in this study were procured from American Type Culture Collection (ATCC), United 
States. The synthesized test compounds were evaluated for their in vitro anti-proliferative 
activity in these three human cancer cell lines. A protocol of 48 h continuous drug exposure 
was used, and a SRB cell proliferation assay was used to estimate cell viability or growth. All 
the cell lines were grown in Dulbecco's modified Eagle's medium (containing 10% FBS in a 
humidified atmosphere of 5% CO2 at 37 °C). Cells were trypsinized when sub-confluent from 
T25 flasks/60 mm dishes and seeded in 96-well plates in 100 μL aliquots at plating densities 
depending on the doubling time of individual cell lines. The micro titer plates were incubated 
at 37 °C, 5% CO2, 95% air, and 100% relative humidity for 24 h prior to addition of 
experimental drugs and were incubated for 48 h with different doses (0.01, 0.1, 1, 100, 1000 
µM) of prepared derivatives. After 48 h incubation at 37 °C, cell monolayers were fixed by 
the addition of 10% (wt/vol) cold trichloroacetic acid and incubated at 4 °C for 1h and  were 
then stained with 0.057% SRB dissolved in 1% acetic acid for 30 min at room temperature. 
Unbound SRB was washed with 1% acetic acid. The protein–bound dye was dissolved in 
10mM Tris base solution for OD determination at 510 nm using a micro plate reader 
(Enspire, Perkin Elmer, USA). Using the seven absorbance measurements [time zero, (Tz), 
control growth, (C), and test growth in the presence of drug at the five concentration levels 
(Ti)], the percentage growth was calculated at each of the drug concentrations levels. 
Percentage growth inhibition was calculated as:  
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         for concentrations for which Ti>/=Tz 
 
     
  
      for concentrations for which Ti<Tz.  
Growth inhibition of 50 % (GI50) was calculated from (
     
  
)         which the drug 
concentration resulting in a 50% reduction in the net protein increase (as measured by SRB 
staining) in control cells during the drug incubation. 
30
 
Tubulin polymerization assay 
     An in vitro assay for monitoring the time-dependent polymerization of tubulin to 
microtubules was performed employing a fluorescence-based tubulin polymerization assay 
kit (BK011, Cytoskeleton, Inc.) according to the manufacturer’s protocol. The reaction 
mixture in a final volume of 10 µL in PEM buffer (80 mM PIPES, 0.5 mM EDTA, 2 mM 
MgCl2, pH 6.9) in 384 well plates contained 2 mg/mL bovine brain tubulin, 10 µM 
fluorescent reporter, 1 mM GTP  in the presence or absence of test compounds (3 µM final 
concentration) at 37
o
C. Tubulin polymerization was followed by monitoring the fluorescence 
enhancement due to the incorporation of a fluorescence reporter into microtubules as 
polymerization proceeds. Fluorescence emission at 420 nm (excitation wavelength is 360 nm) 
was measured for 1 h at 1 min intervals in a multimode plate reader (Tecan M200). 
Podophyllotoxin was used as positive control under similar experimental conditions. To 
determine the IC50 values of the compounds against tubulin polymerization, the compounds 
were pre-incubated with tubulin at varying concentrations (1, 2, 3, 4 and 5 M). Assays were 
performed under similar conditions as employed for polymerization assays as described 
above.
33 
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Analysis of cell cycle  
     Human cervical cancer cell line (HeLa) in 60 mm dishes were incubated for 24 h in the 
presence or absence of test compounds 17, 19 and 20 (5 µM). Cells were harvested with 
Trypsin-EDTA, fixed with ice-cold 70% ethanol at 4 
o
C for 30 min, ethanol was removed by 
centrifugation and cells were stained with 1 mL of DNA staining solution [0.2 mg of 
Propidium Iodide (PI), and 2 mg RNase A] for 30 min as described earlier . The DNA 
contents of 20,000 events were measured by flow cytometer (BD FACSCanto II). Histograms 
were analyzed using FCS express 4 plus.
35 
Immunohistochemistry of tubulin and analysis of nuclear morphology 
 
     HeLa cells were seeded on glass cover slip, incubated for 24 h in the presence or absence 
of test compounds 19 and 20 at a concentration of 5 μM. Cells grown on coverslips were 
fixed in 3.5% formaldehyde
 
in phosphate-buffered saline (150 mM PBS) pH 7.4 for 10 
minutes at
 
room temperature. Cells were permeablized for 6 minutes in PBS containing 0.5%
 
Triton X-100 (Sigma) and 0.05% Tween-20 (Sigma). The permeablized cells were blocked 
with 2% BSA (Sigma)
 
in PBS for 1h. Later, the cells were incubated
 
with primary antibody 
for tubulin from (sigma) at (1:200) diluted in blocking solution for 4h
 
at room temperature. 
Subsequently the antibodies were removed and the cells were
 
washed thrice with PBS. Cells 
were then incubated with
 
FITC labeled anti-mouse
 
secondary antibody (1:500) for 1h at room 
temperature. Cells were washed thrice with PBS and mounted in medium containing DAPI. 
Images were captured using
 
the Olympus confocal microscope and analyzed with Provision 
software.
33 
Western blot analysis of soluble versus polymerized tubulin. 
 
     Cells were seeded in 12-well plates at 1×10
5
 cells per well in complete growth medium. 
Following treatment of cells with respective compounds (19, 20, podophyllotoxin and 
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paclitaxel) for duration of 24 h, cells were washed with PBS and subsequently soluble and 
insoluble tubulin fractions were collected. To collect the soluble tubulin fractions, cells were 
permeablized with 200 µL of pre-warmed lysis buffer [80 mM Pipes-KOH (pH 6.8), 1 mM 
MgCl2, 1 mM EDTA, 0.2% Triton X-100, 10% glycerol, 0.1% protease inhibitor cocktail 
(Sigma-Aldrich)] and incubated for 3 min at 30 
o
C. Lysis buffer was gently removed, and 
mixed with 100 µL of 3×Laemmli’s sample buffer (180 mM Tris-Cl pH 6.8, 6% SDS, 15% 
glycerol, 7.5% -mercaptoethanol and 0.01% bromophenol blue). Samples were immediately 
heated to 95 
o
C for 3 min. To collect the insoluble tubulin fraction, 300 L of 1×Laemmli’s 
sample buffer was added to the remaining cells in each well, and the samples were heated to 
95
o
C for 3 min.  Equal volumes of samples were run on an SDS-10 % polyacrylamide gel and 
were transferred to a nitrocellulose membrane employing semidry transfer at 50 mA for 1h. 
Blots were probed with mouse anti-human α-tubulin diluted 1:2,000 ml (Sigma) and stained 
with rabbit anti-mouse secondary antibody coupled with horseradish peroxidase, diluted 
1:5000 ml (Sigma). Bands were visualized using an enhanced Chemiluminescence protocol 
(Pierce) and radiographic film (Kodak.).
35  
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NMR and Mass spectra of selected compounds 
 
1
H NMR spectrum of compound 17 
 
13
C NMR spectrum of compound 17 
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ESI-MS spectrum of compound 17 
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HRMS spectrum of compound 17 
 
1
H NMR spectrum of compound 19 
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13
C NMR spectrum of compound 19 
     
HRMS spectrum of compound 17 
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1
H NMR spectrum of compound 20 
 
 
13
C NMR spectrum of compound 20 
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HRMS spectrum of compound 20 
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Chapter-III 
Synthesis and biological evaluation of podophyllotoxin 
congeners as tubulin polymerization inhibitors 
 
Abstract 
A series of new podophyllotoxin derivatives containing structural modifications at C-7, C-8, 
and C-9 was synthesized and evaluated for their cytotoxic activity against three human cancer 
cell lines. All the synthesized compounds showed significant growth inhibition with GI50 
values in micro molar levels while some of the compounds were several times more potent 
against MCF-7 and HeLa cell lines than MIA PaCa-2 cell line. Three compounds (12, 15 and 
16) emerged as potent compounds with broad spectrum of cytotoxic activity against all the 
tested cell lines with GI50 values in the range of 0.01-2.1 µM. These compounds induce 
microtubule depolymerisation and arrests cells at the G2/M phase of the cell cycle. Moreover, 
compounds 15 and 16 disrupted microtubule network and accumulated tubulin in the soluble 
fraction in a similar manner to their parent podophyllotoxin scaffold. In addition, structure 
activity relationship studies within the series were also discussed. Molecular docking studies 
of these compounds into the colchicine-binding site of tubulin, revealed possible mode of 
inhibition by these compounds. 
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3.1 Introduction 
      Podophyllotoxin 1, the main component of Podophyllum resin, has long been used as 
cathartic, antirheumatic, antiviral and antitumor agent.
1
 Inspite of its initial potential as an 
anticancer agent, its high toxicity and severe adverse effects
2
 has limited its application as a 
drug in cancer chemotherapy, making this cyclolignan a lead compound for drug design in 
the search for improved pharmacological profiles. Extensive efforts on structural 
modification of podophyllotoxin has led to the clinical introduction of semisynthetic 
derivatives like etoposide (2), teniposide (3) and etopophos (4) for the treatment of a variety 
of malignancies including lung and testicular carcinoma, lymphoma, nonlymphocytic 
leukaemia, etc.
3-6
 Despite their wide clinical applications, there are several limitations such as 
poor water solubility, development of drug resistance, metabolic inactivation, and toxic 
effects which has inspired to further search for new effective antitumor agents based on this 
scaffold.
7
 
      Interestingly, podophyllotoxin and these semisynthetic derivatives, substantially differ in 
their mechanism of action. Podophyllotoxin and its related 4′-methoxy congeners inhibits 
tubulin polymerization through interaction at the colchicine binding site, preventing the 
formation of the spindle and arresting cell division in metaphase.
8,9
 Whereas,  4′-
demethylepipodophyllotoxin derivatives (etoposide and its analogues) primarily inhibit DNA 
topoisomerase II, induce a premitotic blockade in late S stage of the cell cycle.
10
 Etoposide 
binds to and stabilizes the DNA-protein complex preventing relegation of the double-
stranded breaks.
11
  
      The core structural features like transfused γ-lactone, fused dioxole ring, and the almost 
orthogonal free-rotating 3,4,5-trimethoxyphenyl fragment are considered essential for 
antitubulin activity of podophyllotoxin derivatives.
12
 Although, literature survey revealed that 
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podophyllic aldehyde (5) and its analogues that lack trans-lactone D-ring, showed significant 
cytotoxicity against various tumor cell lines confirming that the γ-lactone ring is not an 
essential feature for cytotoxicity and antimitotic activity, whereas the presence of an 
electrophilic function at C-7/ C-9 seemed to be important for the cytotoxicity for this type of 
derivatives.
13-14
 Structural activity relationship studies of podophyllic aldehyde revealed that 
the C-8 neighbouring area is favourable for generating structural modification and 
diversification, with the aim of adding extra fragments that would increase receptor site 
occupation and could enhance the affinity and selectivity of interaction of podophyllotoxin 
related lignans with the tubulin protein.
15
 
 
Figure.3.1 Structures of podophyllotoxin (1), etoposide (2), teniposide (3), etopophos (4), 
podophyllic aldehyde (5), nocodazole (6) and target molecules (12-23) 
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      Recently, there has been increasing interest in molecules containing benzimidazole rings 
due to their broad range of pharmacological activities such as antimicrobial,
16
 anti-HIV,
17
 anti 
inflammatory,
18
 antiulcer,
19
 antihypertensive
20
 and anticancer.
21
 Benzimidazoles can easily 
interact with biomolecules of the living systems due to their structural similarity with 
naturally occurring compounds such as indole and purine nuclei, that are present in a number 
of fundamental cellular components as well as bioactive compounds. Benzimidazole 
substituted derivatives like nocodazole (6) are also known as inhibitors of tubulin 
polymerisation and are useful for inhibiting cell proliferation for the treatment of cancer.
22
 
      In view of the above observations and in continuation to previous efforts that were aimed 
to find newer podophyllotoxin based molecules with potential anticancer activities,
23-25
 a 
series new hybrid molecules that comprises of both podophyllotoxin as well as benzimidazole 
ring systems were designed 
 To synthesise large no. of  new hybrid molecules with structural simplification of 
podophyllotoxin 
 To produce potent cytotoxic hybrid molecules better than their individual 
podophyllotoxin and benzimidazole analogues. 
 To establish structure activity relationship of the new hybrid scaffold 
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Scheme 3.1 Synthesis of Podophyllotoxin-benzimidazole hybrid molecules (12-23) 
Reagents and conditions: (a) PDC/CH2Cl2, rt, 2 h; (b) H2SO4/CH3OH, reflux, 2 h; (c) 
NaBH4/CH3OH, rt, 0.5 h; (d) (COCl)2, DMSO, Et3N, CH2Cl2, -55  
o
C, 0.5 h - 0 
o
C, 1h; (e) 
corresponding o-phenylenediamines, sodium metabisulpfite, EtOH, reflux, 2–5 h. 
3.2 Results and discussion 
3.2.1 Chemistry 
      As illustrated in Scheme 3.1, these compounds (12-23) were synthesized using 
podophyllotoxin (1) as the starting matierial.
13
 Briefly, intermediate 9 was prepared from 1 
through successive oxidation with pyridinium dichromate (PDC) and subsequent acid-
catalyzed methanolysis to give the D-ring opened compound (9). Stereo selective reduction 
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of the 7-carbonyl group of compound 9 afforded the dihydroxy compound 10. The swerns 
oxidation of the dihydroxy-ester (10) led to the oxidation of the hydroxyl group at C-9 and 
the elimination of the hydroxyl group at C-7 to afford the unsaturated aldehyde 11. Finally 
the target compounds 12-23 were synthesized by reacting the unsaturated aldehyde with 
appropriate o-phenylenediamine in presence of sodium metabisulfite (oxidant). The structures 
of all target compounds were confirmed by 
1
H NMR, 
13
C NMR, MS and HRMS. 
3.2.2 In vitro anti-proliferative activity 
      All the synthesized podophyllotoxin-benzimidazole conjugates 12-23 were evaluated for 
their antiproliferative activity against the three tumor cell lines: MIA PaCa-2 (pancreatic), 
HeLa (cervical) and MCF-7 (breast carcinoma) employing SRB assay. Podophyllotoxin and 
etoposide were used as the reference standards and the he results obtained are shown in Table 
1. It is observed that, the majority of the tested compounds displayed significant growth 
inhibition on MCF-7 and HeLa cancer cell lines as compared with MIA PaCa-2 cell line. 
With the exception of compounds 17, 18, 22, the tested compounds showed significant 
cytotoxicity, with GI50 values in sub micromolar level, while some of the hybrid compounds 
12, 13, 15, 16, 19 and 20 exhibited potent growth inhibition values in the nano molar range 
close to, or even better than, those of the individual molecules podophyllotoxin, etoposide 
and nocodazole on certain cell lines. However, compound 15 exhibited enhanced activity 
than etoposide and podophyllotoxin against all the three cancer cell lines with GI50 values in 
the range of 0.01- 0.54 µM. 
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Table 3.1. Anti-proliferative activity (
a
GI50 µM) of podophyllotoxin-benzimidazole hybrid 
molecules (12-23). 
Compound 
b
MIA PaCa-2 
c
MCF-7 
d
HeLa 
11 0.73±0.021 0.91±0.01 0.69±0.03 
12 1.2±0.7 0.2±0.01 0.2±0.1 
13 3.9±4.4 0.02±0.01 4.3±6.4 
14 1.3±0.1 2.09±0.2 2.16±1.4 
15 <0.01 0.54±0.4 0.21±0.21 
16 1.6±0.5 2.1±0.3 1.04±0.01 
17 18.1±2.4 3.07±0.4 2.8±0.4 
18 NA 4.8±0.8 5.08±0.5 
19 1.5±2.5 0.16±0.1 3.6±0.6 
20 3.2±2.6 0.58±0.06 19.7±3.4 
21 NA 2.3±0.9 24.2±0.9 
22 3.1±0.2 2.1±0.6 6.4±0.6 
23 2.56±0.2 1.2±1.1 3.8±1.5 
Podophyllotoxin 0.51±0.1 0.31±0.19 0.74±0.23 
Etoposide 1.1±0.32 0.25±0.21 0.62±0.17 
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Nocodazole 0.95±0.013 0.94±0.02 0.81±0.01 
a
50 Growth inhibition and the values are mean of three independent experiments;  
b
pancreatic cancer,
 c
breast cancer, 
d
cervix cancer,  NA = not active. 
        
         Based on the cytotoxicity data, the structure activity relationship (SAR) for these new 
podophyllotoxin congeners (12-23) was examined. The introduction of electron withdrawing 
substituents at 4-position of the benzimidazole ring such as fluoro, chloro and bromo 
improved the activities as exemplified by analogues 13, 14 and 15. However, electron 
releasing groups like methoxy and methyl substituent at 4-position of the benzimidazole ring 
produced compounds 16 and 17 with moderate cytotoxic activities. Moreover, the presence of 
different di substitutions on the phenyl ring of the benzimidazole, such as 3,4-dimethyl (19), 
3,5-dichloro (20), 3-fluoro-4-chloro (21) and 3-bromo-5-trifluoromethyl (22) groups  are 
selectively active on MCF-7 cell lines with GI50 values in the range of 0.16-2.1 µM and 
showed moderate activity towards the other cell lines. It is also observed that the extension of 
ring A to the naphthalene (23) showed selective cytotoxicity on MCF-7 cell lines in nano 
molar range. Finally, it is worth highlighting that the introduction of relatively large and 
bulky substituent like benzimidazole ring at position C-9, these compounds showed 
significant growth inhibition on three tumor cell lines, despite the lack of the γ-lactone ring, 
which is generally considered as an essential structural feature for the cytotoxicity of this 
class of compounds. The significant growth inhibitory activity exhibited by promising 
compounds like 12, 15 and 16 prompted us to evaluate their detailed biological effects. 
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3.2.3 Inhibition of in vitro tubulin polymerization 
      To examine whether these compounds bind to tubulin and inhibit its polymerization, 
representative compounds 12, 15 and 16 were subjected to evaluation by tubulin assembly 
assay. Podophyllotoxin was also evaluated by this assay as a positive control.  To test this, 
varying concentrations of compounds 12, 15 and 16 were incubated with tubulin protein. The 
result indicated that, compound 15 significantly decreased tubulin assembly with IC50 value 
0.86 µM and is comparable to IC50 of podophyllotoxin (1). In contrast, 12 and 16 decreased 
tubulin polymerization with an IC50 of 1.29 µM and 0.91 µM respectively (Table 3.2). These 
results show the rational relationship between the inhibition of tubulin polymerization and the 
corresponding cytotoxic activities. The order of inhibition of tubulin polymerization was 1 > 
15>16> 12. 
Table 3.2 Antitubulin activity of compounds 12, 15 and 16. 
S.No Compound IC50 ( µM) 
1 12 1.29±0.11 
2 15 0.86±0.09 
3 16 0.91±0.13 
4 1 0.83±0.06 
 
3.2.4 Effects of active compounds on cell cycle arrest 
      As the inhibition of tubulin polymerization has been implicated in G2/M phase of the cell 
cycle arrest in various cancer cell lines, 
26 
the effect of compounds 12, 15 and 16 on the cell 
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cycle progression of the HeLa cells was determined by flow cytometric analysis.  HeLa cells 
were treated with 5 µM concentration of compounds for 24 h. As shown in Figure 3.2, 
DMSO treated cells showed predominant G1 phase, with 18.35% of cells in G2/M. In 
contrast, 16 treated cells showed 68.91% cells in G2/M phase, which increased to 73.96% on 
treatment by 15 treatments. However, 12 manifested 56.05% of cells in G2/M phase. Overall, 
these results suggest that these compounds efficiently stall cells at G2/M phase. 
 
Figure 3.2. Induction of HeLa cell cycle G2/M arrest by compounds 12, 15 and 16. The 
percentage of cells in each phase of cell cycle was quantified by flow cytometry 
3.2.5 Effects of 15 and 16 on cellular microtubules and nuclear morphology 
      Microtubule depolymerizing drugs cause improper chromosome separation by inhibiting 
the organization of the mitotic spindle, and predominantly arrest chromosomes in metaphase 
of mitosis.
27
 Therefore to identify the effect of compounds 15 and 16 on tubulin cytoskeleton 
by immunocytochemistry, human cervical cancer (HeLa) cells were treated with the 
compounds at 5 μM concentrations for 24 h and later the cells were stained with antitubulin 
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antibody. It is observed that the tubulin network was severely disrupted in cells treated with 
15 and 16. In contrast, cells treated with DMSO demonstrated a normal and intact tubulin 
organization (Figure 3.3). 
 
Figure 3.3. Effect of 15 and 16 on microtubules and nuclear condensation of HeLa cells 
treated with 15 and 16 for 24 h.  
 
3.2.6 Distribution of soluble versus polymerized tubulin in cell 
      Microtubules are in dynamic equilibrium with tubulin dimers as tubulin is polymerized 
into microtubules and depolymerized as free tubulin and this dynamic equilibrium is targeted 
by microtubule disrupting agents.
28
 Therefore, in order to assess the effect of 15 and 16 on 
the cellular microtubules, we analyzed the levels of soluble and polymerized fractions of 
tubulin in HeLa cells by treatment with compounds 15 and 16 for 24 h. In DMSO treated 
HeLa cells, there was relatively even distribution of the tubulin was found among both the 
fractions. In cells treated with podophyllotoxin, a tubulin depolymerizing agent, a remarkable 
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shift was obtained in tubulin protein, most of the tubulin protein was found in soluble 
fraction. Similarly, 15 treated cells showed a predominant accumulation of tubulin in soluble 
fraction. In comparison, paclitaxel (tubulin polymerizing agent) contained tubulin in the 
polymerized fraction (Figure 3.4). Therefore, these results suggest that 15 and 16 function as 
microtubule-destabilizing agent. 
 
Figure 3.4 Distribution of tubulin in polymerized vs soluble fractions as analysed by 
immunobloting in 15 and 16 treated HeLa cells. 
3.2.7 Molecular docking 
      Molecular docking has been commonly used in rational drug design of many medicinally 
active compounds. Docking is a term used for computational schemes that finds the “best” 
matching between receptor and a ligand. The molecular docking can be defined as, predicting 
the correct bound association of the given atomic coordinates of two molecules.  In this 
various docked conformations are explored to identify the right one with higher affinity to the 
receptors or protein. The sampling procedure is based on genetic algorithm, simulated 
annealing, Monte Carlo simulation, distance geometry, or other miscellaneous methods. 
Various docking programs, such as DOCK, Auto Dock, FlexX and GOLD predict the 
protein-ligand complex structures binding affinities with reasonable accuracy and speed. 
These docking programs has been a focus of attention from many years in virtual database 
screening approaches in which thousands of molecules are docked into the binding pocket of 
the target molecule to identify probable binders. Generally, molecular docking programmes 
are used prior to experimental screening, as powerful computational filters to reduce labour 
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and cost. With increase in the number of “druggable” targets in this postgenomic era, 
molecular docking will certainly continue to play an important role in design of medicinally 
active drugs.
29 
    
      Molecular docking studies in this study were performed using Maestro 9.5 (Schrodinger 
package) 
30
 to validate whether the synthesized compounds have comparable binding mode to 
that of podophyllotoxin for α,β-tubulin. Compounds 12, 15 and 16 exhibiting the most potent 
cytoxicity in all the cell lines tested were docked into the colchicine binding site of tubulin-
podophyllotoxin crystal structure (PDB code: 1SA1). As depicted in Figure 3.5, the 
compounds interacted with the colchicine binding site formed from the αSer178, αThr179, 
βCys241, βLeu242, βLeu248, βAla250, βLys254, βLeu255, βAsn258, βMet259, βAla316, 
βAla317, βLys352, βThr353 and βIle378 residues in a similar manner to that of 
podophyllotoxin. As in the case of podophyllotoxin, the benzodioxole binds into the 
hydrophobic pocket formed by βMet259, βAla316, and βLys352; whereas the 
trimethoxyphenyl ring inserted quasiaxially in the  hydrophobic cavity formed by  βCys241, 
βLeu242, βLeu248, βAla250, βLys254, βLeu255, βAsn258,  βAla317 and βThr353. The 
hydrogen bonding exhibited by the C ring –OH group with αThr179 in podophyllotoxin is 
compensated by that of –NH of the benzimidazole ring in our conjugates. Further, one of the 
oxygens of the trimethoxyphenyl ring formed H-bonding with βCys241. All these 
interactions together contribute to the hypothesis that the synthesized compounds exhibit 
efficient binding into the colchicine binding site on tubulin and thus, the ensuing antimitotic 
activity as in the case of podophyllotoxin. 
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Figure 3.5  Molecular docking of (a) 12 (lime green), (b)15 (magenta), (c)16 (yellow)  into 
the colchicine binding site of tubulin (PDB code: 1SA1). (d) all molecules overlaid with 
podophyllotoxin (in white). α-chain is shown in green and  β-chain in blue. 
 
Table 3.3 Glide scores of compounds 12, 15 and 16 docked into the colchicine binding site of 
tubulin-podophyllotoxin crystal structure (PDB code: 1SA1). 
Compound Glide score 
12 -9.173 
15 -10.503 
16 -9.044 
Podophyllotoxin -9.199 
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3.3 Conclusion 
A series of lactone ring opened podophyllotoxin congeners (12-23) with modifications at 
C-7, C-8, C-9 were synthesized and tested for their cytotoxic activity. These compounds have 
retained the antineoplastic cytotoxicity despite the lack of the γ-lactone ring, which is 
generally considered as an essential structural feature for the cytotoxicity of the 
podophyllotoxin class of compounds. Three compounds 12, 15 and 16 emerged as lead 
molecules with broad spectrum of anticancer activity against all the tested tumor cell lines 
and inhibited the tubulin polymerization, comparable to that of podophyllotoxin. The flow 
cytometric analysis indicated that these compounds induced G2/M cell cycle arrest in HeLa 
treated cells and inhibited tubulin assembly, disrupted microtubules, increased the amount of 
tubulin in soluble fraction as other antitubulin agents. The molecular modelling study on 
tubulin demonstrated that these molecules bind well with the tubulin and are involved in a 
series of interactions with the protein. Thus this study reveals that incorporating certain 
structural fragments that are bioactive by themselves, such as benzimidazole moiety at the C-
9 position of podophyllotoxin scaffold could lead to better anticancer agents.  
3.4 Experimental section 
All chemicals and reagents were obtained from Aldrich (Sigma–Aldrich, St. Louis, MO, 
USA), Lancaster (Alfa Aesar, Johnson Matthey Company, Ward Hill, MA, USA) and were 
used without further purification. Reactions were monitored by TLC, performed on silica gel 
glass plates containing 60 F-254, and visualization on TLC was achieved by UV light or 
iodine indicator. 
1
H and 
13
C NMR spectra were recorded on INOVA (400 MHz) or Gemini 
Varian-VXR-unity (200 MHz) or Bruker UXNMR/XWIN-NMR (300 MHz) instruments 
using CDCl3 or DMSO as solvents. Chemical shifts (δ) are reported in ppm downfield from 
internal TMS standard. ESI spectra were recorded on Micro mass, Quattro LC using ESI
+ 
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software with capillary voltage 3.98 kV and ESI mode positive ion trap detector. Melting 
points were determined with an Electro thermal melting point apparatus, and are uncorrected. 
HRMS spectra were recorded on a Q-TOF6510 spectrograph. 
(5aR,8aR,9R)-9-(3,4,5-Trimethoxyphenyl)-5a,6,8a,9-tetrahydrofuro [3',4':6,7] naphtha 
[2,3-d][1,3]dioxole-5,8-dione (8) 
      PDC (2.0 g, 5.34 mmol) was added to a solution of podophyllotoxin (1, 2 g, 4.83 mmol) 
in dry CH2Cl2 at 0 
0
C and was stirred at rt for 3h. The reaction mixture was quenched and 
diluted with 50 mL CH2Cl2. The organic layer was dried over anhydrous Na2SO4 and 
concentrated in vacuo. The resulting product was purified by column chromatography using 
EtOAc/hexane as eluent to afford pure compound 8 in 1.84 g (92%) yield. Physical and 
spectroscopic data were identical to those reported. Mp ; 177−179 °C [literature, 174 °C].30 
[α]D 
25.6
 = -71.39 ± 57.97 (c 0.91 mg/mL, CHCl3).  
(5R,6R,7R)-Methyl 7-(hydroxymethyl)-8-oxo-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-
tetrahydronaphtho[2,3-d][1,3]dioxole-6-carboxylate (9) 
      To a solution of compound 8 (1.5 g, 3.64 mmol) in methanol was added 4 equivalents of 
H2SO4 at 0 
o
c. The reaction mixture was stirred at reflux for 5 h. Then the solvent was 
removed invacuo, and quenched with sodium bicarbonate, diluted with EtOAc. The organic 
layer was dried over Na2SO4 and evaporated. The residue was purified by column 
chromatography using EtOAc/hexane as eluent to afford pure product in 0.73 g, 89% isolated 
yield of 9 based upon recovered 8.  
Mp. 137-139 
o
C.; [α]D 
26.6
 = -89.34 ± 30.34 (c 1.23 mg/mL, CHCl3).
 1
H NMR (300 MHz, 
CDCl3) δ 7.28 (s, 1H), 7.09 (s, 1H), 6.36 (s, 1H), 6.28 (s, 2H), 5.95 (s, 2H), 4.78 (d, J = 8.1 
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Hz, 1H), 4.05-4.28 (m, 2H), 3.81 (s, 3H), 3.78 (s, 6H), 3.55 (s, 3H), 3.01 (dd, J = 12.0, 5.6 
Hz, 1H), 2.39 (m, 2H). MS (ESI): m/z 468 [M+Na]
+ 
(5R,6R,7R,8R)-Methyl 8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-
5,6,7,8-tetrahydronaphtho[2,3-d][1,3]dioxole-6-carboxylate (10) 
      To a stirred solution of compound 9 (1.0 g, 2.25 mmol) in methanol (20 mL) was added 
NaBH4 (100 mg, 2.7 mmol) at 0 
0
C and the reaction was stirred for 2 h at room temp. The 
reaction mixture was then quenched with saturated aq NH4Cl and diluted with EtOAc (150 
mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under vacuum. 
The resulting crude product was purified by column chromatography using EtOAc/hexane as 
eluent to afford pure product in 66 % yield.  
Mp. 145-149 
o
C.; [α]D 
26.6
 = -114.34 ± 26.59 (c 1.09 mg/mL, CHCl3). 
1
H NMR (500 MHz, 
CDCl3) δ 7.29 (s, 1H), 7.08 (s, 1H), 6.38 (s, 1H), 6.22 (s, 2H), 5.92 (d, J = 0.8 Hz, 2H), 4.78 
(d, J = 8.1 Hz, 1H), 4.31 (d, J = 5.6 Hz, 1H), 4.05 (dd, J = 10.3, 3.6 Hz, 1H), 3.82 (s, 3H), 
3.76 (s, 6H), 3.56 (s, 3H), 3.01 (dd, J = 12.0, 5.6 Hz, 1H), 2.39 (m, 2H). MS (ESI): m/z 469 
[M+Na]
+
. HRMS (ESI) calcd for C23H26O9Na [M+Na]
+
 469.14690; found: 469.14708 
(5R,6R)-Methyl 7-formyl-5-(3,4,5-trimethoxyphenyl)-5,6-dihydronaphtho[2,3-
d][1,3]dioxole-6-carboxylate (11) 
      To a stirred solution of oxalyl chloride (0.24 mL, 2.7 mmol) in dry CH2C12 (5 mL) at -55 
°C, was added DMSO (0.4 mL, 5.6 mmol) drop wise. After 5 min, a solution of 400 mg (0.90 
mmol) of compound 10 in 3 mL of dry CH2C12 was slowly added. The mixture was stirred at 
the same temperature for 30 min, and then triethylamine (1.27 mL, 9.10 mmol) was added 
drop wise. Then, the reaction mixture was warmed to 0 °C and stirred for 1 h, quenched with 
water and extracted with CH2C12 (100 mL). The organic layer was dried over Na2SO4, 
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concentrated in vacuo. The obtained residue was purified by column chromatography using 
EtOAc/hexane as eluent to afford compound 11 in 58 % yield.  
Mp: 154-156°C.; [α]D 
25.7
 = 129.57 ± 38.86 (c 0.94 mg/mL, CHCl3). 
1
H NMR (300 MHz, 
CDCl3) δ 9.61 (s, 1H), 7.37 (s, 1H), 6.89 (s, 1H), 6.62 (s, 1H), 6.46 (s, 2H), 5.95 (d, J = 1.3 
Hz, 1H), 5.94 (d, J = 1.3 Hz, 1H), 4.41 (d, J = 7.1 Hz, 1H), 3.98 (d, J = 7.4 Hz, 1H), 3.87 (s, 
3H), 3.81 (s, 6H), 3.50 (s, 3H). MS (ESI): m/z 427 [M+H]
+
. HRMS (ESI) calcd for C23H23O8 
[M+H]
+
 427.13874; found: 427.13872. 
General Preparation of Compounds 12-23:  
      To a mixture of compound 11 (0.46 mmol) and appropriate o-phenylenediamines (0.46 
mmol) in ethanol was added a solution of Na2S2O5 (770 mg, 4 mmol) in H2O (1.6 mL). The 
resulting mixture was stirred at reflux for 4 h. after completion of reaction; the solution was 
evaporated under reduced pressure to remove ethanol, and partitioned between EtOAc and 
water. The organic layer was dried over Na2SO4, and concentrated in vacuo. The crude 
product was purified by column chromatography using EtOAc/hexane as eluent to afford 
pure compounds 12(a-l) in good yields. 
((5R,6R)-Methyl 7-(1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-5,6-
dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (12) 
White solid, 76% yield. Mp: 161–164 oC.;  [α]D
25
 = 276 ± 32.07  (c 0.99 mg/mL, CHCl3). 
1
H 
NMR (300 MHz, CDCl3) δ 7.51 (dd, J = 6.0, 3.1 Hz, 2H), 7.27 (s, 1H), 7.20 (dd, J = 6.0, 3.1 
Hz, 2H), 6.83(s, 1H), 6.61 (s, 1H), 6.20 (s, 2H), 5.95  (d, J = 1.3 Hz, 1H), 5.94 (d, J = 1.3 Hz, 
1H), 4.57 (d, J = 4.3 Hz, 1H), 4.38 (d, J = 4.4 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 6H), 3.48 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ 172.2, 153.3, 150.9, 148.1, 146.3, 144.1, 139.3, 138.0, 
137.2, 134.8, 129.1, 126.9, 122.9, 114.3, 109.8, 108.5, 106.5, 101.2, 61.0, 56.0, 51.9, 48.7, 
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48.1. MS (ESI): m/z 515 [M+H]
+
. HRMS (ESI) calcd for C29H27O7N2 [M+H]
+
 515.18128; 
found: 515.18064. 
((5R,6R)-Methyl 7-(6-fluoro-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-5,6-
dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (13) 
White solid, 70% yield. Mp: 245–248 oC.; [α]D 
25.1
 = 198 ± 65.01 (c 0.87 mg/mL, CHCl3). 
1
H 
NMR (300 MHz, CDCl3) δ  7.39-7.48 (m, 2H), 7.21 (s, 1H), 6.91-7.02 (m, 2H), 6.61 (s, 1H), 
6.29 (s, 2H), 5.99 (s, 2H),  4.60 (d, J = 4.3 Hz, 1H), 4.00 (d, J = 4.4 Hz, 1H), 3.87 (s, 3H), 
3.80 (s, 6H), 3.46 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ 172.1, 157.9, 153.3, 151.7, 148.1, 
146.9, 144.1, 141.2, 138.2, 137.6, 135.1, 128.8, 126.8, 119.1, 110.7, 109.5, 108.2, 107.8, 
101.8, 101.4, 60.8, 56.3, 52.1, 47.9, 45.7. MS (ESI): m/z 533 [M+H]
+
. HRMS (ESI) calcd for 
C29H26O7N2F [M+H]
+
 533.17186; found: 533.17099 
((5R,6R)-Methyl 7-(6-chloro-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-5,6-
dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (14) 
White solid, 66% yield. Mp: 165–169 oC.; [α]D 
26.6
 = 116.73 ± 35.64 (c 1.40 mg/mL, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ 7.89 (s, 1H), 7.48 (d, J = 7.1 Hz, 1H), 7.29 (d, J = 7.3 Hz, 2H), 
6.91 (s, 1H), 6.76 (s, 1H), 6.28 (s, 2H), 5.95 (s, 2H), 4.69 (d, J = 4.3 Hz, 1H), 4.05 (d, J = 4.5 
Hz, 1H), 3.80 (s, 3H), 3.76 (s, 6H), 3.48 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.8, 153.9, 
151.6, 148.0, 146.4, 139.3, 138.6, 138.1, 137.3, 134.9, 129.2, 128.8, 126.6, 124.6, 118.1, 
111.5, 109.8, 108.8, 106.7, 101.3, 60.9, 56.1, 52.2, 48.8, 47.9. MS (ESI): m/z 549 [M+H]
+
. 
HRMS (ESI) calcd for C29H26O7N2Cl [M+H]
+
 549.14231; found: 549.14188. 
((5R,6R)-Methyl 7-(6-bromo-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-5,6-
dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (15) 
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White solid, 67% yield. Mp: 231–235 oC.; [α]D 
26.6
 = 127.14 ± 84.03 (c 0.78 mg/mL, CHCl3).
 
1
H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H), 7.46-7.51 (m, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.20 
(s, 1H), 6.91 (s, 1H), 6.62 (s, 1H), 6.27 (s, 2H), 6.05 (s, 2H),  4.61 (d, J = 4.7 Hz, 1H), 4.01-
4.07 (m, 1H), 3.89 (s, 3H), 3.81 (s, 6H), 3.48 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.9, 
154.0, 151.6, 148.1, 146.6, 139.9, 138.5, 137.9, 137.4, 135.0, 129.3, 126.6, 125.8, 119.1, 
115.6, 112.3, 109.9, 108.6, 106.5, 101.2, 60.7, 56.3, 52.1, 48.9, 47.6. MS (ESI): m/z 593 
[M+H]
+
. HRMS (ESI) calcd for [M+H]
+
 593.09228; found: 593.09193.
 
((5R,6R)-Methyl 7-(6-methoxy-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-
5,6-dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (16) 
Off white solid, 67% yield. Mp: 249–251 oC.; [α]D 
26.6
 = 31.84 ± 20.96 (c 1.19 mg/mL, 
CHCl3).
 1
H NMR (300 MHz, CDCl3) δ  7.36 (d, J = 8.8 Hz, 1H), 7.29 (s, 1H), 7.23 (s, 1H), 
6.96 (d, J = 8.7 Hz, 1H), 6.87 (s, 1H), 6.55 (s, 1H), 6.35 (s, 2H), 5.97 (d, J = 3.7 Hz, 2H), 
4.68 (d, J = 3.9 Hz, 1H), 3.99 (d, J = 4.4 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.73 (s, 6H), 
3.44 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ 173.0, 156.5, 154.1, 151.3, 148.2, 146.5, 139.3, 
138.4, 137.5, 136.9, 134.9, 129.3, 126.6, 118.8, 112.2, 109.9, 108.6, 106.5, 101.2, 99.3, 60.7, 
56.3, 55.9, 52.1, 48.9, 47.6. MS (ESI): m/z 545 [M+H]
+
; HRMS (ESI) calcd for C30H29O8N2 
[M+H]
+
 545.19240 ; found: 545.19226 
((5R,6R)-Methyl 7-(6-methyl-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-5,6-
dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (17) 
Off white solid, 64% yield. Mp: 164–166 oC.; [α]D 
26.6
 = 14.22 ± 83.26 (c 0.90 mg/mL, 
CHCl3). 
1
H NMR (500 MHz, CDCl3) δ  7.59 (d, J = 7.41 Hz, 1H), 7.46 (s, 1H), 6.99 (d, J = 
7.3 Hz, 1H), 6.88 (s, 1H), 6.58 (s, 1H), 6.36 (s, 2H), 5.95 (d, J = 1.3 Hz, 1H), 5.94 (d, J = 1.3 
Hz, 1H), 4.61 (d, J = 3.7 Hz, 1H), 4.25-4.21 (m, 1H), 3.89 (s, 3H), 3.85 (s, 6H), 3.49 (s, 3H), 
2.36 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 173.6, 153.0, 151.0, 148.1, 146.9, 144.1, 139.4, 
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138.0, 137.3, 135.1, 128.8, 126.8, 121.9, 117.9, 114.1, 109.6, 108.2, 107.7, 101.3, 60.6, 52.8, 
52.1, 47.6, 46.2, 21.6. MS (ESI): m/z 529 [M+H]
+
. HRMS (ESI) calcd for C30H29O7N2 
[M+H]
+ 
529.19693; found: 529.19517. 
((5R,6R)-Methyl 7-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-
trimethoxyphenyl)-5,6-dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (18) 
Off white solid, 60% yield. Mp: 149–153 oC.; [α]D 
26.1
 = 95.06 ± 39.89 (c 1.54 mg/mL, 
CHCl3). 
1
H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.9 Hz, 1H), 7.78 (s, 1H), 7.36 (d, J = 8.8 
Hz, 1H), 7.29 (s, 1H), 6.71 (s, 1H), 6.52 (s, 1H), 6.35 (s, 2H), 5.97 (d, J = 3.7 Hz, 2H), 4.68-
4.73 (m, 1H), 3.97 (d, J = 4.4 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 6H), 3.53 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ 173.0, 153.9, 151.8, 148.2, 146.4, 139.0, 137.7, 137.2, 135.1, 134.4, 129.2, 
128.3, 126.5, 124.3, 119.6, 118.8, 112.3, 109.8, 108.7, 106.6, 101.1, 60.8, 56.2, 52.0, 48.4, 
47.3. MS (ESI): m/z 583 [M+H]
+
.HRMS (ESI) calcd for C30H26O7N2F3 [M+H]
+
 583.16866; 
found: 583.16893. 
((5R,6R)-Methyl 7-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-
5,6-dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (19) 
Off white solid, 66% yield. Mp: 156–160 oC.; [α]D 
26.6
 = 95.76 ± 28.92 (c 1.14 mg/mL, 
CHCl3). 
1
H NMR (300 MHz, CDCl3) δ 7.48 (s, 1H), 7.46 (s, 1H), 7.22(s, 1H), 6.96 (s, 1H), 
6.76 (s, 1H),  6.34 (s, 2H), 5.96 (s, 2H), 4.68 (d, J = 4.11 Hz, 1H), 4.09-4.14 (m, 1H), 3.79 (s, 
3H), 3.76 (m, 6H), 3.56 (s, 3H), 2.38 (s, 6H).
 13
C NMR (75 MHz, CDCl3) δ 172.2, 153.3, 
150.9, 148.1, 146.3, 144.1, 139.3, 138.7, 137.2, 134.8, 130.2, 129.1, 126.9, 115.7, 
109.8,108.5, 106.5, 101.2, 61.0, 56.0, 51.9, 48.7, 48.1, 20.3. MS (ESI): m/z 543 [M+H]
+
. 
HRMS (ESI) calcd for C31H31O7N2 [M+H]
+ 
543.21258; found: 543.21219. 
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((5R,6R)-Methyl 7-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-
5,6-dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (20) 
Off white solid, 56.2% yield. Mp: 151–155 oC.; [α]D 
25.4
 = 29.50 ± 27.36 (c 1.01 mg/mL, 
CHCl3). 
1
H NMR (500 MHz, CDCl3) δ 7.66 (s, 2H), 7.23 (s, 1H), 6.92 (s, 1H), 6.78 (s, 1H), 
6.36 (s, 2H), 5.96 (d, J = 1.3 Hz), 5.94 (d, J = 1.3 Hz, 1H), 4.69 (d, J = 4.1 Hz, 1H), 4.01 (d, J 
= 4.1 Hz, 1H), 3.79 (s, 3H), 3.74 (s, 6H), 3.52 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 169.2, 
153.4, 151.1, 148.2, 146.1, 142.6, 139.6, 137.9, 135.2, 134.5, 129.3, 126.6, 123.2,  117.5, 
115.7, 108.9, 107.2, 106.4, 101.4, 61.0, 56.1, 52.0, 48.4, 47.1. MS (ESI): m/z 583 [M+H]
+
. 
HRMS (ESI) calcd for C29H25O7N2Cl2 [M+H]
+
 583.10333; found: 583.10369. 
(5R,6R)-Methyl 7-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-
trimethoxyphenyl)-5,6-dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate (21) 
Off white solid, 60% yield. Mp: 235–238 oC.; [α]D 
26.1
 = 62.72 ± 40.00 (c 1.02 mg/mL, 
CHCl3).
 1
H NMR (300 MHz, CDCl3) δ 7.75 (s, 1H), 7.36 (s, 1H), 7.21(s, 1H), 6.96 (s, 1H), 
6.75 (s, 1H),  6.29 (s, 2H), 5.95 (s, 2H), 4.68-4.77 (m, 1H), 4.08 (d, J = 3.7 Hz, 1H), 3.81 (s, 
3H), 3.78 (s, 6H), 3.48 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 166.2, 154.3, 150.6, 150.0, 
146.4, 145.9, 139.3, 177.2, 134.7, 133.0, 128.7, 125.0, 121.1, 114.7, 108.8, 107.8, 105.5, 
104.5, 103.1, 101.2, 60.8, 56.0, 51.9, 48.2, 46.8. MS (ESI): m/z 567 [M+H]
+
. HRMS (ESI) 
calcd for C29H25O7N2ClF [M+H]
+
 567.13288; found: 567.13219. 
(5R,6R)-Methyl 7-(7-bromo-5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-5-(3,4,5-
trimethoxyphenyl)-5,6-dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate (22) 
Off white solid, 59% yield, Mp: 191–193 oC.; [α]D 
26
 = 11.13 ± 89.23 (c 0.88 mg/mL, 
CHCl3). 
1
H NMR (300 MHz, CDCl3) δ 7.71 (s, 1H), 7.65(S, 1H), 7.21 (s, 1H), 6.95 (s, 1H), 
6.78 (s, 1H), 6.30 (s, 2H), 5.99 (s, 2H), 4.66 (d, J = 3.4 Hz, 1H), 4.08 (d, J = 3.7 Hz, 1H), 
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3.81 (s, 3H), 3.76 (s, 6H), 3.66 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.8, 153.6, 152.0, 
148.3, 146.5, 141.2, 139.3, 137.5, 137.2, 135.0, 129.3, 128.2, 126.6, 124.3, 119.6, 115.7, 
114.1, 109.9, 108.6, 106.4, 101.0, 60.6, 56.3, 51.9, 48.8, 47.6. MS (ESI): m/z 661 [M+H]
+
. 
HRMS (ESI) calcd for C30H25O7N2BrF3 [M+H]
+
 663.07794; found: 663.07853. 
((5R,6R)-Methyl 7-(1H-naphtho[2,3-d]imidazol-2-yl)-5-(3,4,5-trimethoxyphenyl)-5,6-
dihydronaphtho[2,3-d][1,3]dioxole-6-carboxylate) (23) 
Off white solid, 66% yield. Mp: 247–249 oC.; [α]D 
26.6
 = 238.54 ± 69.47 (c 0.82 mg/mL, 
CHCl3). 
1
H NMR (300 MHz, CDCl3) δ 7.86-7.90 (m, 2H), 7.69-7.81 (m, 4H), 7.19 (s, 1H), 
6.92 (s, 1H),  6.69 (s, 1H), 6.34 (s, 2H), 5.95 (s, 2H), 4.68 (d, J = 4.1 Hz, 1H), 4.01 (d,  J = 
4.3 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 6H), 3.51 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 172.8, 
153.1, 150.2, 148.8, 146.6, 144.2, 139.3, 137.3, 135.4, 134.8, 130.0, 129.1, 127.8, 127.3, 
126.8, 112.7, 109.9, 108.8, 106.3, 101.1, 60.9, 55.9, 51.8, 48.8, 48.3. MS (ESI): m/z 565 
[M+H]
+
. HRMS (ESI) calcd for C33H29O7N2 [M+H]
+
 565.19693; found: 565.19532. 
Cell cultures, maintenance and anti-proliferative evaluation 
      The cell lines, MIAPaCa-2 (pancreatic), MCF-7 (breast), HeLa (cervical) which were 
used in this study were procured from American Type Culture Collection (ATCC), United 
States. The synthesized test compounds were evaluated for their in vitro anti-proliferative 
activity in these three human cancer cell lines. A protocol of 48 h continuous drug exposure 
was used, and a SRB cell proliferation assay was used to estimate cell viability or growth. All 
the cell lines were grown in Dulbecco's modified Eagle's medium (containing 10% FBS in a 
humidified atmosphere of 5% CO2 at 37 °C). Cells were trypsinized when sub-confluent from 
T25 flasks/60 mm dishes and seeded in 96-well plates in 100 μL aliquots at plating densities 
depending on the doubling time of individual cell lines. The microtiter plates were incubated 
at 37 °C, 5% CO2, 95% air, and 100% relative humidity for 24 h prior to addition of 
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experimental drugs and were incubated for 48 h with different doses (0.01, 0.1, 1, 100, 1000 
µM) of prepared derivatives. After 48 h incubation at 37 °C, cell monolayers were fixed by 
the addition of 10% (wt/vol) cold trichloroacetic acid and incubated at 4 °C for 1 h and  were 
then stained with 0.057% SRB dissolved in 1% acetic acid for 30 min at room temperature. 
Unbound SRB was washed with 1% acetic acid. The protein –bound dye was dissolved in 
10mM Tris base solution for OD determination at 510 nm using a microplate reader (Enspire, 
Perkin Elmer, USA). Using the seven absorbance measurements [time zero, (Tz), control 
growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)], the 
percentage growth was calculated at each of the drug concentrations levels. Percentage 
growth inhibition was calculated as:  
    for concentrations for which Ti>/=Tz 
 for concentrations for which Ti<Tz.  
Growth inhibition of 50 % (GI50) was calculated from which the drug 
concentration resulting in a 50% reduction in the net protein increase (as measured by SRB 
staining) in control cells during the drug incubation.
32 
 
Tubulin polymerization assay 
      An in vitro assay for monitoring the time-dependent polymerization of tubulin to 
microtubules was performed employing a fluorescence-based tubulin polymerization assay 
kit (BK011, Cytoskeleton, Inc.) according to the manufacturer’s protocol. The reaction 
mixture in a final volume of 10 µL in PEM buffer (80 mM PIPES, 0.5 mM EDTA, 2 mM 
MgCl2, pH 6.9) in 384 well plates contained 2 mg/mL bovine brain tubulin, 10 µM 
fluorescent reporter, 1 mM GTP  in the presence or absence of test compounds at 37
o
C. 
Tubulin polymerization was followed by monitoring the fluorescence enhancement due to the 
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incorporation of a fluorescence reporter into microtubules as polymerization proceeds. 
Fluorescence emission at 420 nm (excitation wavelength is 360 nm) was measured for 1 h at 
1 min intervals in a multimode plate reader (Tecan M200). Podophyllotoxin was used as 
positive control under similar experimental conditions. To determine the IC50 values of the 
compounds against tubulin polymerization, the compounds were pre-incubated with tubulin 
at varying concentrations (1, 2, 3, 4 and 5 µM). Assays were performed under similar 
conditions as employed for polymerization assays as described above.
28
 
Cell cycle analysis  
       Human cervical cancer cell line (HeLa) in 60 mm dishes were incubated for 24 h in the 
presence or absence of test compounds 12, 15 and 16 (5 µM). Cells were harvested with 
Trypsin-EDTA, fixed with ice-cold 70% ethanol at 4 
o
C for 30 min, ethanol was removed by 
centrifugation and cells were stained with 1 mL of DNA staining solution [0.2 mg of 
Propidium Iodide (PI), and 2 mg RNase A] for 30 min. The DNA contents of 20,000 events 
were measured by flow cytometer (BD FACSCanto II). Histograms were analyzed using FCS 
express 4 plus.
33
 
Immunohistochemistry of tubulin and analysis of nuclear morphology 
      HeLa cells were seeded on glass cover slip, incubated for 24 h in the presence or absence 
of test compounds 15 and 16 at a concentration of 5 μM. Cells grown on coverslips were 
fixed in 3.5% formaldehyde
 
in phosphate-buffered saline (150 mM PBS) pH 7.4 for 10 
minutes at
 
room temperature. Cells were permeablized for 6 minutes in PBS containing 0.5%
 
Triton X-100 (Sigma) and 0.05% Tween-20 (Sigma). The permeablized cells were blocked 
with 2% BSA (Sigma)
 
in 150 mM PBS for 1 h. Later, the cells were incubated
 
with primary 
antibody for tubulin from (sigma) at (1:200) diluted in blocking solution for 4h
 
at room 
temperature. Subsequently the antibodies were removed and the cells were
 
washed thrice with 
150 mM PBS. Cells were then incubated with
 
FITC labeled anti-mouse
 
secondary antibody 
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(1:500) for 1h at room temperature. Cells were washed thrice with 150 mM PBS and 
mounted in medium containing DAPI. Images were captured using
 
the Olympus confocal 
microscope and analysed with Provision software.
28
 
Western blot analysis of soluble versus polymerized tubulin.  
      HeLa cells were seeded in 12-well plates at 1×10
5
 cells per well in complete growth 
medium. Following treatment of cells with respective compounds (15, 16, podophyllotoxin 
and paclitaxel) for a duration of 24 h, cells were washed with 150 mM PBS and subsequently 
soluble and insoluble tubulin fractions were collected. To collect the soluble tubulin fractions, 
cells were permeablized with 200 µL of pre-warmed lysis buffer [80 mM Pipes-KOH (pH 
6.8), 1 mM MgCl2, 1 mM EDTA, 0.2% Triton X-100, 10% glycerol, 0.1% protease inhibitor 
cocktail (Sigma-Aldrich)] and incubated for 3 min at 30 
o
C. Lysis buffer was gently removed, 
and mixed with 100 µL of 3× Laemmli’s sample buffer (180 mM Tris-Cl pH 6.8, 6% SDS, 
15% glycerol, 7.5% -mercaptoethanol and 0.01% bromophenol blue). Samples were 
immediately heated to 95 
o
C for 3 min. To collect the insoluble tubulin fraction, 300 µL of 
1×Laemmli’s sample buffer was added to the remaining cells in each well, and the samples 
were heated to 95 
o
C for 3 min.  Equal volumes of samples were run on an SDS-10 % 
polyacrylamide gel and were transferred to a nitrocellulose membrane employing semidry 
transfer at 50 mA for 1 h. Blots were probed with mouse anti-human α-tubulin diluted 
1:2,000 mL (Sigma) and stained with rabbit anti-mouse secondary antibody coupled with 
horseradish peroxidase, diluted 1:5000 mL (Sigma). Bands were visualized using an 
enhanced Chemiluminescence protocol (Pierce) and radiographic film (Kodak.).
33  
Molecular docking 
      Molecular docking was performed using Maestro 9.5 (Schrodinger package). For the 
binding site preparation, the structure of tubulin in complex with podophyllotoxin (PDB: 
1SA1) was downloaded from the RCSB Protein Data Bank (http://www.rcsb.org/pdb). The 
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preparation was done using the Schrodinger’s protein preparation tool (PPrep) followed by 
energy minimization using OPLS 2005 force field with Polak–Ribiere Conjugate Gradient 
(PRCG) algorithm. The ligands were built using the builder feature in Maestro and each 
structure was prepared for docking using Ligprep 2.7 followed by molecular mechanics 
energy minimization using Macromodel 10.1. These geometrically optimized structures were 
used for Glide (grid-based ligand docking with energetics) docking using the “Extra 
Precision” (XP) mode of Glide 6.0.  The receptor-grid files were generated with a van der 
Waals scaling 0.4 and grid volume of 10 ˚A ×10 ˚A ×10 ˚A at the centroid of each predicted 
binding site. Upon completion of each docking calculation, 100 poses per ligand were 
generated and the best docked structure was chosen using a GlideScore (Gscore) function.
30
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NMR and Mass spectra of selected compounds 
 
1
H NMR spectrum of compound 12 
13
C NMR spectrum of compound 12 
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ESI-MS spectrum of compound 12 
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1
H NMR spectrum of compound 15 
 
 
13
C NMR spectrum of compound 15 
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ESI-MS spectrum of compound 15 
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1
H NMR spectrum of compound 16 
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C NMR spectrum of compound 16 
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ESI-MS spectrum of compound 16 
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Chapter-IV 
Design, synthesis and biological evaluation of phenanthrene 
based tylophorine derivatives containing triazole nucleus as 
NF-κB inhibitors and apoptosis inducing agents 
 
 Abstract    
  Tylophorine, a phenanthrene indolizidine alkaloid, and its analogues typically exhibit highly 
potent anticancer activities. However, the clinical development of these derivatives has been 
limited due to their non-specific central nervous system (CNS) toxicity. A series of 36 new 
triazole-containing polar phenanthrene-based tylophorine derivatives were designed to reduce 
their lipophilicity, so that their CNS toxicity may be potentially reduced and to enhance their 
cytotoxicity. All these compounds were evaluated for their anti-proliferative activity against 
three human cancer cell lines including pancreatic (MIA Paca-2), breast (MCF-7) and 
cervical (HeLa) carcinomas. Among these, the specific impact of three most potent 
compounds (26, 29 and 34) was further evaluated on cell signaling transduction pathways and 
cell cycle to obtain deeper mechanistic understanding. Western blot analysis revealed that the 
expression levels of phospho NF-κB in MCF-7 cells were down-regulated by these potent 
compounds. Further, flow cytometry analysis showed that these compounds blocked cell 
cycle progression in the G1 phase, as evident by associated marked decrease in cyclin D2, 
G1/S regulatory protein. These compounds were also seen to induce apoptosis in MCF-7 cells 
through mitochondria-dependent pathways. Further, molecular docking studies of these 
compounds into the NF-κB-DNA complex, demonstrated that these molecules bind well with 
the target in the active site and are involved in a series of interactions with the protein.  
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4.1 Introduction 
      Natural products serve as an excellent source of new drugs, new drug leads and new 
chemical entities and have long been used as major sources of anticancer and other drugs. 
Approximately 60% of the clinically approved anti-cancer agents are either natural products or 
their derivatives or were developed based on their knowledge of molecules that exists in nature.
1
 
Among natural products; plants have a long history of use in the treatment of cancer. The 
phenanthroindolizidine alkaloids tylophorine (1) and its analogs were isolated primarily from 
plants of Asclepiadaceae family.
2
 These alkaloids possess various biological activities such as 
anti-fungal,
3 
anti-arthritis,
4
 anti-inflammatory,
5 
anti-cancer
6-9
 and have been the target of 
synthetic modification for many years because of their profound cytotoxicity. For instance, 
tylophorine and antofine (Figure 4.1) showed uniform and potent growth inhibitory effects in the 
National Cancer Institute’s antitumor screening, against 60 cancer cell lines, which has aroused 
great interest in exploring the synthesis and biological activities of these compounds and their 
derivatives.
10 
Notably, phenanthroindolizidine alkaloid tylocerebrine (3) failed in clinical trials in 
1966 due to central nervous system (CNS) toxicity, manifested by ataxia and disorientation. 
Similarly, tylocerebrine (3) failed in clinical trials due to CNS toxicity. Therefore, the very 
profound cytotoxicity makes these alkaloids as target of synthetic modification. Staerk et al. 
proposed that the CNS side effects could possibly be minimized by use of more polar analogs 
that would be unable to cross the blood–brain barrier.11 Later Lee et al reported a series of novel 
Phenanthrene-based tylophorine derivatives (4) by opening the indolizidine ring and introducing 
polar chemical moieties into the phenanthrene skeleton.
12 
Preliminary structural activity 
relationship studies suggested that C-2, C-3, and C-6 positions are favorable for modifications 
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and an N-containing substituent at the C-9 is an ideal position for introducing more polar, water 
solubility enhancing moieties, such as a terminal hydroxyl or carboxylic acid.
13,14.
 
 
Figure 4.1 Structures of Tylophorine (1), Tylocerebrine (2), Antofine (3), PBT-1 (4), 
Carboxyamidotriazole (5), and the Target Molecules (11-46) 
      Several mechanisms have been described to elucidate the cytotoxic activities of tylophorine 
derivatives, such as the inhibition of DNA synthesis, inhibition of protein synthesis at the 
elongation stage of the translation cycle, and inhibition of metabolic enzymes, including 
thymidylate, synthase and dihydrofolate reductase.
15-16 
The recent reports imply that active 
tylophorine compounds possess a novel mechanism of anticancer action different from the 
current anticancer agents, which inhibits nuclear factor Kappa B (NF-κB) mediated 
transcription.
17-18
 The NF-κB is a group of transcriptional factors that plays an important role in 
cancer, immunology, inflammation and regulates the transcription of many genes that are 
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involved in tumor promotion, angiogenesis, metastasis as well as increased cell survival.
19-20
 
Further, over expression of NF-κB is linked to increased resistance of tumors to 
chemotherapeutic drugs and radiation therapy because of its anti-apoptotic activity.
21 
Thus, 
inhibition of NF-κB is a novel strategy for both chemotherapy and chemoprevention. 
      Triazoles are an important class of heterocycles, which display wide range of biological 
activities such as antibacterial, antifungal, anthelmintic and anti-cancer activity.
22-27
Among 
triazoles, 1,2,3-Triazole moieties are attractive connecting units because they are stable to 
metabolic degradation and capable of hydrogen bonding, which can be favorable in the binding 
of bio molecular targets and can improve the solubility to which these are attached.
28 
There are 
very few 1,2,3-triazole-containing molecules on the market or  in the last stage of clinical trials. 
Potential pharmaceuticals based on 1,2,3-triazoles include the anticancer compound 
carboxyamidotriazole (CAI). 
29
 Therefore, the importance of triazolic compounds in medicinal 
chemistry is undeniable.  
 
Scheme 4.1 Mechanism of copper catalyzed formation of triazole. 
      Hein and Fokin
 
investigated the mechanism of triazole formation from reaction of azide and 
alkyne using DFT study (scheme 4.1).
30
 In this reaction, the formation of copper (I) acetylide 
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followed by the activation of azide by coordination to copper forming the intermediate has been 
observed. Next, the reaction proceeds with the formation of C-N bond and subsequently to the 
copper metallacycle and copper triazolide to yield triazole. However, the formation of dinuclear 
copper acetylides was also suggested which was explored both computationally as well as 
experimentally.  
Based on these previous reports, a series of novel polar phenanthrene-based tylophorine 
derivatives containing triazole nucleus were designed  
 To allows a drastic reduction of the structural complexity of the natural product.  
 To produce potential cytotoxic agents  
 To establish the preliminary structure-activity relationships (SAR) details.  
 To study the specific impacts of the most potent compounds on cell cycle progression 
and some cell signaling transduction pathways such as NF-κB signaling pathway  
4.2 Results and discussion 
4.2.1 Chemistry 
      Compounds (11–46) were synthesized following the procedure31 outlined in Scheme 1. 
Commercially available veratraldehyde (6) was treated with 4-methoxy (7a) or 3,4 di methoxy 
phenyl acetic acid (7b) in the presence of Ac2O and triethylamine (Perkin condensation) to yield 
an intermediate substituted cinnamic acids 8 (a-b). Construction of phenanthrene-9-carboxylic 
acids 9 (a-b) from the cinnamic acids 8 (a-b) was achieved by an intramolecular oxidative 
coupling reaction using iron (III) chloride at room temperature in excellent yield. The substituted 
phenanthrene-9-carboxylic acids 9 (a-b) were then coupled with the propargyl amine in presence 
of N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), 4-(dimethylamino) 
pyridine (DMAP) and 1-hydroxybenzotriazole (HOBT) to yield terminal alkyne substituted 
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phenanthrene derivatives 10 (a-b). By using the click chemistry protocol, the obtained terminal 
alkyne compounds were allowed to react with synthesized benzyl or aliphatic azide esters, in the 
presence of CuSO4.5H2O and sodium ascorbate, in t-butyl alcohol and water (1:2) at room 
temperature to afford phenanthrene based triazole derivatives 11-18 and 35-46 in excellent 
yields. The hydroxyl alkyl analogs 22-29 were generated by reduction of terminal methyl esters 
with lithium aluminum hydride and the carboxylic acid analogs were synthesized by basic 
hydrolysis of appropriate ester compounds.  
Scheme 4.2 
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Scheme.4.2 Synthesis of Phenanthrene based tylophorine derivatives containing triazole nucleus 
(11-46). Reagents & conditions; (a) Ac2O, Et3N, reflux, 24h; (b) FeCl3, CH2Cl2, r.t, N2; (c) EDC, 
DMAP, HOBt/DMF, Propargyl amine; (d) different substituted aliphatic azides, CuSO4 5H2O, 
sodium ascorbate, tBuOH/H2O (1:2), rt, 8 h; (e) NaOH/MeOH; (f) LiAlH4/THF (g) different 
substituted aromatic azides, CuSO4 5H2O, sodium ascorbate, tBuOH/H2O (1:2), rt, 8 h. See 
Table. 4.1 for structures of final compounds.  
4.2.2 Evaluation of phenanthrene based tylophorine derivatives against human cancer cell 
lines in vitro and summary of preliminary SAR study 
Table 4.1 Anti-proliferative activity of the phenanthrene base tylophorine derivatives containing 
triazole nucleus (11-46) 
 
Compound R1 R Miapaca-2 
(Pancreatic) 
MCF7(Breast) HeLa 
(Cervical) 
Clogp 
11 
 
H 13.4±2.1 9.41±1.2 6.2±1.3 3.05 
12 
 
H 13.6±1.8 1.64±0.5 8.71±0.8 2.99 
13 
 
H 7.96±1.1 10.1±1.3 9.23±1.6 3.41 
14 
 
H 64.1±3.1 8.67±0.6 6.73±2.3 4.16 
15 
 
OMe 27.2±2.5 31.9±4.1 8.53±0.2 2.9 
16 
 
OMe 1.05±0.3 3.87±0.4 1.06±0.3 2.87 
17 
 
OMe 8.63±1.2 3.76±0.4 2.38±1.6 3.28 
18 
 
OMe 7.57±2.1 33.5±6.3 53.7±1.3 4.04 
19 
 
H 1.73±0.8 1.26±1.2 3.63±0.1 2.48 
20 
 
H 0.92±0.2 3.76±1.5 4.42±0.7 2.93 
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21 
 
H 2.43±0.69 1.25±0.2 3.26±0.5 3.35 
22 
 
H 6.92±1.3 3.73±0.8 3.61±1.2 3.77 
23 
 
OMe 1.28±0.4 3.72±1.3 7.0±1.5 2.35 
24 
 
OMe 1.02±0.2 5.16±0.6 6.88±2.3 2.81 
25 
 
OMe 2.08±0.7 1.13±0.2 3.3±0.8 3.22 
26 
 
OMe 0.94±0.3 0.71±0.2 1.38±0.1 3.64 
27     H 1.76±0.6 0.92±0.4 3.6±1.1 2.45 
28 
 
H 1.21±0.2 1.17.±0.4 2.46±0.6 2.73 
29 
 
H 0.83±0.1 0.98±0.3 1.23±0.5 3.15 
30 
 
H 1.12±0.2 3.34±0.2 7.75±2.6 3.56 
31  OMe 1.82±0.4 1.39±0.1 3.66±0.7 2.32 
32 
 
OMe 1.37±0.2 0.87±0.3 4.16±1.7 2.60 
33 
 
OMe 1.28±0.2 1.63±0.2 2.96±0.1 3.02 
34 
 
OMe 1.46±0.3 0.78±0.1 1.37±0.8 3.44 
35 
 
H 3.84±0.5 7.36±2.1 1.13±0.4 4.78 
36 
 
H 7.82±1.5 2.93±0.2 8.62±1.4 5.18 
37 
 
H 15.7±2.7 1.16±0.7 2.82±1.5 4.5 
38 
 
H 4.62±0.3 4.37±1.1 12.5±3.4 5.54 
39 
 
H 20.5±1.2 1.27±0.5 1.54±0.2 4.37 
40 
 
H 1.33±0.26 1.21±0.1 2.89±0.4 4.24 
41 
 
OMe 6.34±0.56 1.87±0.3 1.64±0.4 4.65 
42 
 
OMe 11.7±1.1 3.44±0.1 5.93±0.8 5.05 
43 
 
OMe 20.4±2.4 >100 6.87±3.9 4.37 
44 
 
OMe 1.17±0.3 0.96±0.2 2.15±0.4 5.42 
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45 
 
OMe 12.8±1.3 1.67±0.3 4.96±0.9 4.24 
46 
 
OMe 2.73±0.4 10.7±0.3 8.27±3.6 4.12 
                 5-Fluorouracil 3.64±0.6 2.31±0.2 4.32±0.4  
 
GI50 values are the test compounds concentration (µM) that inhibited the cell growth by 50%. Data represent the 
mean values plus standard deviation of three dependent experiments performed in triplicate. 
      All the synthesized compounds were screened for their anticancer activity against three 
human tumor cell lines; Pancreatic (MiaPaca-2), Breast (MCF-7), Cervical (HeLa) carcinomas 
and compound structures as well as growth inhibition values are shown in Table 4.1. 5-
fluorouacil was used as reference compound. Most of the synthesized compounds showed 
remarkable cell growth inhibition on MCF-7 breast cancer cells selectively in comparison to the 
other two cell lines. Some of the compounds such as 26, 27, 29, 33 and 34 showed potent growth 
inhibition on all the three tested tumor cell lines with GI50 values superior to the standard 5-
fluorouracil. The most potent growth inhibition was observed with the compound 26 against 
MCF-7 cancer cells (0.76 µM).  Some structure activity relationship could be observed based on 
the cytotoxicity of the tested compounds. The carboxy ester derivatives (11-18) were moderately 
active in inhibiting the cell proliferation on all the tested cell lines. Interestingly, the polar 
carboxylic acids (27-34) and hydroxyl derivatives (19-26), possessed significantly remarkable 
growth inhibition than their ester derivatives. A hydrogen-bonding interaction between the 
terminal carboxylic acid or hydroxyl group and a biological target may play an important role in 
binding with the target. This finding is in agreement with the previous reports that polar 
carboxylic acid or hydroxyl derivatives of various phenanthroindolizidines were much more 
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potent in cancer cell growth inhibition assays than their corresponding esters. The spacing (three 
or six-carbon) chain between the terminal group and the remainder of the molecule doesn’t have 
impact on the cell growth inhibition. We also synthesized some terminal non polar aromatic 
substituted derivatives (35-46), to compare their cytotoxicity with aliphatic derivatives. The 
compounds with terminal aromatic substitution (35-46) showed moderate to low cell growth 
inhibition and some of the compounds such as 40, 41, 44 and 45 were selectively cytotoxic to 
breast cancer cell lines with GI50 values in the range of 0.96 to 1.87 µM. Further, the substitution 
on the phenanthrene ring doesn’t have impact on the cytotoxicity. To sum up, the presence of a 
hydrogen-bond acceptor/- donor group at the C-9 chain terminus appears essential for cytotoxic 
activity, suggesting that further exploration of these compounds as selective anticancer drug 
leads will be worthwhile. 
4.2.3 Morphological analysis 
      To determine whether the treatment with the compounds can lead to loss of cell viability, 
cells were treated with most potent compounds in the series 26, 29, and 34 for 48 h. Cells were 
observed and photographs were taken under a phase contrast microscope (Nikon). The number of 
viable cells of MCF-7 decreased markedly after treatment with compounds as observed by the 
distinctive morphological features of cells including detachment and cell shrinkage (Figure 4.2). 
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Figure 4.2 Morphological characteristics of MCF-7 cells treated with compounds 26, 29 and 34 
for 48 h. The changes in cell morphology were observed microscopically.  
4.2.4 Effect on in vitro cell migration 
      Cancer patients die more often from metastasis rather than primary neoplastic lesions.
32
 Cell 
migration is a key feature of tumor progression and metastasis. To ascertain the breast cancer 
metastasis inhibitory effect of the compounds 26, 29 and 34, an in vitro wound healing assay 
33
 
was used to investigate the effect on the migration potential of MCF-7 cells. As shown in figure 
4.3, there is a significant inhibition on the ability of the compound treated cells to migrate into 
the wound compared to the control. The results indicated that the compounds 26, 29 and 34 
significantly suppress the migration of breast cancer cells compared to the control. 
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Figure 4.3 Suppression of migration of breast cancer cells treated with the compounds 26, 29 
and 34. Wounds were induced with 200 µl pipette. The edges of wound were captured at 0, 24, 
48 and 72 h after treatment. The data are representative of three independent experiments and 
viewed at 4X magnification. 
4.2.5 Effect on expression of NF-κB and Phospho NF-κB 
      As previous reports suggested that,
34 
Tylophorine derivatives affect cell growth by inhibiting 
the NF-κB signaling pathway, the newly synthesized compounds 26, 29 and 34 were examined 
for their effect on NF-κB signaling pathway employing western blotting analysis. It was found 
that treatment with compounds resulted in an altered NF-κB protein expression in the nuclear 
fractions of MCF-7 cells (Figure 4.4A). Further, the expression levels of phospho NF-κB were 
decreased to 55%, 37%, and 39% after treatment with the compounds 26, 29 and 34 respectively, 
indicating that these compounds induce cytotoxicity through NF-κB signaling pathway (Figure 
4.4B). 
 
 
                                                                                 Fig. 4.4A 
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Fig 4.4B 
Figure 4.4A Effect of compounds on NF-κB signaling pathway. The cells were treated with 
compounds 26, 29 and 34. After 24 h, the cells were harvested. Total cell lysates were prepared, 
and proteins were subjected to Western blotting analysis with monoclonal antibodies against β-
actin, NF-κB and Phospho NF-κB respectively. Figure 4.4B Quantitation of NF-κB and Phospho 
NF-κB protein levels normalized with β-actin expression by densitometer scanning. Each 
histogram represents the mean values ± standard deviation of three dependent experiments. (*, p 
<0.05 compared with control; **, p <0.01 compared with control).  
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4.2.6 Effect on cell cycle progression 
      NF-κB contributes to cell cycle progression, and one of its potential targets is cyclin D2. NF-
κB was found to stimulate transcription of cyclin D2, a key regulator of G1 checkpoint control.
35
 
To confirm this, we further explored the effects of these three compounds on cell cycle 
distribution by flow cytometry. As revealed by flow cytometry (Figure 4.5A), suppression of cell 
proliferation with these potent compounds was accompanied by the significant accumulation of 
cells in the G1 phase as compared with the control. For instance, cell populations in the G0/G1, 
S, G2/M phases were 36.8%, 24.8%, and 24.7% respectively in the control group (Figure 4.5B) 
However, after exposure to compounds 26, 29 and 34 for 24 h, cell populations in the G1 phase 
were noticeably enhanced by additional 16%, 12% and 10% respectively. These results 
suggested that, compounds induced prominent G1 arrest in MCF-7 cells, and this was 
accompanied by significantly decrease in S phase. 
 
 
Figure 4.5A 
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Figure 4.5B 
Figure 4.5A Cell cycle analysis of MCF-7 cells following treatment with compounds 26, 29 and 
34 for 24 h; Cells were fixed with ethanol and stained with propidium iodide, and then cell cycle 
distribution was analyzed by flow-cytometry. Data from 10,000 cells were collected for each 
data file. Figure 4.5B The percentage of cells in G0/G1, S and G2/M phases were quantified by 
using BD-FACS Canto-II software. 
4.2.7 Effect on cyclin D2 and cyclin B1 expression 
      MCF-7 Cells treated with the compounds showed reduced levels of CyclinD2 (required for 
cell cycle G1/S transition) and the expression levels of Cyclin B1 are not altered significantly, 
which is a G2/M related cyclin, suggesting the G1 phase of the cell cycle arrest (Figure 4.6A).
36
 
Their potency, in terms of cyclin D2 down regulation, correlates with the degree of their 
cytotoxicity, as 26, 29 and 34 are the most active against both tumor cell growth and cyclin D1 
down-regulation. These results indicate that the compounds inhibit cell growth through the 
interruption of proteins involved in the cell cycle progression 
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Figure 4.6A 
 
 
Figure 4.6B 
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Figure 4.6. Effects of compounds on cyclin D2 and cyclin B1 expression. MCF-7 cells were 
treated with 26, 29 and 34 as indicated for 24 h. (4.6A) cyclin D2 and cyclin B1 expressions 
were analyzed by Western blot using a specific monoclonal antibody; β-actin was used as the 
internal control. (4.6B) Quantitation of cyclin D2 and cyclin B1 protein levels normalized with 
β-actin expression by densitometer scanning. Each histogram represents the mean values ± 
standard deviation of three dependent experiments. (*, p <0.05 compared with control; **, p 
<0.01 compared with control). 
4.2.8 Molecular docking studies 
      Molecular docking simulations were carried out using XP Glide 6.0 (Schrödinger 2013)
37 
with default settings into NF-kappa B (PDB code: 1NFK). The highest scored poses for each 
ligand were chosen for analysis of the interactions with NF-kappa B and compared with that of 
tylophorine. The NF-kappa B - DNA complex consists of one DNA molecule and two p50 
monomer chains. Each of the monomer chains are further made up of two distinct domains 
connected by a10-residue linker, which together form a sequence-specific DNA-binding surface. 
In the Docking simulations, all the compounds interacted with the residues of the protein 
involved in interaction with DNA i.e., the DNA-binding region.  
      Tylophorine occupies the active site interface between A and B chains and interacts with 
Lys145 of B chain with H-bonding of two methoxy oxygens. H-bonding interactions between the 
carboxylic group of compound 29 with Tyr57 and Lys144 have contributed significantly to the 
binding affinity with the protein. Moreover, amide NH made an additional hydrogen bond with 
side chain of Thr143 (B chain). This observation indicates that compound 29 interacts more 
favorably with the NF-kappa B monomer than the homodimer. 
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      Interestingly, the best scored pose for compound 34 occupies and interacts with the active 
site formed by residues of both chains A and B. Interaction with the B chain includes two H-
bonds from to the carboxylic group from Tyr57 and Lys144, whereas the interaction with A 
chain includes H-bonding of amide Oxygen and the π-cation interaction of phenanthrene scaffold 
with Lys144. The bridging interactions from both the chains of the homodimer lead to 
strengthening of the binding of the compound in the DNA binding region,  
       Finally, Compound 26 was also bound in the active site between chains A and B similar to 
compound 34 albeit with weaker affinity. The interactions with the A chain include H-bonding 
of terminal alcohol group with side chain of Thr143 and amide oxygen with side chain of 
Lys145. The interactions with B chain include H-bonding between amide NH and side chain 
ofThr143; π-cation interaction of Lys146 with triazole. Moreover, the phenanthrene scaffold 
could be involved in a weak π-π stacking interaction with the aromatic moiety of Tyr57 of chain 
B. The binding modes of 26, 29 and 34 docked in to the active site of NF-kappa B homodimer 
are shown in figure 4.7. 
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Figure 4.7 Binding modes of 26 (pink), 29 (yellow) and 34 (orange) docked in to the active site 
of NF-κB homodimer. Chain A is shown in green and chain B is shown in blue. The residues 
involved in the interaction with the ligand are shown; the hydrogen bonding is indicated in 
purple. 
4.2.9 Effect on apoptosis inducing ability 
4.2.9.1 Hoechst staining 
   
                                    4.8A                                                                                     4.8B 
Figure 4.8A) Morphological analysis of MCF-7 cells treated with the compounds 26, 29 and 34 
by Hoechst 33242. 4.8B) Quantitative analysis of apoptosis induced by the compounds 26, 29 
and 34. Data are mean ± SD from three independent experiments. 
      Apoptosis can be characterized by morphological and biochemical changes in the cell 
nucleus, including chromatin condensation and nuclear fragmentation.
38 
Therefore it was 
considered of interest to investigate the apoptotic inducing effect of the three potential 
compounds 26, 29 and 34 by Hoechst staining (H 33242) in the breast cancer cell line (MCF-7).            
In this assay, cells were treated with compounds for 24 h. As shown in figure 4.8A, manual field 
quantification of apoptotic cells based on cytoplasmic condensation, presence of apoptotic bodies 
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and nuclear fragmentation, revealed control cells exhibited uniformly dispersed chromatin. 
Conversely, cells treated with compounds 26, 29 and 34 demonstrated typical apoptotic 
characteristics, including condensation of chromatin and appearance of nuclear fragmentation 
and apoptotic bodies. Among them, compound 26 is the most potent in inducing apoptosis 
(53.6%) compared to other two compounds 29 (33.3%) and 34 (28.3%). 
4.2.9.2 Effect on mitochondrial membrane potential (DΨm) 
     
Figure 4.9 Compounds 26, 29 and 34 induced loss of mitochondrial membrane potential in 
MCF-7 cells analyzed using Rhodamine 123 under fluorescence microscopy. The loss in 
intensity of fluorescence measured by BD FACS Canto-II, using the Rhodamine 123 dye. Data 
are mean ± SD from three independent experiments. 
  Mitochondrial membrane potential regulates the mitochondrial permeability and plays an 
important role in triggering apoptosis.
39 
In order to further investigate the apoptosis-inducing 
effect of target compounds 26, 29 and 34, changes in mitochondrial membrane potential were 
measured by rhodamine 123 staining. Uptake of rhodamine-123 into the mitochondria is driven 
by mitochondrial trans membrane potential that allows the determination of cell population with 
active integrated mitochondrial functions. Disruption of MMP (DΨm) is associated with 
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decrease in fluorescence intensity due to lack of rhodamine 123 retention.  MCF-7 cells were 
treated with the compounds for 24 h and untreated cells were used as control. Compound treated 
cells showed dissipation of MMP as indicated by decrease in green fluorescence intensity. In the 
untreated control cells, more than 90% cells were functionally active with high rhodamine123 
signals (Figure 4.9). Therefore, these compounds induce loss of mitochondrial membrane 
potential in MCF-7 cells, amongst them compound 26 has the highest potential (52% loss) 
(Figure 4.9). Thus, decrease in DΨm by the compounds indicates that the mitochondrial 
apoptotic death-signal pathway plays a critical role in induction of apoptosis of this type of 
compounds in MCF-7 cells. 
4.2.9.3 Effect on mitochondria dependent pathway 
    Mitochondrial permeability is believed to be affected by the up-regulation of Bax protein 
resulting in the release of cytochrome c into the cytosol, which triggers activation of caspase-9 
and subsequently activation of caspase-3. Bcl-2 inhibits apoptosis through stabilization of 
mitochondrial membrane potential. Expressed on the outer mitochondrial membranes, it blocks 
the release of apoptosis inducer proteins such as cytochrome c from mitochondria to cytosol and 
thus inhibits the subsequent apoptosis-executing signaling events. Changes in the Bax (pro 
apoptotic)/Bcl-2(anti-apoptotic) ratio suggest a corresponding change in mitochondrial 
permeability to begin the induction of apoptosis.
40
 To assess the effects of these compounds on 
Bax, Bcl-2, Caspase-3 and caspase-9 expression, MCF-7 cells were treated with compounds 26, 
29 and 34 for 24 h and the expression levels of Bcl-2, Bax Caspase-3, caspase-9 in cells were 
determined by western blot analysis. As shown in Figure 4.10A, Compounds treatment resulted 
in a significant increase in expression of proapototic proteins, Bax and cleaved caspase-3 and 
cleaved caspase-9. Moreover, the Bcl-2 (anti-apoptotic) protein expression was decreased. These 
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results suggest that, mitochondrial pathway is also involved in the apoptosis inducing ability of 
this type of compounds. 
 
Figure 4.10A 
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Figure 4.10B 
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Figure 4.10A Effects of compounds on Bax, Bcl-2, Cleaved caspase-3 and Cleaved caspase-9 
expression.  MCF-7 cells were treated with Compounds, 26, 29, and  34 as indicated for 24 h. 
and expressions were analyzed by Western blot using a specific monoclonal antibody; β-actin 
was used as the internal control. Figure 4.10B Each histogram represents the mean values ± 
standard deviation of three dependent experiments. (*, p <0.05 compared with control; **, p 
<0.01 compared with control). 
4.2.9.4 Effect on reactive oxygen species (ROS) production 
      ROS are involved at several different points in the apoptotic pathway, including loss of 
mitochondrial membrane integrity with the attendant release of mitochondrial apoptogenic 
factors, intracellular caspase activation, and DNA damage.
41 
To determine whether this event 
occurs in apoptosis induced by these compound, we examined the intracellular generation of 
ROS using DCFDA by microscopy and flow cytometric analysis. Carboxy-DCFDA is cleaved 
intracellularly by esterase’s and subsequently oxidized to highly fluorescent 2,7-
dichlorofluorescein (DCF) by ROS. As shown in figure 4.11A, compound treated cells exhibited 
increase in fluorescent intensity compared to the control cells and quantitative analysis by 
spectrofluorimetry also revealed that these compounds enhanced ROS generation by 3 to 4-fold 
in MCF-7 treated cells (Figure 4.11B). 
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Figure 4.11A Effect of compounds on the intracellular levels of ROS. MCF-7 cells were treated 
with compounds 26, 29 and 34 for 24 h. Cells were incubated with Carboxy-DCFDA and 
washed with 150 mM. Images were captured by a Nikon fluorescence microscope.
 
Figure 4.11B. Quantitative estimation of ROS were measured fluorimetrically with DCFDA, 
using an excitation wavelength of 485 nm and an emission wavelength of 535 nm. 
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4.3 Conclusion 
      A series of 36 novel phenanthrene-based tylophorine derivatives containing triazole nucleus 
were designed and synthesized. Among them, three compounds 26, 29 and 34, were showed 
more potent cytotoxicity than the remaining compounds against three tumor cells. Preliminary 
mechanistic studies indicated that, these compounds exhibit the inhibitory activity against tumor 
cell growth by inhibition of the NF-κB signaling pathway in MCF-7 cancer cells. Further, these 
compounds arrested the cells in G1 phase of the cell cycle by decreasing the expression levels of 
G1/S check point controller Cyclin D2. The reduction in the anti-apoptotic effect of NF-κB may 
also contribute to the apoptosis inducing effect of the compounds in MCF-7 cells through an 
ROS-dependent and mitochondrial dysfunction mechanism. Taken together, these results 
suggested that compounds 26, 29 and 34 inhibited the cell proliferation by suppression of NF-κB 
activity and induction of apoptosis and may be candidates for further evaluation as 
chemotherapeutic agents for human cancers, especially for breast cancer. 
4.4 Experimental section 
   All chemicals and reagents used for the synthesis were obtained from Aldrich (Sigma–Aldrich, 
St. Louis, MO, USA) and were used without further purification. The progress of the reactions 
was  monitored  by thin layer chromatography (TLC), performed on silica gel glass plates 
containing 60 F-254, and visualization on TLC was achieved by UV light or iodine indicator. 
Melting points were determined with an Electrothermal melting point apparatus, and are 
uncorrected.
1
H and 
13
CNMR spectra were recorded on INOVA (400 MHz) or Gemini Varian-
VXR-unity (200 MHz) or Bruker UXNMR/XWIN-NMR (300 MHz) instruments using CDCl3 or 
DMSO as solvents. Chemical shifts (δ) are reported in ppm downfield from internal TMS 
standard. ESI spectra were recorded on Micro mass, Quattro LC using ESI
+ 
software with 
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capillary voltage 3.98 kV and ESI mode positive ion trap detector. HRMS spectra were recorded 
on a Q-TOF6510 spectrograph. 
The compounds 8a-b and 9a-b were synthesized according to the reported literature method.
31 
The spectroscopic data of the obtained compounds is in agreement with the reported literature 
data. 
(E)-3-(3,4-Dimethoxyphenyl)-2-(4-methoxyphenyl)acrylic acid (8a) 
To a solution of 4-methoxy phenyl acetic acid (9.8 g, 0.5 mol), veratraldehyde  (9.0 g, 0.54 mol) 
in acetic anhydride (20 mL) was added triethylamine (10 mL) and refluxed with stirring under 
nitrogen atmosphere for 18 h. After completion of the reaction, Water (30 mL) was added, while 
maintaining the temperature between 90 and 100 °C.  The reaction mixture was allowed to cool 
to room temperature, and the resulting solid was collected by filtration and  recrystallized from 
EtOH to give E-2,3-bis(3,4-dimethoxyphenyl)acrylic acid 8a as a pale yellow solid (11.8 g, 
69%). Mp 210–212 ºC. (lit.30 Mp 207–208 oC) 
(E)-2,3-bis(3,4-Dimethoxyphenyl)acrylic (8b) 
Pale yellow solid, 67% yield. Mp 214–216 ºC. (lit.30 Mp 216–217 oC) 
2, 3, 6-Trimethoxyphenanthrene-9-carboxylic acid (9a) 
FeCl3 (3.98 g, 0.025 mol) was added to a solution of 8a (2.41 g, 0.007 mol) in CH2Cl2 and the 
mixture was stirred at room temperature for 3 h under nitrogen atmosphere. After completion of 
the reaction, the mixture was quenched with methanol and concentrated. The residue was 
partitioned between EtoAc/water and organic layer was dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by recrystallization from methanol to give 2, 3, 6-
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trimethoxyphenanthrene-9-carboxylic acid 9a (1.28 g, 82%) as a light yellow solid. Mp 212–214 
ºC (lit.
30
 mp 215 
o
C) 
2, 3, 6, 7-Tetramethoxyphenanthrene-9-carboxylic acid (9b) 
Light yellow solid, 81% yield. Mp; 283–285 ºC.; (lit.30 280-282 oC) 
2,3,6-Trimethoxy-N-(prop-2-yn-1-yl)phenanthrene-9-carboxamide (10a) 
To a solution of Acid 9a (0.278 g, 1 mmol) in 10 mL of DMF was added N-(3-
dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride (EDC) (4.4 mmol) and HOBt in 
portions at 0 
o
C. After 30 min, propargyl amine (4 mmol) was added and the reaction mixture 
was stirred overnight at room temp.
30
 After completion of the reaction, the mixture was 
partitioned between EtOAc and water. Organic layer was washed with saturated NaHCO3 and 1 
N HCl, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by 
column chromatography using EtOAc/hexane as eluent to give 2,3,6-trimethoxy-N-(prop-2-yn-1-
yl)phenanthrene-9-carboxamide 10a as a white solid in 75 % yield. Mp 195–198 ºC.; 1H NMR 
(300 MHz, CDCl3) 8.55 (s, 1H), 8.41 (s, 1H), 7.98 (s, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.87 (d, J = 
2.2 Hz, 1H), 7.23 (dd, J = 2.1, 8.7 Hz, 1H), 4.3 (s, 2H),  4.06 (s, 3H), 4.01 (s, 3H), 3.93 (s, 3H) 
2.3 (s, 1H). MS (ESI): m/z 350 [M+H]
+
.  
2, 3, 6, 7-Tetramethoxy-N-(prop-2-yn-1-yl) phenanthrene-9-carboxamide (10b) 
By following the same procedure as for 10a by using compound 9b, gave 2, 3, 6, 7-
tetramethoxy-N-(prop-2-yn-1-yl) phenanthrene-9-carboxamide 10b as a white solid in 66% 
yield. Mp 221–223 ºC; 1H NMR (300 MHz, DMSO-d6) 8.61 (s, 1H), 8.37 (s, 1H), 8.1 (s, 1H), 
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7.87 (s, 1H), 7.57 (s, 1H), 4.32 (s, 2H), 4.05 (s, 3H), 3.99 (s, 3H), 3.93 (s, 3H), 3.89 (s, 3H), 2.19 
(s, 1H). MS (ESI): m/z 380 [M+H]
+
. 
General procedure for the synthesis of compounds 11-18 & 35-46 
To a solution of alkynes 10a or 10b (2 mmol) in a mixture of t-BuOH/H2O 1:2 (8 ml) was added 
CuSO4·5H2O (2 mmol) and sodium ascorbate (10 mmol), followed by corresponding synthesized 
azides (2 mmol). The reaction mixture was stirred at room temperature overnight. After 
completion of the reaction, the mixture was partitioned between CHCl3 and water. The organic 
layer was dried over Na2SO4, and evaporated in vacuo. The crude products were purified by 
column chromatography using EtOAc/hexane as eluent.
25
 
Ethyl 3-(4-((2,3,6-trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)propanoate (11) 
Off white solid, yield 67%, Mp: 225–237 oC.; 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.7 Hz, 
1H), 7.75 (d, J = 12.7 Hz, 2H), 7.71 (s, 1H), 7.62 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.10 (s, 1H), 
4.79 (s, 2H), 4.66 (s, 2H), 4.15 (m, 2H), 4.10 (s, 3H), 4.03 (s, 3H), 3.99 (s, 3H), 2.88-2.73 (m, 
2H), 1.37-1.23 (m, 3H). 
13
C NMR (126 MHz, CDCl3) δ 170.4, 169.9, 158.2, 150.0, 149.5, 131.4, 
130.5, 127.9, 125.7, 125.2, 123.7, 122.5, 115.5, 108.6, 104.1, 103.06, 56.0, 55.9, 55.5, 52.3, 47.8, 
35.4, 29.4, 14.9. MS (ESI): 493 [M+H]
+
.  
 Methyl 4-(4-((2,3,6-trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)butanoate  (12) 
Off white solid, yield 71%, Mp: 231–235 oC.; 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 9.06 
Hz, 1H), 7.78 (d, J = 2.26 Hz, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.64 (s, 1H), 7.20 (dd, J = 3.02, 
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9.06 Hz, 1H), 7.14 (s, 1H), 4.8 (d, J = 6.04 Hz, 2H), 4.44 (t, J = 6.79 Hz, 2H), 4.09 (s, 3H), 4.00 
(s, 6H), 3.69 (s, 3H), 2.41-2.32 (m, 2H), 2.21-2.10 (m, 2H), 
13
C NMR (75 MHz, CDCl3) δ 172.2, 
169.9, 158.2, 150.0, 149.5, 144.7, 131.4, 130.5, 127.9, 125.7, 125.2, 123.6, 122.5, 115.5, 108.5, 
104.1, 103.0, 60.8, 56.0, 55.4, 49.4, 35.4, 30.7, 25.4. MS (ESI): m/z 493 [M+H]
+
.  
Methyl 5-(4-((2,3,6-trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)pentanoate  (13) 
Off white solid, 66% yield. Mp: 229–233 oC.; 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.68 
Hz, 1H), 7.81 (d, J = 1.70 Hz, 1H), 7.71 (s, 1H), 7.78 (s, 1H), 7.65 (s, 1H), 7.18 (d, J = 7.36 Hz, 
1H), 7.14 (s, 1H), 4.8 (s, 2H), 4.39 (t, J = 6.04 Hz, 2H), 4.09 (s, 3H), 3.99 (s, 6H), 3.68 (s, 3H), 
2.38 (t, J = 6.98 Hz, 2H), 2.08-1.91 (m, 2H), 1.78-1.60 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 
173.3, 170.0, 158.1, 149.8, 149.4, 131.3, 130.4, 127.8, 125.6, 125.1, 123.6, 122.4, 115.5, 108.5, 
104.0, 102.9, 55.9, 55.4, 51.7, 50.1, 35.4, 33.1, 29.5, 21.7. HRMS (ESI) calcd for C27H30N4O6 
[M+H]
+
 507.2243; found: 507.2199. 
Ethyl 6-(4-((2,3,6-trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)hexanoate (14) 
Off white solid, yield 74%, Mp: 217–219 oC.; 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 9.1 Hz, 
1H), 7.82 – 7.68 (m, 3H), 7.58 (s, 1H), 7.16 (dd, J = 9.1, 2.2 Hz, 1H), 7.08 (s, 1H), 4.78 (s, 2H), 
4.43 (t, J = 6.7 Hz, 2H), 4.12 (m, 2H), 4.07 (s, 3H), 3.99 (s, 3H), 3.97 (s, 3H), 2.35 (t, J = 6.7 Hz, 
2H), 2.24 (dd, J = 13.2, 6.6 Hz, 2H) 1.78- 1.67 (m, 2H), 1.52 – 1.31 (m, 2H), 1.21-1.30 (m, 3H).  
13
C NMR (75 MHz, CDCl3) δ 172.2, 169.8, 158.2, 149.9, 149.5, 131.4, 130.5, 127.8, 125.6, 
125.2, 123.6, 122.4, 115.5, 108.5, 104.1, 103.0, 56.3, 55.9, 55.4, 51.2, 49.3, 35.4, 33.7, 30.7, 
26.7, 25.2, 15.2. MS (ESI): m/z 535 [M+H]
+
.  
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Ethyl 3-(4-((2,3,6,7-tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)propanoate (15) 
Off white solid, 65% yield. Mp: 221–224 oC.; 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.7 Hz, 
1H), 7.75 (d, J = 12.7 Hz, 2H), 7.62 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.10 (s, 1H), 4.79 (s, 2H), 
4.66 (s, 2H), 4.15 (m, 2H), 4.08 (s, 3H), 3.99 (s, 3H), 3.97 (s, 3H), 2.98 (d, J = 5.7 Hz, 2H), 1.28-
1.12 (m, 2H). 
13C NMR (75 MHz, DMSO) δ 170.2, 150.3, 149.2, 148.9, 128.8, 125.5, 124.9, 
124.7, 124.6, 122.9, 108.6, 106.2, 105.3, 102.5, 102.3, 55.9, 55.8, 51.3, 46.0, 34.2, 29.7, 14.6. 
MS (ESI): m/z 523 [M+H]
+
.  
Methyl 4-(4-((2,3,6,7-tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-
1-yl)butanoate (16) 
Off white solid, 71% yield. Mp: 229–232 oC.; 1H NMR (300 MHz, CDCl3) δ 8.28 (d, J = 9.06 
Hz, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.71 (s, 1H), 7.64 (s, 1H), 7.18 (dd, J = 3.02, 9.06 Hz, 1H), 
7.16 (s, 1H), 4.78 (d, J = 6.08 Hz, 2H), 4.47 (t, J = 6.81 Hz, 2H), 4.12 (s, 3H), 4.04 (s, 6H), 4.00 
(s, 3H), 3.68 (s, 3H), 2.37-2.31 (m, 2H), 2.19-2.10 (m, 2H).; 
13
C NMR (126 MHz, CDCl3) δ 
172.2, 169.8, 150.2, 149.2, 148.9, 125.5, 124.8, 124.5, 122.9, 106.2, 102.5, 102.4, 60.8, 56.0, 
55.9, 35.5, 31.0. MS (ESI): m/z 523 [M+H]
+
. HRMS (ESI) calcd for C27H30N4O7 [M+H]
+
 
523.2187; found: 523.2081. 
Methyl 5-(4-((2,3,6,7-tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-
1-yl)pentanoate (17) 
White solid, 76% yield. Mp: 210–213 oC.; 1H NMR (500 MHz, CDCl3) δ 8.29 (d, J = 9.1 Hz, 
1H), 7.85 – 7.76 (m, 2H), 7.64 (s, 1H), 7.19 (dd, J = 9.1, 2.3 Hz, 1H), 7.14 (s, 1H), 4.80 (s, 2H), 
4.38 (t, J = 7.0 Hz, 2H), 4.15 (s, 3H), 4.09 (s, 3H), 4.00 (s, 3H), 3.99 (s, 3H), 3.68 (s, 3H), 2.36 
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(t, J = 7.2 Hz, 2H), 2.01 – 1.93 (m, 2H), 1.76-1.67 (m, 2H). 13C NMR (75 MHz, CDCl3+DMSO-
d6) δ 172.7, 169.4, 157.7, 149.4, 149.1, 130.8, 130.3, 127.5, 125.3, 124.5, 123.1, 122.1, 115.1, 
108.1, 103.4, 102.6, 55.5, 55.4, 54.9, 51.0, 49.3, 34.9, 32.6, 29.0, 21.2. MS (ESI): m/z 537 
[M+H]
+
. HRMS (ESI) calcd for C28H33N4O7 [M+H]
+
 537.2343; found: 537.2324. 
Ethyl 6-(4-((2,3,6,7-tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)hexanoate (18) 
Off white solid, 70% yield. Mp: 221–224 oC.; 8.21 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 12.4 Hz, 2H), 
7.67 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 7.12 (s, 1H), 4.78-4.72 (m, 2H), 4.65-4.58 (m, 2H), 4.21 
(m, 2H), 4.14 (s, 3H), 4.09 (s, 3H), 3.99 (s, 3H), 3.96 (s, 3H), 2.55 (t, J = 6.8 Hz, 2H), 2.29 (dd, J 
= 13.1, 6.8 Hz, 2H) 1.82-1.71 (m, 2H), 1.48– 1.30 (m, 2H), 1.27-1.13 (m, 3H). 13C NMR (126 
MHz, CDCl3) δ 173.3, 170.1, 150.2, 149.2, 148.8, 129.3, 125.4, 124.8, 124.6, 124.4, 123.1, 
108.5, 106.2, 102.6, 102.4, 60.5, 56.0, 55.9, 55.8, 50.20, 35.5, 33.9, 30.0, 25.9, 24.2., 15.6. MS 
(ESI): m/z 565 [M+H]
+
. 
General procedure for the synthesis of compounds 19-26 
To a solution of appropriate ester compounds (11-18, 1 mmol) in 5 mL of dry THF was added 
LiAlH4 (1 mmol) in portions at 0 °C. After addition, the reaction mixture was stirred at r.t for 4 
h. The reaction mixture was quenched with MeOH by maintaining the temperature at 0 c, and 
then 10% Rochelle salt was added. The reaction mixture was extracted with 10% MeOH/CH2Cl2 
and the organic layer was dried over Na2SO4. The crude product obtained was chromatographed 
using with MeOH/CH2Cl2 as eluent to give the respective hydroxyl derivatives in good yields.  
N-((1-(3-Hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-9-
carboxamide  (19) 
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Off white solid, 67% yield. Mp: 230–233 oC.; 1H NMR (300 MHz, CDCl3) δ 8.52 (d, J = 5.5 Hz, 
1H), 8.27 (d, J = 9.1 Hz, 1H), 7.89 (t, J = 8.2 Hz, 2H), 7.77 – 7.62 (m, 2H), 7.35 (s, 1H), 4.73 (d, 
J = 5.5 Hz, 2H), 4.51 (dd, J = 8.8, 5.2 Hz, 2H), 4.08 (s, 3H), 4.04 (s, 6H), 3.65 – 3.44 (m, 2H), 
2.59 (s, 1H), 2.27 – 1.97 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 168.8, 156.5, 148.34, 148.0, 
143.4, 129.6, 129.5, 126.3, 124.1, 123.2, 121.8, 121.3, 120.9, 114.2, 107.2, 102.3, 102.1, 56.1, 
54.4, 54.1, 53.8, 45.2, 33.5, 31.4. MS (ESI): m/z 451 [M+H]
+
. HRMS (ESI) calcd for 
C24H26N4O5 [M+H]
+
 451.1976; found: 451.1954. 
N-((1-(4-Hydroxybutyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-9-
carboxamide (20) 
Off white solid, 63% yield. Mp: 243–246 oC.; 1H NMR (300 MHz, DMSO-d6) δ 8.58 (s, 1H), 
8.27 (d, J = 9.1 Hz, 1H), 7.88 (d, J = 9.8 Hz, 2H), 7.71 (d, J = 6.9 Hz, 2H), 7.29 (s, 1H), 4.73 (d, 
J = 5.6 Hz, 2H), 4.42 (t, J = 7.2 Hz, 2H), 4.12 (s, 3H), 4.02 (s, 6H), 3.57 (d, J = 5.1 Hz, 2H), 2.59 
(s, 1H), 2.10 – 1.92 (m, 2H), 1.65 – 1.48 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 168.3, 148.7, 
147.7, 147.5, 147.2, 143.6, 128.7, 123.6, 123.3, 122.9, 121.7, 121.4, 107.3, 105.2, 101.7, 56.3, 
54.6, 54.5, 54.4, 54.2, 45.4, 33.8, 31.6, 23.4. HRMS (ESI) calcd for C27H30N4O6 [M+H]+ 
465.2137; found: 465.2091. 
N-((1-(4-Hydroxypentyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-9-
carboxamide (21) 
Off white solid, 73% yield. Mp: 217–220 oC.; 1H NMR (300 MHz, CDCl3) δ 8.29 (d, J = 9.1 Hz, 
1H), 7.87 – 7.80 (m, 2H), 7.76 (s, 1H), 7.68 (s, 1H), 7.45 (s, 1H), 7.32 (s, 1H), 4.77 (d, J = 5.3 
Hz, 2H), 4.37 (t, J = 7.1 Hz, 2H), 4.11 (s, 3H), 4.01 (s, 6H), 3.53 (dd, J = 11.1, 5.7 Hz, 2H), 2.56 
(s, 2H), 1.99 (dd, J = 14.5, 7.3 Hz, 2H), 1.53 (dd, J = 14.2, 6.5 Hz, 2H).  
13
C NMR (75 MHz, 
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CDCl3) δ 167.9, 156.5, 148.2, 148.0, 143.5, 129.6, 129.5, 126.4, 124.2, 123.2, 121.9, 121.0, 
114.2, 107.2, 102.4, 102.1, 59.4, 54.4, 54.2, 53.8, 48.2, 33.6, 30.3, 28.3, 22.3. HRMS (ESI) calcd 
for C26H30N4O5 [M+H]+ 479.2294; found: 479.2231. 
N-((1-(6-Hydroxyhexyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-9-
carboxamide (22) 
Off white solid, 59% yield. Mp: 225–228 oC.; 1H NMR (300 MHz, CDCl3) δ 8.83 (d, J = 5.2 Hz, 
1H), 8.24 (dd, J = 9.0, 4.6 Hz, 1H), 8.03 – 7.81 (m, 3H), 7.71 (d, J = 3.9 Hz, 1H), 7.19 (dd, J = 
9.1, 2.3 Hz, 1H), 4.68 (d, J = 5.4 Hz, 2H), 4.40 (dd, J = 12.3, 6.1 Hz, 2H), 4.10 (s, 3H), 4.00 (s, 
6H), 3.55 (t, J = 4.9 Hz, 2H), 2.77-2.65 (m, 2H), 1.95-1.83 (m, 2H), 1.70 – 1.50 (m, 2H), 1.52 – 
1.31 (m, 2H).  
13
C NMR (75 MHz, CDCl3) δ 167.8, 156.5, 148.5, 148.0, 143.5, 129.5, 126.3, 
124.2, 123.1, 121.9, 120.9, 114.2, 107.1, 102.4, 102.1, 58.9, 54.4, 54.1, 53.8, 48.1, 33.6, 28.9, 
27.8, 25.3, 21.7 MS (ESI): m/z 493 [M+H]
+
.  
N-((1-(3-Hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxy phenanthrene-
9-carboxamide (23) 
Off white solid, 66% yield. Mp: 229–233 oC.; 1H NMR (300 MHz, CDCl3) δ 9.05 (t, J = 5.6 Hz, 
1H), 8.09 – 8.00 (m, 2H), 7.82 (s, 2H), 7.44 (s, 1H), 4.64 (d, J = 5.6 Hz, 2H), 4.47 (t, J = 7.1 Hz, 
2H), 4.09 (s, 6H), 3.96 (s, 3H), 3.89 (s, 3H), 3.57-3.52 (m, 2H), 2.10 – 1.94 (m, 2H). 13C NMR 
(75 MHz, CDCl3) δ 168.9, 149.4, 143.4, 129.5, 129.3, 126.7, 125.2, 123.1, 121.9, 121.2, 119.8, 
114.4, 107.3, 102.5, 102.3, 59.7, 54.4, 54.1, 53.6, 45.2, 33.5, 31.4. HRMS (ESI) calcd for 
C25H28N4O6 [M+H]+ 481.2010; found: 481.2069. 
N-((1-(4-Hydroxybutyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxy phenanthrene-
9-carboxamide(24) 
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Off white solid, 60% yield. Mp: 237–239 oC.; 1H NMR (500 MHz, CDCl3) δ 7.71 (s, 1H), 7.69 
(s, 1H), 7.54 (s, 2H), 7.51 (s, 1H),  7.38 (t, J = 5.49 Hz, 1H), 4.74 (d, J = 5.49 Hz, 2H), 4.38 (t, J 
= 7.17 Hz, 2H), 4.04 (s, 6H), 3.92 (s, 6H), 3.62 (t, J = 6.1 Hz, 2H), 2.08-1.97 (m, 2H), 1.57 – 
1.42 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ 168.2, 148.6, 147.6, 147.4, 143.5, 128.6, 123.6, 
123.2, 122.8, 121.6, 121.4, 107.2, 10.1, 101.7, 59.2, 54.5, 54.4, 54.3, 54.1, 45.4, 33.7, 31.6, 27.3. 
HRMS (ESI) calcd for C26H30N4O6 [M+H]+ 495.2238; found: 495.2212. 
N-((1-(4-Hydroxypentyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxy phenanthrene-
9-carboxamide (25) 
Off white solid, 64% yield. Mp: 208–210 oC.; 1H NMR (300 MHz, DMSO-d6) δ  8.20 (d, J = 9.1 
Hz, 1H), 8.04 – 7.93 (m, 2H), 7.70 (s, 1H), 7.36 (s, 1H), 7.16 (dd, J = 9.1, 2.3 Hz, 1H), 4.59 (d, J 
= 5.5 Hz, 2H), 4.35 (t, J = 7.0 Hz, 2H), 4.06 (s, 3H), 3.99 (s, 3H), 3.93 (s, 3H), 3.40 (t, J = 6.3 
Hz, 2H), 2.54 – 2.45 (m, 2H), 1.92 – 1.78 (m, 2H), 1.47 (dt, J = 13.1, 6.4 Hz, 2H).13C NMR (126 
MHz, CDCl3) δ 167.8, 156.5, 148.3, 129.6, 129.5, 126.4, 126.3, 124.2, 123.1, 122.0, 121.9, 
120.9, 114.2, 107.1, 102.3, 102.1, 59.3, 54.4, 54.1, 53.8, 48.2, 33.6, 30.3, 28.3, 25.7. MS (ESI): 
m/z 509 [M+H]
+
.   
N-((1-(6-Hydroxyhexyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxy phenanthrene -
9-carboxamide (26) 
Off white solid, 75% yield. Mp: 215–219 oC.; 1H NMR (300 MHz, CDCl3) δ 7.77 (s, 1H), 7.70 
(d, J = 7.4 Hz, 1H), 7.61 (s, 2H), 7.57 (s, 1H), 7.03 (s, 1H), 4.77 (d, J = 5.6 Hz, 2H), 4.33 (t, J = 
7.1 Hz, 2H), 4.06 (s, 6H), 3.95 (s, 3H), 3.94 (s, 3H), 3.56 (t, J = 6.3 Hz, 2H), 2.00 (s, 3H), 1.89 
(dt, J = 13.7, 7.0 Hz, 2H), 1.49 (dd, J = 12.9, 6.3 Hz, 2H), 1.43 – 1.22 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 168.8, 151.2, 148.4, 129.9, 129.6, 127.1, 126.5, 124.8, 123.1, 121.9, 120.7, 
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113.9, 107.2, 102.5, 102.3, 58.9, 54.5, 54.1, 53.6, 48.2, 33.6, 30.3, 28.3, 25.3, 21.1. MS (ESI): 
m/z 523 [M+H]
+
. 
General procedure for the synthesis of compounds 27-35. 
A solution of appropriate ester compounds (11-18) in 4 N NaOH, and MeOH (1:1) was refluxed 
for 4 h. The reaction mixture was acidified with 1N HCl and partitioned between 10% 
MeOH/CH2Cl2. The organic layer was dried over Na2SO4 and concentrated invacuo. The crude 
product was chromatographed using MeOH/CH2Cl2 as eluent to give the final target acid 
derivatives (27-35) in moderate yields.
30
  
3-(4-((2,3,6-Trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-yl) 
propanoic acid (27) 
Off white solid, 73% yield. Mp: 225–228 oC.; 1H NMR (300 MHz, DMSO-d6) δ 8.97 (s, 1H), 
8.15 (s, 1H), 8.03 (d, J = 7.6 Hz, 2H), 7.71-7.58 (m, 2H), 7.16 (d, J = 8.4 Hz, 1H), 4.57 (d, J = 
5.0 Hz, 2H), 4.39 (t, J = 6.6 Hz, 2H), 4.11 (s, 3H), 4.06 (s, 3H), 3.94 (s, 3H),  2.42-2.36 (m, 2H) 
13
C NMR (75 MHz, DMSO-d6) δ 172.3, 169.4, 159.3, 147.9, 147.3, 147.0, 146.7, 146.4, 142.6, 
128.7, 127.8, 122.8, 122.5, 121.0, 120.7, 106.8, 104.3, 101.5, 101.2, 53.9, 53.8, 53.5, 53.3, 44.7, 
34.8, 32.8. MS (ESI): m/z 465 [M+H]
+
. 
4-(4-((2,3,6-Trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)butanoic acid (28) 
White solid in 67% yield. Mp: 217–221 oC.; 1H NMR (300 MHz, CDCl3+DMSO-d6) δ 8.92 (t, J 
= 5.6 Hz, 1H), 8.23 (d, J = 9.1 Hz, 1H), 7.97 (d, J = 6.5 Hz, 2H), 7.72 (s, 1H), 7.19 (dd, J = 9.1, 
2.3 Hz, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.44 (t, J = 6.8 Hz, 2H), 4.10 (s, 3H), 4.02 (s, 3H), 3.98 (s, 
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3H), 2.28 (t, J = 7.0 Hz, 2H), 2.20 – 2.08 (m, 2H). 13C NMR (75 MHz, CDCl3+DMSO-d6) δ 
171.9, 170.3, 159.6, 143.5, 132.1, 129.5, 129.1, 127.5, 123.0, 114.0, 8. 54.6, 54.3, 53.1, 47.8, 
33.3, 27.3.; MS (ESI): m/z 479 [M+H]
+
. 
5-(4-((2,3,6-Trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-yl) 
pentanoic acid (29) 
Off white solid, 77% yield. Mp: 209–212 oC.; 1H NMR (300 MHz, CDCl3+DMSO-d6) δ 8.96 (s, 
1H), 8.20 (d, J = 9.0 Hz, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.71 (s, 1H), 7.37 (s, 1H), 7.18 (d, J = 8.0 
Hz, 1H), 4.61 (s, 2H), 4.37 (s, 2H), 4.06 (s, 3H), 4.00 (s, 3H), 3.94 (s, 3H), 2.26-2.17 (m, 2H), 
1.89-1.82 (m, 2H), 1.53-1.47 (m, 2H). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) δ 172.2, 167.2, 
158.2, 148.1, 147.8, 143.1, 129.3, 129.2, 126.0, 123.9, 122.8, 121.5, 120.8, 113.9, 107.0, 102.4, 
102.2, 54.3, 53.4, 47.3, 33.1, 31.2, 27.5, 19.7. MS (ESI): m/z 493 [M+H]
+
. 
6-(4-((2,3,6-Trimethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-yl) 
hexanoic acid (30) 
Off white solid, 73% yield. Mp: 216–219 oC.; 1H NMR (300 MHz, DMSO-d6) δ 9.01 (s, 1H), 
8.30 – 8.15 (m, 1H), 8.03 (d, J = 7.7 Hz, 2H), 7.73 (s, 1H), 7.41 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 
4.59 (d, J = 4.8 Hz, 2H), 4.36 (t, J = 6.7 Hz, 2H), 4.06 (s, 3H), 4.00 (s, 3H), 3.93 (s, 3H),  2.19 (t, 
J = 7.1 Hz, 2H), 1.93 – 1.77 (m, 2H), 1.65 – 1.47 (m, 2H), 1.28 (t, J = 11.1 Hz, 2H).13C NMR 
(75 MHz, CDCl3+DMSO-d6) δ 171.2, 168.1, 156.7, 148.5, 148.2, 129.8, 129.5, 126.5, 124.3, 
123.3, 122.1, 121.2, 114.4, 107.3, 102.5, 102.1, 54.5, 54.3, 54.0, 48.2, 35.4, 33.7, 28.3, 24.3, 
22.6. HRMS (ESI) calcd for C27H30N4O6 [M+H]+ 507.2243; found: 507.2230. 
3-(4-((2,3,6,7-Tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-yl) 
propanoic acid (31) 
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Off white solid, 65% yield. Mp: 211–214 oC.; 1H NMR (300 MHz, CDCl3+DMSO-d6) δ  8.09 
(s, 1H), 8.04 (s, 1H), 7.87 (d, J = 9.2 Hz, 2H), 7.76 (d, J = 9.0 Hz, 1H), 7.30 (s, 1H), 4.69 – 4.48 
(m, 4H), 4.07 (s, 6H), 3.95 (s, 3H), 3.86 (s, 3H), 2.72 (s, 2H). 
13
C NMR (75 MHz, DMSO-d6) δ 
171.1, 170.7, 147.9, 147.3, 147.0, 146.7, 146.4, 142.6, 128.7, 127.8, 122.8, 122.5, 121.0, 120.7, 
106.8, 104.3, 101.5, 101.2, 53.9, 53.8, 53.5, 53.3, 44.7, 34.8, 32.8. HRMS (ESI) calcd for 
C25H26N4O7 [M+H]+ 495.1874; found: 495.1811. 
4-(4-((2, 3, 6, 7-Tetramethoxyphenanthrene-9-carboxamido) methyl)-1H-1,2,3-triazol-1-yl) 
butanoic acid (32) 
Off white solid, 69% yield. Mp: 205–209 oC 1H NMR (500 MHz, CDCl3) δ 7.75 – 7.54 (m, 2H), 
7.57 (s, 1H), 7.51 (t, J = 7.01 Hz, 2H), 7.46 (d, J = 9.3 Hz, 1H), 4.64-4.80 (m, 2H), 4.22-4.38 (m, 
2H), 4.01 (s, 6H), 3.88 (s, 6H), 2.34-2.20 (m, 2H), 2.11-2.03 (m, 2H). 
13
C NMR (75 MHz, 
CDCl3) δ 170.9, 170.4, 150.1, 149.0, 148.6, 129.0, 128.9, 125.3, 124.7, 124.4, 123.1, 122.7, 
108.4, 106.1, 105.0, 102.5, 102.3, 55.8, 55.8, 55.7, 50.03, 49.31, 35.1, 33.0, 21.5. MS (ESI): m/z 
509 [M+H]
+
.  
5-(4-((2,3,6,7-Tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-yl) 
pentanoic acid (33) 
Off white solid, 62% yield. Mp: 220–224 oC.; 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.65 
(s, 2H), 7.60 (s, 1H), 7.29 (s, 1H), 7.07 (s, 1H), 4.78 (d, J = 5.4 Hz, 2H), 4.34 (t, J = 7.19 Hz, 
2H), 4.06 (s, 6H), 3.96 (s, 3H), 3.95 (s, 3H), 2.31 (t, J = 7.19 Hz, 2H), 1.99 (t, J = 7.32 Hz, 2H), 
1.66 (t, J = 7.32 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 173.4, 170.2, 150.1, 149.1, 148.8, 
144.6, 129.4, 125.4, 124.8, 124.6, 124.4, 122.9, 122.4, 108.6, 106.3, 102.6, 102.5, 102.4, 55.9, 
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55.8, 50.0, 35.3, 33.1, 29.4, 21.7. HRMS (ESI) calcd for C27H30N4O7 [M+H]+ 523.2187; found: 
523.2156. 
6-(4-((2,3,6,7-Tetramethoxyphenanthrene-9-carboxamido)methyl)-1H-1,2,3-triazol-1-
yl)hexanoic acid (34) 
Off white solid, 71% yield. Mp: 226–228 oC.; 1H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 7.71 – 
7.46 (m, 3H), 7.31 (s, 1H), 7.14 (s, 1H), 4.80 (s, 2H), 4.31 (s, 2H), 4.04 (s, 6H), 3.94 (s, 3H), 
3.89 (s, 3H), 2.27-2.21 (m, 2H), 2.17-2.08 (m, 2H), 1.87-1.65 (m, 2H), 1.29-1.23 (m, 2H). 
13
C 
NMR (75 MHz, CDCl3) δ 173.9, 170.4, 150.0, 149.1, 148.7, 131.5, 129.0, 125.4, 124.8, 124.6, 
122.8, 108.5, 106.1, 102.5, 102.2, 55.9, 55.8, 50.2, 35.1, 33.4, 29.5, 25.5, 23.7 MS (ESI): m/z 
537 [M+H]
+
.  
N-((1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-9-
carboxamide (35) 
Off white solid, 76.3% yield. Mp: 218–220 oC.; 1H NMR (300 MHz, DMSO-d6) δ 9.05 (s, 1H), 
8.21 – 8.02 (m, 4H), 7.72 (s, 1H), 7.47 – 7.36 (m, 2H), 7.19 (t, J = 8.2 Hz, 3H), 5.60 (s, 2H), 4.57 
(d, J = 5.3 Hz, 2H), 4.05 (s, 3H), 4.01 (s, 3H), 3.92 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO-
d6) δ 169.3, 161.8, 156.2, 148.1, 147.8, 143.6, 130.2, 129.3, 128.3, 126.0, 123.8, 122.8, 121.5, 
121.0, 120.6, 113.9, 113.5, 107.0, 102.1, 54.1, 53.8, 53.6, 50.4, 33.1. MS (ESI): m/z 501 [M+H]
+
. 
N-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-9-
carboxamide (36) 
Off white solid, 79.7 % yield. Mp: 232–236 oC. 1H NMR (300 MHz, CDCl3+DMSO-d6) δ 8.91 
(t, J = 5.6 Hz, 1H), 8.20 (d, J = 9.1 Hz, 1H), 8.00 (d, J = 4.3 Hz, 2H), 7.97 (s, 2H), 7.71 (s, 1H), 
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7.38 – 7.30 (m, 3H), 7.15 (dd, J = 9.1, 2.1 Hz, 1H), 5.59 (s, 2H), 4.65 (d, J = 5.5 Hz, 2H), 4.10 
(s, 3H), 4.03 (s, 3H), 3.98 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) δ 169.4, 156.2, 148.1, 
147.8, 143.7, 132.9, 129.4, 129.2, 127.9, 126.9, 126.1, 123.9, 122.9, 121.6, 121.2, 120.6, 113.9, 
107.0, 102.4, 102.1, 54.2, 53.8, 53.6, 50.5, 33.2. MS (ESI): m/z 517 [M+H]
+
. 
2,3,6-Trimethoxy-N-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)phenanthrene-9-
carboxamide (37) 
Off white solid, 73.9 % yield. Mp: 237–239 oC.; 1H NMR (300 MHz, CDCl3) 8.97 (s, 1H), 8.18-
8.09 (m, 3H), 7.86 (s, 2H), 7.77 (s, 1H), 7.31- 7.39 (m 3H), 7.18 (s, 1H), 6.96 (d, J = 8.1 Hz, 
2H), 5.47 (s, 2H), 4.69 (s, 2H), 4.11 (s, 3H), 4.04 (s, 3H), 3.98 (s, 3H), 3.85 (s, 3H).; 
13
C NMR 
(75 MHz, CDCl3) δ 168.7, 159.3, 158.2, 150.1, 149.8, 143.6, 131.5, 130.2, 127.8, 125.3, 122.3, 
121.2, 115.5, 111.4, 108.6, 104.4, 103.2, 56.3, 56.1, 55.8, 55.3, 29.6. MS (ESI): m/z 513 [M+H]
+
. 
N-((1-(3,4-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6-trimethoxyphenanthrene-
9-carboxamide (39) 
Off white solid, 66.6 % yield. Mp: 236–238 oC.; 1H NMR (300 MHz, CDCl3) δ 8.97 (s, 1H), 
8.16 – 7.98 (m, 4H), 7.79 (s, 1H), 7.48-7.37 (m, 3H), 7.18 (t, J = 8.1 Hz, 1H), 5.67 (s, 2H), 4.68 
(d, J = 6.1 Hz), 4.14 (s, 3H), 4.08 (s, 3H), 3.97 (s 3H).; 
13
C NMR (75 MHz, CDCl3) δ 169.1, 
158.2, 150.2, 149.7, 131.5, 127.8, 125.7, 125.4, 122.4, 121.4, 115.5, 111.4, 108.8, 104.2, 103.1, 
56.1, 56.0, 55.9, 55.5, 29.6. MS (ESI): m/z 543 [M+H]
+
.  
2,3,6-Trimethoxy-N-((1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-triazol-
4yl)methyl)phenanthrene-9-carboxamide (40) 
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Off white solid, 66.5 % yield. Mp: 243–245 oC.; 1H NMR (300 MHz, CDCl3+DMSO-d6) δ 8.88 
(t, J = 5.6 Hz, 1H), 8.18 (t, J = 11.1 Hz, 1H), 7.96-7.85 (m, 3H), 7.69 (s, 1H), 7.14 (dd, J = 9.1, 
2.2 Hz, 1H), 6.61 (d, J = 14.1 Hz, 2H), 5.56 (s, 2H), 4.67 (d, J = 5.6 Hz, 2H), 4.11 (s, 3H), 4.02 
(s, 3H), 3.99 (s, 3H), 3.79 (s, 6H), 3.73 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) δ 168.6, 
157.1, 152.2, 148.8, 148.5, 144.5, 130.2, 129.9, 129.6, 126.8, 124.7, 123.8, 122.4, 121.6, 114.6, 
107.6, 104.3, 102.8, 102.3, 59.4, 55.0, 54.7, 54.3, 52.8, 34.2. MS (ESI): m/z 573 [M+H]
+
. 
N-((1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxyphenanthrene-9-
carboxamide (41) 
Off white solid, 74.7% yield. Mp: 247–249 oC.; 1H NMR (300 MHz, CDCl3) δ 7.82 (s, 1H), 7.6 
7-7.61 (m, 2H), 7.58 (s, 2H), 7.35-7.28 (m, 2H), 7.23 – 7.16 (m, 2H), 7.01 (s, 1H), 5.46 (s, 2H), 
4.81 (d, J = 5.4 Hz, 2H), 4.12 (s, 3H), 4.08 (s, 3H), 3.96 (s, 3H), 3.93 (s, 3H), 
13
C NMR (75 
MHz, CDCl3) δ 168.2, 159.4, 150.2, 149.7, 131.5, 127.8, 125.7, 125.4, 122.4, 121.4, 115.5, 
111.4, 108.8, 104.2, 103.1, 56.1, 56.0, 55.9, 55.5, 29.6, MS (ESI): m/z 531 [M+H]
+
.  
N-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxyphenanthrene-9-
carboxamide (42) 
Off white solid, 68.3% yield. Mp: 231–233 oC.; 1H NMR (300 MHz, CDCl3) δ 7.78 (s, 1H), 7.65 
(s, 2H), 7.61 (s, 2H), 7.32-7.28 (m, 2H), 7.24 – 7.18 (m, 2H), 7.05 (s, 1H), 5.47 (s, 2H), 4.76 (d, 
J = 5.4 Hz, 2H), 4.08 (s, 6H), 3.96 (s, 3H), 3.93 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) 
δ 168.4, 148.7, 147.8, 147.6, 147.3, 144.2, 132.8, 132.5, 128.7, 128.2, 127.5, 123.7, 123.3, 122.9, 
121.7, 121.4, 107.3, 105.2, 101.8, 101.7, 54.6, 54.4, 54.2, 51.3, 33.9. MS (ESI): m/z 547 [M+H]
+
. 
2,3,6,7-Tetramethoxy-N-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4yl)methyl) 
phenanthrene-9-carboxamide (43) 
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Off white solid, 59.7% yield. Mp: 231–235 oC.; 1H NMR (500 MHz, CDCl3) δ 8.77 (d, J = 2.7 
Hz, 1H), 7.96 (d, J = 3.0 Hz, 1H), 7.87 (d, J = 2.7 Hz, 1H), 7.84 (d, J = 3.3 Hz, 1H), 7.82 (d, J = 
3.2 Hz, 1H), 7.77 (d, J = 2.9 Hz, 1H), 7.64 (d, J = 5.9 Hz, 1H), 7.48 (d, J = 5.8 Hz, 1H), 5.68 (d, 
J = 2.1 Hz, 2H), 4.76 – 4.68 (m, 3H), 4.09 (m, 3H), 4.00 (s, 3H), 3.91 (s, 3H). 13C NMR (75 
MHz, CDCl3) δ 170.5, 149.0, 148.6, 144.5, 129.0, 125.3, 124.7, 124.4, 123.0, 122.7, 108.4, 
106.1, 105.0, 102.4, 102.2, 55.8, 50.1, 49.0, 35.1 MS (ESI): m/z 581 [M+H]
+
. 
2,3,6,7-Tetramethoxy-N-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)phenanthrene-
9-carboxamide (44) 
Off white solid, 66% yield. Mp: 251–254 oC.; 1H NMR (300 MHz, CDCl3) δ 7.76 (s, 1H), 7.67 – 
7.53 (m, 3H), 7.30 – 7.19 (m, 3H), 7.03 (s, 1H), 6.87 (d, J = 8.1 Hz, 2H), 5.44 (s, 2H), 4.76 (s, 
2H), 4.06 (s, 6H), 3.95 (s, 3H), 3.92 (s, 3H), 3.77 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 169.8, 
159.8, 150.1, 149.1, 148.8, 129.7, 129.3, 126.3, 125.4, 124.8, 124.5, 124.4, 122.9, 114.4, 108.5, 
106.2, 102.5, 102.3, 55.9, 55.8, 55.7, 55.3, 53.8, 35.4.; MS (ESI): m/z 543 [M+H]
+
. 
N-((1-(3,4-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,6,7-tetramethoxy 
phenanthrene-9-carboxamide (45) 
Off white solid, 70.5% yield. Mp: 247–249 oC.; 1H NMR (300 MHz, CDCl3) δ 7.79 (s, 1H), 7.64 
(t, J = 3.3 Hz, 2H), 7.61 (s, 2H), 7.16 (t, J = 5.5 Hz, 1H), 7.04 (s, 1H), 6.89 – 6.78 (m, 2H), 5.43 
(s, 2H), 4.76 (d, J = 5.5 Hz, 2H), 4.07 (s, 6H), 3.95 (s, 3H), 3.94 (s, 3H), 3.85 (s, 3H), 3.82 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ 170.0, 150.2, 149.4, 149.2, 148.8, 144.9, 129.3, 126.7, 125.4, 
124.9, 124.6, 124.3, 122.9, 122.14, 120.9, 111.2, 108.5, 106.2, 102.5, 102.4, 55.9, 55.8, 54.1, 
35.4. MS (ESI): m/z 573 [M+H]
+
.  
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2,3,6,7-Tetramethoxy-N-((1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl) 
phenanthrene-9-carboxamide (46) 
Off white solid, 62% yield. Mp: 242–244 oC.; 1H NMR (500 MHz, CDCl3) δ 7.85 (, 1H), 7.74 (d, 
J = 4.6 Hz, 1H), 7.68-7.74 (m, 2H), 7.64 (s, 1H), 7.17 – 7.12 (m, 1H), 6.51 (s, 2H), 5.45 (s, 2H), 
4.80 (d, J = 5.49 Hz, 2H), 4.10 (s, 6H), 4.00 (s, 3H), 3.97 (s 3H), 3.82 (s, 3H), 3.81 (s, 6H). 
13
C 
NMR (75 MHz, CDCl3) δ 170.1, 153.6, 150.2, 149.2, 148.9, 129.8, 129.3, 125.4, 124.9, 124.6, 
124.3, 122.9, 122.3, 108.5, 106.2, 105.3, 102.6, 102.4, 60.8, 56.1, 55.9, 55.8, 55.8, 54.5, 35.4. 
MS (ESI): m/z 603 [M+H]
+
.  
Cell culture 
      The cell lines, MIA PaCa-2 (pancreatic), MCF-7 (breast), HeLa (cervical) which were used 
in this study were procured from American Type Culture Collection (ATCC), United States and 
were maintained in the Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine 
serum (FBS; HyClone, Logan, UT) supplemented with 100 units/mL of penicillin and 
streptomycin (Sigma-Aldrich, St. Louis, MO). All cells were cultured at 37 ºC in a humidified 
atmosphere with 5% CO2. Test compounds were dissolved in DMSO (Sigma-Aldrich) to prepare 
10 mM stock solution for the following experiments. The stock was diluted with culture medium 
to desired concentrations for drug treatment. 
Evaluation of anti-proliferative activity 
      The anti-proliferative activity of the synthesized phenanthrene based tylophorine derivatives 
was evaluated SRB assay. A protocol of 48 h continuous drug exposure was used to estimate cell 
viability or growth. MiaPaca-2, MCF-7 and HeLa cells were seeded in 96-well plates in 100 μL 
aliquots at plating densities depending on the doubling time of individual cell lines. The 
microtiter plates were incubated at 37 °C, 5% CO2, 95% air, and 100% relative humidity for 24 h 
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and then cells were treated with different doses (0.01, 0.1, 1, 10, 100 µM) of synthesized 
compounds. After 48 hours incubation at 37 °C, cells were fixed with 10% (wt/vol) cold 
trichloroacetic acid and incubated at 4 °C for 1h and were then stained with 0.057% SRB 
dissolved in 1% acetic acid for 30 min at room temperature. Unbound SRB was washed with 1% 
acetic acid. The protein–bound dye was dissolved in 10 mM Tris base solution for OD 
determination at 510 nm using a microplate reader (Enspire, Perkin Elmer, USA). Using the 
seven absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the 
presence of drug at the five concentration levels (Ti)], the percentage growth was calculated at 
each of the drug concentrations levels. Percentage growth inhibition was calculated as: [(Ti-
Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz , [(Ti-Tz)/Tz] x 100 for concentrations 
for which Ti<Tz. Growth inhibition of 50 % (GI50) was calculated from [(Ti-Tz)/(C-Tz)] x 100 = 
50, which is the drug concentration resulting in a 50% reduction in the net protein increase (as 
measured by SRB staining) in control cells during the drug incubation.
40
2 
Morphological analysis 
      MCF-7 cells were plated in 6 well culture plate with a cell density of 1 X10
5
 cells/ml and 
allowed to adhere for 24 h. Cells were treated with compounds 26, 29, and 34 at their GI50 
concentrations. After 48 h treatment, cells were observed and photographs were taken under a 
phase contrast microscope (Nikon). 
In Vitro cell migration assay 
      MCF-7 cells (5x10
5
 cells/well) were seeded in a 6 well plate and allowed to grow to 
confluence. Wounds were created in the confluent monolayers with a 200 µL pipette tip, and 
then rinsed with 150 mM PBS (phosphate buffered saline) to remove detached cells and cellular 
debris. The medium with GI50 concentrations of test compounds was then added for 24 h 
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incubation. The cells were observed under microscope immediately after treatment 0, 24, 48 and 
72 h after treatment. The images were captured using phase contrast microscope (Nikon) under 
4X magnification.
33
 
Cell cycle analysis 
      MCF-7 cells were seeded at 1X10
6 
cells/mL in 6 well plates. After 24 h, cells were treated 
with compounds at their GI50 concentration for 24 h. Both floating and trypsinised adherent cells 
were collected, centrifuged, washed with 150 mM PBS. The pellet was re suspended in 1 mL of 
150 mM PBS at room temp and then the whole volume of re suspended cells were added to 4 mL 
of cold absolute ethanol by pipetting the cell suspension slowly in to ethanol, while vortex in at 
high speed and cells were kept at -20 ºC for 10-15 min. Then, the cells were centrifuged to 
remove ethanol and 5 mL 150 mM PBS was added at room temp. Cells were allowed to 
rehydrate for 15 min and then centrifuged. Supernatant was removed, and cells were incubated 
with propidium iodide (sigma aldrich) (50 µg/mL) staining buffer for 30 min at room temp. The 
DNA content of the stained cells was analyzed using Diva software with FACS flow cytometry 
(BD, Bioscience, CA, USA).
43
 
 Hoechst staining  
      The MCF-7 cells were seeded in 24-well plates at the density of 1X10
5
 cells per ml. After 
24h, cells were incubated with test compounds 26, 29 and 34 at GI50 concentrations for 24 h. 
Cells treated with vehicle (0.001% DMSO) were included as controls for all experiment. After 
washing with 150 mM PBS, cells were fixed with 4% para formaldehyde (PFA) in 150 mM PBS 
for 10 min at 4 
º
C and stained with Hoechst 33242 (life technologies) (2 µg/mL) for 10 min at 
room temp. Cells were washed twice with 150 mM PBS to remove the excess dye. Cells from 
each well were captured from randomly selected fields under fluorescence microscope (Nikon) 
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to qualitatively determine the proportion of viable and apoptotic cells based on their relative 
fluorescence and nuclear fragmentation.
43
 
Determination of mitochondrial membrane potential 
      The MCF-7 cells were plated at 1X10
5
 cells/mL in 24-well culture plates and allowed to 
adhere for 24 h. Cells were treated with GI50 concentrations of the compounds 26, 29 and 34 for 
24 h. After washing twice with 150 mM PBS, cells were incubated with Rhodamine123 (sigma 
Aldrich) (5 µg/mL) for 30 min in the dark at 37 ºC and cells were washed twice with 150 mM 
PBS to remove the excess dye. The decrease in intensity of fluorescence because of 
mitochondrial membrane potential loss was analyzed using fluorescence microscope (Nikon).
43
 
Measurement of reactive oxygen species level 
     The MCF-7 cells were plated at 1X10
5
 cells/mL in 24-well culture plates and allowed to 
adhere for 24 h. Cells were treated with compounds 26, 29 and 34 for 24 h, washed with 150 mM 
PBS and fixed with 4 % paraformaldehyde. Cells were exposed with Carboxy-DCFDA dye (life 
technologies) (10 µM/mL) for 30 min in the dark at room temp and washed with 150 mM PBS to 
remove the excess dye. The increase in intensity of fluorescence because of generation of 
reactive oxygen species was analyzed using fluorescence microscope (Nikon).
43
 
 Western blotting 
      MCF-7 Cells (8 × 106/dish) were seeded in 10 cm dish and allowed to adhere for 24 h. cell 
were treated with test compounds at their GI50 conc for 24 h, washed with  150 mM PBS, 
harvested by scraping them in 1 mL 150 mM PBS. For whole cell extracts, cell pellets were re 
suspended in 1 mL lysis buffer (20 mM Tris-Hcl pH 8.5, 1 mM EDTA, 1 mM PMSF), sonicated 
and centrifuged. The protein concentration was determined by DC Bio-Rad assay using the 
manufacturer's protocol (Bio Rad Laboratories, Hercules, CA). For Western blotting, 50–100 µg 
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of total cell protein were subjected to SDS-PAGE. The protein was transferred to PVDF 
membranes using transfer buffer (50 mM Tris, 190 mM glycine, 20% methanol, and 1% SDS). 
The membranes were incubated with blocking buffer (50 mM Tris, 200 mM NaCl, 0.2% Tween 
20, and 3% BSA) overnight at 4 ºC. After washing three times with washing buffer (blocking 
buffer without 3% BSA) for 10 min each, the membrane was incubated for 2 h at room 
temperature with the respective primary antibody (Cell signaling technologies) directed against 
NF-κB, Phospho NF-κB, cyclin D2, Cyclin B1, Bax, Bcl-2, Cleaved caspase-3, cleaved 
caspase-9 and β-actin. After the membranes were washed three times in washing buffer for 10 
min, they were incubated with horseradish peroxidase-labeled secondary antibody for 1 h. The 
membranes were washed again, and detection was performed using the enhanced 
chemiluminescence Western blotting detection system (Amersham, USA).
44
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Chapter-V 
Design, synthesis and biological evaluation of 1,3-diphenyl-
1H-pyrazole linked to  benzimidazoles as potential 
anticancer and apoptosis inducing agents 
        
Abstract 
A series of forty different pyrazole containing benzimidazole hybrids have been designed, 
synthesized and evaluated for their potential anti-proliferative activity against three human 
tumor cell lines, that is lung (A549), breast (MCF-7), and cervical (HeLa). Some of the 
compounds like 9, 17, and 28 showed potent growth inhibition against all the tested cell lines 
with GI50 values in the range of 0.83-1.81 µM. Further, we investigated the mechanism of cell 
growth inhibition and apoptotic inducing effect of these three potent compounds in MCF-7 
cell line. The morphology, cell migration and long term clonogenic survival of the MCF-7 
cell line were severely affected by treatment with these compounds. Flow-cytometry analysis 
reveals that they arrest the MCF-7 cells in G1 phase of the cell cycle through down regulation 
of cyclin D2 and CDK2. Results from fluorescent staining such as Hoechst staining, and 
DNA laddering assay showed that they inhibit cell proliferation through induction of 
apoptosis. Moreover, they also lead to collapse in mitochondrial membrane potential and 
increased levels of Reactive Oxygen Species (ROS). The ease of synthesis and their 
remarkable biological activities make them promising new scaffolds in the development of 
cancer therapeutics. 
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5.1 Introduction 
      Cancer is one of the major causes of deaths in the world. The mortality and incidence of 
cancer patients became one of the important issues discussed globally.
1 
Chemotherapy is one of 
the strategies to treat cancer with drugs which interfere in cell division, angiogenesis or induced 
cancer cell death by various signaling pathways. However, due to the several side effects, and 
development of resistance against the existing anticancer drugs, there is an impulsion to design, 
synthesize and develop more potent and safer chemotherapeutic agents for the treatment of 
cancer.
2 
      Apoptosis is a programmed cell death that plays an important role in the maintenance of 
tissue homeostasis. Generally, it is considered that apoptosis is regulated by pro and anti-
apoptotic proteins, such as the Bcl-2 and inhibitor of apoptosis protein (IAP) family members, 
and executed through caspases; mainly via two major and inter-related pathways, the 
mitochondrial-dependent ‘intrinsic’ pathway and the death receptor-mediated ‘extrinsic’ caspase-
8 pathway.
3
 Disruption or inappropriate regulation of these processes results in several diseases 
including cancer.
4
 Thus, targeting critical regulators of apoptosis with the goal of inducing 
apoptosis in cancer cells has emerged as an attractive strategy in cancer therapy.
5
 
      Pyrazoles are important class of heterocyclic compounds and are considered as promising 
scaffolds in the medicinal chemistry. Over the years, much attention has been paid to pyrazole 
based compounds because of their broad range of biological activities such as anti-inflammatory, 
anti-microbial, anti-oxidant, anti-depressant, anti-influenza and anti-cancer activities.
6-10
 
Recently, many researchers have reported several pyrazole derivatives as promising anticancer 
agents indicating the use of pyrazole scaffold in the development of new anticancer agents.
11-14 
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Among the anticancer pyrazoles, 1,3-diphenyl pyrazoles were reported to be highly potent and 
efficient cytotoxic agents.
15-17
  
      On the other hand, benzimidazole ring system has evolved as an important heterocyclic 
system due to its wide range of biological activities as well as synthetic applications in medicinal 
chemistry.
18-19
 Recently, various benzimidazole derivatives have been reported to have potential 
anti-tumor/anti-proliferative activity against different cancers.
20-22
 Due to the structural similarity 
of the benzimidazole nuclei with some of the naturally occurring moieties such as purine, they 
can easily interact with biomolecules of the living systems. Moreover, benzimidazoles attached 
with other heterocyclic moieties resulted in compounds (hybrid molecules) with improved anti-
cancer activities.
23-24
 
       A pharmacophore hybridization approach for the synthesis of new bioactive compounds is 
an effective strategy and is recently being used in modern medicinal chemistry. Hybridization of 
two different bioactive molecules with complementary pharmacophoric functions or with 
different mechanisms of action often showed enhanced effects.
25-26
 Prompted by these 
observations and in continuation of previous reports on benzimidazole and pyrazole derivatives 
which showed significant anti-cancer activities,
27-28
 synthesis of pyrazole containing 
benzimidazole derivatives (6-45) was carried out  
 To develop new hybrid molecules of pyrazoles and benzimidazole through easily 
accessible routes 
 To yield promising anti-cancer agents with potent cytotoxic activities on different cancer 
cells better than individual pyrazole and benzimidazole derivatives 
 To establish structure activity relationship studies for further structural modifications. 
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5.2 Results and discussion 
5.2.1 Chemistry 
      The synthetic route for 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazoles (6-45) is 
outlined in Scheme 5.1. These analogs were synthesized by adapting a reported procedure; 
16
 the 
key aldehyde intermediates (4a-d) were prepared in two steps. Condensation of the 
acetophenones (1a-d) with phenyl hydrazine (2) in ethanol afforded the corresponding 
acetophenone phenyl hydrazones (3a-d) followed by cyclization of the acetophenone phenyl 
hydrazones with Vilsmeier–Haack reaction. The desired target compounds (6-45) were obtained 
in good yields by refluxing aldehyde intermediates (4a-d) with different substituted O-
phenylenediamines (5a-d) in ethanol and sodium metabisulfite. 
Scheme 5.1 
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Scheme 5.1 General synthesis of 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole 
derivatives (6-45). Reagents and conditions: (a) ethanol, 50–60 ºC, 3 h; (b) DMF, POCl3, 50–60 
ºC, 5 h; (c) ethanol, Na2S2O5, 50–60 ºC, 5 h. 
5.2.2 In vitro anticancer activity 
      All the newly synthesized 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazoles (6-45) 
were evaluated for their cytotoxicity against three human tumor cell lines: lung (A549), breast 
(MCF-7), cervical (HeLa) carcinoma by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliun 
bromide growth inhibition assay (MTT). 5-Fluorouracil was used as a positive control and the 
results are summarized in Table 5.1. As shown in Table 5.1, the compounds 9, 17 and 28 
exhibited potent broad spectrum of anti-proliferative activity against the three cancer cell lines 
with IC50 values of 0.83 - 1.81 μM, and these were superior to 5-fluorouracil which showed IC50 
values of 2.13–4.16 μM. The highest growth inhibitory activity among the series was observed 
against the MCF-7 cancer cell line with IC50 value 0.83 μM by the compound 9 followed by the 
compounds 17 (0.93 µM) and 28 (1.17 µM). The other two remaining cell lines also showed 
maximum sensitivity towards these three compounds with not more than 1.81 μM concentration. 
All compounds with the exception of 13-15, 23-25, 33-35 and 43-45 exhibited higher or 
comparable cytotoxic activity against certain cell lines with respect to the standard. By 
investigating the variation in selectivity of the tested compounds over these three cell lines, it 
was revealed that structure variation and modification on the B ring of pyrazolo-benzimidazole 
derivatives led to different cytotoxic activities. Structure–activity relationships in these hybrids 
demonstrated that the compounds with mono substituted halogens (fluorine, chlorine, and 
bromine) on the benzimidazole B ring (7-9, 17-19, 27-29 and 37-39) showed more potent 
activities than those with the compounds having methoxy (11, 20, 30 and 40) and methyl (10, 21, 
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31 and 42) substituents. An electron withdrawing trifluoromethyl (CF3) substitution on the B-
ring (12, 22, 31 and 41) resulted in compounds with moderate to lower cytotoxic activity. 
Moreover, the presence of different disubstitutions on the phenyl ring such as di chloro (14, 24, 
34 and 44), dimethyl (13, 23, 33 and 43) groups on benzimidzole B ring determined a marked 
decrease or lower inhibitory activity against these cell lines. Similarly, considering different 
substituents on the A-ring demonstrated that the substitution pattern on A ring does not provide 
significant impact on the anti-proliferative activity in such hybrids. Based on the promising 
cytotoxic activity, three most potent compounds from this series 9, 17 and 28 were taken up for 
their mechanism of cell growth inhibition studies. 
Table 5.1 In vitro anticancer activity (IC50-µM) of the pyrazolo-benzimidazole derivatives (6-
45) 
Compound R R1 R2 A549
b
 MCF-7
c
 HeLa
d
 
6 H H H 2.71±0.6 3.19±0.9 1.55±0.4 
7 H F H 1.72±0.5 2.43±1.1 3.61±1.3 
8 H Cl H 2.37±0.2 1.96±0.6 3.48±0.3 
9 H Br H 1.81±0.4 0.83±0.3 1.76±0.7 
10 H Me H 3.61±0.1 5.94±1.3 6.56±1.6 
11 H OMe H 1.23±0.3 1.59±0.4 2.87±0.2 
12 H CF3 H 5.93±0.7 2.66±0.9 1.92±0.3 
13 H Me Me 14.5±3.3 >50 41.5±6.9 
14 H Cl Cl 11.1±1.9 7.56±1.0 13.4±1.5 
15 H cbz 19.3±2.7 12.6±1.4 21.3±3.2 
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16 F H H 1.51±0.3 3.20±0.6 2.33±0.8 
17 F F H 1.13±0.2 0.95±0.3 1.57±0.3 
18 F Cl H 1.32±0.5 2.23±0.7 2.77±0.3 
19 F Br H 5.83±0.8 3.21±0.3 4.94±0.9 
20 F OMe H 1.96±0.3 0.97±0.2 7.51±1.9 
21 F Me H 1.44±0.4 1.12±0.3 3.63±0.6 
22 F CF3 H 2.34±1.4 2.13±0.6 3.52±0.7 
23 F Me Me >50 27.2±4.2 10.2±2.6 
24 F Cl Cl 15.7±3.1 6.93±1.0 11.6±2.7 
25 F cbz   21.5±2.9 9.24±1.4 23.6±4.1 
26 Cl H H 5.96±1.8 3.03±1.1 1.65±0.7 
27 Cl F H 4.61±0.9 2.83±1.2 2.77±1.2 
28 Cl Cl H 1.34±0.2 1.17±0.2 1.63±0.3 
29 Cl Br H 2.17±0.3 1.92±0.2 2.16±0.5 
30 Cl OMe H 2.42±0.4 1.76±0.6 3.63±0.8 
31 Cl CF3 H 3.36±0.3 4.21±1.1 4.42±0.9 
32 Cl Me H 4.64±1.5 8.23±1.0 5.36±1.7 
33 Cl Me Me 17.7±2.3 13.0±1.6 21.8±2.5 
34 Cl Cl Cl 19.1±3.1 48.3±5.7 12.1±1.9 
35 Cl cbz 7.73±1.8 13.9±2.5 8.13±1.7 
36 OMe H H 2.36±0.6 2.54±0.3 3.67±0.5 
37 OMe F H 1.98±0.7 1.51±0.4 1.74±0.6 
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38 OMe Cl H 3.13±1.1 1.76±0.3 1.29±0.2 
39 OMe Br H 6.37±0.8 1.83±0.7 1.06±0.4 
40 OMe OMe H 22.7±2.9 3.13±1.1 1.14±0.2 
41 OMe CF3 H 4.82±1.2 5.73±1.7 2.76±0.7 
42 OMe Me H 5.07±1.3 6.61±2.0 3.29±0.4 
43 OMe Me Me 5.85±0.43 12.8±2.7 8.93±2.5 
44 OMe Cl Cl 7.33±1.2 13.2±1.1 6.6±1.2 
45 OMe cbz 11.9±2.3 7.46±1.3 12.4±2.7 
5-Fluorouracil 2.13±0.3 2.36±0.2 4.6±0.9 
a
 IC50 values are  the concentrations that cause 50% inhibition of cancer cell growth.  Data 
represent the mean values plus standard deviation of three dependent experiments performed in 
triplicate. b- lung cancer cell line ; c- breast cancer cell line ; d- cervical cancer cell line. 
5.2.3 Morphological analysis 
      To determine whether the treatment with these compounds could lead to loss of cell viability, 
MCF-7 cells were treated with the IC50 concentrations of 9, 17 and 28 for 48 h and these cells 
were observed under a phase contrast microscope (Nikon). As shown in figure 5.1, the numbers 
of viable MCF-7 cells were reduced significantly after treatment with the compounds as 
observed by the distinctive morphological features of cells including detachment and cell 
shrinkage whereas such morphological changes were not apparent in control cells. 
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Figure 5.1 Morphology of MCF-7 cells treated with IC50 concentrations of the compounds 9, 17 
and 28 for 48 h. 
5.2.4 Colony formation inhibition assay 
      In order to investigate the long term cytotoxic potential of these compounds (9, 17 and 28), 
clonogenic cell survival assay was performed which reflects the ability of a single cell to grow 
into a colony. It is considered as a standard for measuring long term cell viability because they 
reflect all modes of cell death or arrest.
29
 As shown in figure 5.2, exposure of MCF-7 cells to the 
compounds, inhibit the colony formation of MCF-7 cells and all the compounds reduced 
clonogenic survival by approximately 50%. These results are in correlation with GI50 values, 
indicating that these compounds can effectively suppress the MCF-7 cell growth and 
proliferation. 
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Figure 5.2 Colony formation inhibition assay: MCF-7 cells were exposed to DMSO 
(control)/compounds 9, 17 and 28 for 24 h. Medium was removed, and cells were incubated in 
fresh medium for 14 days. The Viable cells formed colonies that were stained with crystal violet. 
Representative images depict results of experiments performed at least three times 
5.2.5 In vitro cell migration assay 
      Further in vitro cell migration assay/wound healing assay was performed, as migration of 
cancer cells is a key step in tumor metastasis and such migration capacity could be directly 
correlated with the metastatic potential of cancer cells.
30 
Cellular migration was assessed by 
comparing the number of cells migrated into the induced wound area between the control and the 
treatment wells. Photographs, taken at different time intervals during the assay (0, 24, 48 and 72 
h) indicate that the number of invasive breast cancer cells that penetrated into the respective 
wound area were inhibited after treatment with these compounds (9, 17 and 28)  when compared 
to the control group (Figure 5.3). These results indicate that the compounds can suppress the 
migration of MCF-7 cells. 
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Figure 5.3 Effect of compounds 9, 17 and 28 on migration of MCF-7 cells. The images were 
captured immediately (0 h), 24, 48 and 72 h after treatment using phase contrast microscope 
(Nikon). 
5.2.6 Effect of compounds on cell adhesion markers in mRNA expression 
      The process of cellular migration and invasiveness were considered to be associated with a 
decrease in the expression of cell adhesion markers, such as E-cadherin and β-catenin.31 E-
cadherin is a trans membrane protein acting in the cell-to-cell junction which influences 
epithelial-mesenchymal transition.  In cancer cells, the lack of E-cadherin expression will result 
in a loss of function in the cell–cell junction, resulting in cancer metastasis. Previous studies 
have shown that down-regulation of the E-cadherin expression is found in carcinomas of many 
organs including human breast.
32
  β-Catenin  also plays an important role in the regulation of wnt 
pathway which is crucial for cell development and functioning.
33
 To evaluate the effect of these 
compounds (9, 17 and 28) on the E-cadherin, β-catenin expression, total RNA was extracted 
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from compound treated MCF-7 cells and relative E-cadherin, β-catenin expression levels were 
determined by RT-PCR. The results from the figure 5.4 indicated that these pyrazolo-
benzimidazole hybrids enhance the expression of the markers, E-cadherin (1.6-2.2 times) and β-
catenin (1.4-1.6 times) in MCF-7 cancer cells. Compound 9 which is more potent in inhibiting 
the cellular migration showed the strongest up regulation of E-cadherin expression (2.2 times). 
These results clearly indicate that such hybrids inhibit the cell migration through up regulation of 
cell adhesion markers, E-cadherin and β-catenin expression levels in MCF-7 cells. 
 
 
Figure 5.4 Effect of compounds on E-cadherin and β-Catenin mRNA expression levels. MCF-7 
cells were treated with IC50 concentrations of compounds 9, 17 and 28 for 24 h and total RNA 
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was extracted.  The expression levels were measured by RT-PCR. Target gene expression is 
normalized to β-actin. The experiment was repeated independently three times producing similar 
results. 
5.2.7 Cell cycle analysis 
      We further explored the effects of these three compounds (9, 17 and 28) on cell cycle 
distribution by flow cytometry. MCF-7 cells were treated with the IC50 concentrations of the 
compounds for 24 h and the cells were fixed with ethanol and stained with propidium iodide. As 
shown in figure 5.5A and 5.5B, treatment of MCF-7 cells with the compounds 9, 17 ad 28 
increases the cell cycle arrest at the G1 phase, resulting in concomitant population increase in the 
G1 phase (85.2%, 84.7% and 81.3%) compared to the control cells (72.3%) while the population 
in the S and G2/M phases decreases significantly after the treatment. These results demonstrated 
that the cytotoxicity of the compounds in MCF-7 cells is due the G0/G1 phase of the cell cycle  
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Figure 5.5A.  Cell cycle analysis of MCF-7 cells treated with compounds 9, 17 and 28 for 24 h; 
Cells were fixed with ethanol and stained with propidium iodide, and then cell cycle distribution 
was analysed by flow-cytometry (BD FACS-Canto-II).  
 
 
 
 
 
 
 
 
 
 
Figure 5.5B. The percentage of cells in G0/G1, S and G2/M phases were quantified by using 
Flowjo software. 
5.2.8 Effect of compounds on expression levels of cell cycle check points 
      To determine mechanisms responsible for G1 phase arrest by these compounds, we examined 
the effect on expression levels of some cell cycle specific genes such as cyclins and cyclin 
dependent kinases (CDKs) by RT-PCR. As shown in figure 5.6, these hybrids (9, 17 and 28) 
remarkably down regulate expression of Cyclin D1, which is known to be involved in both G1/S 
phase regulator. There was only a slight up regulation of 1.1 to 1.3 times in the expression levels 
of cyclin B1, whereas the mRNA levels of CDK1 were not significantly changed. Moreover, 
cyclin D1 mRNA expression levels were significantly down regulated by them. Thus, these 
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results indicate that pyrazole-benzimidazole hybrids down-regulate expression of cell cycle 
regulators such as Cyclin D1 and CDK2 in MCF-7 cells which leads to the cell cycle arrest and 
cell growth inhibition. 
 
 
Figure 5.6 Effect of compounds on mRNA expression of cell cycle regulatory molecules. MCF-
7 cells were treated with IC50 concentrations of compounds 9, 17 and 28 for 24 h and total RNA 
was extracted.  The expression levels of Cyclin B1, Cyclin D1, CDK1 and CDK2 were measured 
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by RT-PCR. Target gene expression is normalized to β-actin. The experiment was repeated 
independently three times producing similar results. 
5.2.9 Apoptosis Studies 
      Apoptosis is one of the major pathways that leads to the process of cell death and is 
associated with chromatin condensation, nuclear shrinking and fragmented nuclei. Tumor cells 
often have irregular apoptotic pathways and the induction of tumor cell apoptosis by natural or 
synthetic compounds is considered as an effective therapy for cancer.
34-35
 Moreover, many 
pyrazole and benzimidazole derivatives were found to induce apoptosis in different cancer cell 
lines.
36-39
 Hence it was considered of interest to investigate the apoptotic inducing effect of these 
hybrids in breast cancer cells (MCF-7). 
5.2.9.1 Hoechst staining 
      To examine the apoptosis inducing effect, MCF-7 cells were treated with the IC50 
concentration of the compounds 9, 17 and 28 for 24 h and the morphological changes of MCF-7 
cells were studied using Hoechst 33242 staining. As shown in figure 5.7, control cells with 
0.001% DMSO treatment exhibited uniformly dispersed chromatin, whereas compound treated 
cells (25-34 %) showed typical apoptotic characteristics; including condensation of chromatin  
(brightly stained cells) and appearance of nuclear fragmentation (the arrowhead indicates an 
apoptotic nucleus). Among them, compound 9 is the most potent in inducing apoptosis (42%) 
compared to other two compounds that is 17 (26%) and 28 (32%). These results demonstrate that 
such hybrids have the potential to induce cellular apoptosis in MCF-7 cells. 
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Figure 5.7A Compounds 9, 17 and 28 induced nuclear morphological changes of MCF-7 cells 
after treatment for 24 h. 
 
Figure 5.7B Quantitative analysis of apoptosis induced by the compounds 9, 17 and 28. Data are 
mean ± SD from three independent experiments. 
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5.2.9.2 DNA fragmentation assay 
      During the apoptotic process, activated nucleases degrade the higher order chromatin 
structure of DNA into mono and oligo nucleosomal DNA-fragments. Thus, fragmentation of 
DNA leads to loss of DNA content which results in a characteristic DNA ladder.
40
 As these 
compounds promotes the activation of caspases which leads to DNA fragmentation; DNA 
fragmentation assay was carried out to further confirm the apoptosis inducing effect. Therefore, 
MCF-7 cells were treated with the IC50 concentration of these hybrids (9, 17 and 28) for 24 h and 
chromosomal DNA was extracted. Apoptotic degradation of DNA was analysed by agarose gel 
electrophoresis and the results showed a typical DNA ladder formation in the pyrazole-
benzimidazole compound treated cells which indicate fragmentation of DNA leading to smear in 
the lanes (figure 5.8). In contrast, there was little or no cleaved DNA in the case of control cells. 
The observed smear is the result of DNA breaks at multiple positions across the chromosomal 
DNA. The smear intensity was higher in case of 9 and 28, whereas 17 showed moderate smear 
formation, and these results further suggest that compounds induce apoptosis in MCF-7 cells. 
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Figure 5.8 DNA ladder assay of MCF-7 cells treated with IC50 concentrations of the compounds 
9, 17 and 2. The lanes 1-3 are compound treated Cells; lane 4 control cells; M marker 
5.2.9.3 Effect of compounds on mitochondrial membrane potential 
The maintenance of mitochondrial membrane potential (DΨm) is significant for mitochondrial 
integrity and bioenergetics function. Previous reports have suggested that, the loss of 
mitochondrial membrane potential could lead to apoptosis.
41 
To determine this aspect; MCF-7 
cells were treated with these hybrids (9, 17, 28) for 24 h and incubated with rhodamine 123. 
Mitochondria that maintain normal DΨm can retain the rhodamine 123, which gives strong green 
fluorescence. However, loss of mitochondrial membrane potential leads to depolarization of 
mitochondrial membrane which results less uptake of rhodamine 123. Thus, the loss of DΨm can 
be monitored by reduction of rhodamine 123 green fluorescence.
42
 As shown in figure 5.9A, 
compared with the untreated control, compounds 9, 17 and 28 treated cells exhibit a marked 
reduction in green fluorescence due to less rhodamine 123 uptake and this decrease in 
fluorescence intensity reflects the loss of DΨm.  The results from the figure 5.9B demonstrate 
that the compound treated cells exhibited 44-62 % loss of mitochondrial membrane potential in 
comparison to the control cells. Among these hybrids, compound 9 is more potent in inducing 
mitochondrial depolarisation (62%). These results suggest that the compounds induce apoptosis 
through collapse of mitochondrial membrane potential in MCF-7 cells. 
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Figure 5.9A Compounds 9, 17 and 28 induced loss of mitochondrial membrane potential in 
MCF-7 cells analysed using rhodamine 123 under fluorescence microscopy (Nikon).   
 
Figure 5.9B. The quantitative determination of loss in intensity of fluorescence was measured by 
spectrofluorimeter. 
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5.2.9.4 Effect of compounds on reactive oxygen species (ROS) levels 
The increase in levels of the ROS in the mitochondrion may result in oxidative damage to the 
mitochondrial membrane which leads to apoptosis.
43
 We herein examined the effect of these 
hybrids (9, 17 and 28) in generation of ROS by using 2,7-dichlorofluorescein diacetate 
(DCFDA) dye. DCFDA is cleaved intracellularly by esterases and subsequently oxidized to 
highly fluorescent 2,7-dichlorofluorescein (DCF) by ROS. As shown in figure 5.10A, an increase 
in ROS production was observed in compound treated cells which showed strong green 
fluorescence in comparison to the control cells. Quantitative analysis by spectroflorimetry 
revealed that the ROS levels increased 2-4 times higher when compared to the control cells 
(figure 5.10B). This data suggest that the cytotoxicity of these hybrids was also dependent on the 
production of ROS. 
 
Figure 5.10 Effect of compounds on reactive oxygen species levels. (5.10A) MCF-7 cells were 
treated with compounds 9, 17, 28 and carboxy-DCFDA fluorescence in the cells was captured by 
a Nikon fluorescence microscope.  
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Figure 5.10B Quantitative estimation of ROS was done fluorimetrically with DCFDA, using an 
excitation wavelength of 485 nm and an emission wavelength of 535 nm. 
5.2.9.5 Effect of compounds 17, 23 and 29 on the mitochondrial mediated apoptotic 
pathway 
Mitochondria play an important role in cell death signaling pathways such as apoptosis.
43
 
Mitochondrial dependent apoptotic pathway is regulated by proteins of Bcl-2 family which are 
associated with both pro and anti-apoptotic effects in cancer cells. The relative equilibrium of 
proapoptotic (Bax) and anti-apoptotic (Bcl-2) proteins is critical for maintaining cellular 
homeostasis. A change in the ratio of Bax/Bcl-2 induces the release of cytochrome C into the 
cytosol from mitochondria, resulting in activation of caspases which leads to induction of 
apoptotic cell death.
45
 To examine the possible role of mitochondrial mediated apoptotic 
pathway, the effect of these hybrids (9, 17 and 28) on the expression of Bcl-2, Bax, caspases-3, 
and 7 was analysed by RT-PCR. As shown in figure 5.11, treatment of MCF-7 cells with IC50 
concentrations of 9, 17 and 28 resulted in significant increase in expression levels of Bax 
(proapoptotic) and reduction in expression levels of Bcl-2 (anti-apoptotic) genes. We next 
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analyzed the effects of these hybrids on caspases-3, and 7, and the results from figure 5.11 
indicated that they up regulate the expression of proapoptotic genes, caspases-3 and 7 in MCF-7 
cells. These results reveal that mitochondrial mediated pathway plays an important role in 
inducing apoptosis by pyrazole-benzimidazole hybrids. 
 
 
Figure 5.11. Effect of compounds 9, 17 and 28 on the mRNA expression of apoptotic signalling 
molecules (Bcl-2, Bax, Caspase-3 and Caspase-7) in MCF-7 cells. Cells were treated with IC50 
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concentration of the compounds for 24 h. The mRNA expression levels were analysed by real-
time PCR. Target gene expression is normalized to β-actin.  
5.3 Conclusion 
In summary, we synthesized a series of pyrazole-benzimidazole hybrids and investigated their 
antiproliferative activities on four different human tumor cell lines. The results revealed that 
most of the synthesized compounds remarkably inhibited the cell proliferation and some of the 
compounds showed superior anticancer activity than 5-fluorouracil. Some of them like 9, 17 and 
28 showed potent broad spectrum of cytotoxic activity against all the tested cancer cell lines. The 
preliminary structure activity relationship among the series is established and discussed. The 
compounds inhibit the in vitro cell migration through restoration of E-cadherin, β-catenin 
expression and also inhibit the long term colonogenic survival of MCF-7 cells. Treatment with 
compounds results in G1 phase of the cell cycle arrest in MCF-7 cells and down regulation of 
cyclin D1 as well as CDK2 which are G1 phase cell cycle checkpoints. In addition, the apoptotic 
inducing effects of these compounds on MCF-7 cells was studied by Hoechst staining and DNA 
laddering assay. These results suggested that compounds induced apoptosis through increased 
production of ROS levels, elevation of Bax/Bcl2 ratio, and activation of caspase-3 and 7. 
Therefore, these results imply that the pyrazolyl-benzimidazole hybrids could be used as hit 
compounds for further optimization in development of anticancer agents for breast cancer cells.  
5.4 Experimental Section 
General procedure for the synthesis of 1, 3 diphenyl pyrazole carboxaldehydes (4a-d) 
The 1,3-diphenyl-1H-pyrazole-4-carboxaldehydes intermediates (4a-d) were synthesized based 
on a literature method, as following: para-substituted acetophenones (1a-d, 20 mmol) interact 
with phenyl hydrazine (2, 25 mmol)  in anhydrous ethanol to form 
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acetophenonephenylhydrazones (3a-d), which were added to a cold solution of DMF (25 mL) 
and POCl3 (5 mL), stirred at 50–60 ºC for 6 h. The resulting mixture was poured into ice-cold 
water; a saturated solution of sodium bi carbonate was added to neutralize the mixture, extracted 
with EtOAc and concentrated in vacuo. The obtained residue was purified by column 
chromatography using EtOAc/hexane as eluent to afford pure 1,3-diphenyl-1H-pyrazole-4-
carbaldehydes (4a-d) in good yields (70-82%). The electron donating groups (F, Cl) and electron 
with drawing groups (OMe, 3,4,5 OMe) on aromatic ring of phenyl hydrazine doesn’t have any 
effect on yield of pyrazole carboxaldehyde derivatives. The spectroscopic data of the obtained 
aldehyde compounds was in agreement with the reported data.
 16, 46
 
4.1.2 General procedure for the synthesis of 2-(1,3-Diphenyl-1H-pyrazol-4-yl)-1H-
benzo[d]imidazole derivatives (6-45) 
A solution of Na2S2O5 (40 mmol) in H2O (1.6 mL) was added to a mixture of appropriate 1,3 
diphenyl carboxaldehydes (10 mmol) and different substituted o-phenylenediamines (10 mmol) 
in ethanol. The resulting mixture was stirred at reflux for 4 h, after completion of the reaction; 
the mixture was diluted with 50 mL of H2O and then extracted with EtOAc (2X40 mL). The 
combined extracts were washed with brine, dried over Na2SO4, and evaporated in vacuo. The 
crude product was purified by column chromatography using EtOAc/hexane as the eluent to 
produce pure 2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole derivatives in good 
yields. 
2-(1,3-Diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (6) 
White solid, yield 77%, Mp: 178-182 ºC.; 
1
H NMR (300 MHz, CDCl3+DMSO-d6) δ 8.60 (s, 
1H), 7.82 – 7.73 (m, 4H), 7.55 (dd, J = 6.0, 3.1 Hz, 2H), 7.45 (t, J = 7.8 Hz, 2H), 7.39 – 7.27 (m, 
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4H), 7.20 (dd, J = 6.0, 3.2 Hz, 2H). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) δ 150.2, 145.2, 
138.7, 138.3, 131.8, 128.8, 128.7, 127.8, 127.7, 126.3, 121.5, 118.2, 114.3, 112.3. MS (ESI): m/z 
337 [M+H]
+
. HRMS (ESI) calcd for C22H16N4 [M+H]
+
 337.14477; found: 337.14257. 
2-(1,3-Diphenyl-1H-pyrazol-4-yl)-6-fluoro-1H-benzo[d]imidazole (7) 
Light brown solid, yield 71%, Mp: 189-192 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.74 
(d, J = 7.8 Hz, 2H), 7.71-7.62 (m, 2H), 7.59-7.46 (m, 6H), 7.37 (t, J = 7.36 Hz, 2H), 7.03 – 6.93 
(m, 1H). 
13
C NMR (75 MHz, CDCl3) δ 161.1, 157.9, 150.7, 146.9, 139.2, 132.3, 129.5, 129.2, 
129.1, 128.8, 128.6, 127.4, 119.1, 112.5, 111.0, 110.7.; MS (ESI): m/z 355 [M+H]
+
. HRMS 
(ESI) calcd for C22H16N4F [M+H]
+
 355.13535; found: 355.13342. 
6-Chloro-2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (8) 
White solid, yield 69%, Mp: 196-198 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 7.77 (d, J 
= 7.8 Hz, 2H), 7.68 (dd, J = 6.4, 3.0 Hz, 2H), 7.55 – 7.42 (m, 6H), 7.35 (t, J = 7.4 Hz, 2H), 7.20 
(d, J = 7.4 Hz, 1H). 
13
C NMR (75 MHz, DMSO-d6) δ 150.1, 147.4, 138.4, 131.4, 128.8, 128.7, 
127.7, 127.6, 126.31, 124.6, 118.1, 117.8, 111.5.; MS (ESI): m/z 371 [M+H]
+
. HRMS (ESI) 
calcd for C22H16N4Cl [M+H]
+ 
371.10580; found: 371.10401. 
6-Bromo-2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (9) 
Light brown solid, yield 75%, Mp: 184-187 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 7.78 
(d, J = 7.62 Hz, 2H), 7.74-7.67 (m, 2H), 7.53 – 7.45 (m, 6H), 7.34 (t, J = 7.32 Hz, 2H), 6.87 (dd, 
J = 8.69, 2.28 Hz, 1H)
. 13
C NMR (75 MHz, CDCl3) δ 150.8, 146.6, 139.1, 132.2, 129.5, 129.2, 
129.1, 128.9, 128.6, 127.3, 125.8, 119.1, 115.6, 112.3.;
 
MS (ESI): m/z 415 [M+H]
+
.
 
HRMS (ESI) 
calcd for C22H16N4Br [M+H]
+
 415.05529; found: 415.05284. 
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2-(1,3-Diphenyl-1H-pyrazol-4-yl)-6-methyl-1H-benzo[d]imidazole (10) 
Light brown solid, yield 67%, Mp: 175-1177 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.64 (s, 1H), 
7.77 (d, J = 7.6 Hz, 2H), 7.69 (d, J = 3.2 Hz, 2H), 7.55 – 7.39 (m, 6H), 7.34 (d, J = 7.4 Hz, 2H), 
7.06 (d, J = 7.5 Hz, 1H), 2.45 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 150.7, 145.8, 139.3, 132.2, 
129.5, 129.2, 129.0, 128.8, 128.7, 127.4, 127.1, 126.5, 124.1, 119.3, 119.1, 118.8, 113.0, 21.6.; 
MS (ESI): m/z 351 [M+H]
+
. HRMS (ESI) calcd for C23H19N4 [M+H]
+
 351.16042; found: 
351.15831. 
2-(1,3-Diphenyl-1H-pyrazol-4-yl)-6-methoxy-1H-benzo[d]imidazole (11) 
Light yellow solid, yield 73%, Mp: 191-193 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 
7.80 – 7.75 (m, 2H), 7.70 (ddd, J = 10.8, 5.8, 3.4 Hz, 2H), 7.53 – 7.44 (m, 6H), 7.34 (t, J = 7.4 
Hz, 2H), 6.88 (dd, J = 8.8, 2.4 Hz, 1H), 3.83 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 156.5, 
150.7, 145.3, 139.3, 132.6, 129.5, 129.3, 129.0, 128.7, 127.9, 127.4, 127.1, 119.3, 119.1, 118.8, 
112.9, 112.2, 55.8.; MS (ESI): m/z 367 [M+H]
+
. HRMS (ESI) calcd for C23 H19ON4 [M+H]
+ 
367.15534; found: 367.15330. 
2-(1,3-Diphenyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-1H-benzo[d]imidazole (12) 
Brown solid, yield 73%, Mp: 201-203 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.71 (s, 1H), 7.77 (d, J 
= 7.3 Hz, 2H), 7.70-7.64 (m, 2H), 7.55 – 7.43 (m, 7H), 7.35 (t, J = 6.9 Hz, 1H), 7.21 (s, 1H). 13C 
NMR (75 MHz, CDCl3) δ 150.9, 148.0, 139.1, 132.1, 129.6, 129.3, 129.1, 128.6, 127.4, 126.5, 
125.2, 124.8, 119.7, 119.2, 112.1.; MS (ESI): m/z 405 [M+H]
+
. HRMS (ESI) calcd for 
C23H16N4F3 [M+H]
+
 405.13216; found: 405.12978. 
2-(1,3-Diphenyl-1H-pyrazol-4-yl)-5,6-dimethyl-1H-benzo[d]imidazole (13) 
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Light brown solid, yield 73%, Mp: 184-186 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.55 (s, 1H), 7.78 
– 7.59 (m, 5H), 7.46-7.35 (m, 3H), 7.34 (s, 2H), 7.17 (t, J = 8.6 Hz, 2H), 2.35 (s, 6H). MS (ESI): 
m/z 365 [M+H]
+
, HRMS (ESI) calcd for C24H21N4 [M+H]
+
 365.17612; found: 365.17662. 
5,6-Dichloro-2-(1,3-diphenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (14) 
Light brown solid, yield 66%, Mp: 213-215 ºC.; 
1
H NMR (300 MHz, DMSO-d6) δ 8.90 (s, 1H), 
7.85 – 7.72 (m, 5H), 7.68 (s, 2H), 7.46 (t, J = 7.8 Hz, 2H), 7.31-7.38 (m, 3H); 13C NMR (75 
MHz, DMSO) δ 150.1, 147.4, 138.4, 131.4, 128.8, 128.7, 127.7, 127.6, 126.3, 124.6, 118.1, 
111.5.; MS (ESI): m/z 405 [M+H]
+
. HRMS (ESI) calcd for C22H15N4Cl2 [M+H]
+
 405.06683; 
found: 405.06473. 
2-(1,3-Diphenyl-1H-pyrazol-4-yl)-1H-naphtho[2,3-d]imidazole (15) 
Light brown solid, yield 76%, Mp: 197-199 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.61 (s, 1H), 
7.92-7.83 (m, 4H), 7.81 – 7.70 (m, 4H), 7.48 (d, J = 7.7 Hz, 2H), 7.39 (d, J = 7.1 Hz, 2H), 7.34 
(s, 2H), 7.20 (t, J = 8.5 Hz, 2H). 
13
C NMR (75 MHz, CDCl3) δ 151.2, 149.7, 139.2, 132.3, 130.6, 
129.6, 129.4, 129.3, 129.1, 128.9, 127.8, 127.3, 123.9, 119.2, 112.7.; MS (ESI): m/z 387 
[M+H]
+
. HRMS (ESI) calcd for C26H19N4 [M+H]
+
 387.16081; found: 387.16105. 
2-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (16) 
White solid, yield 73%, Mp: 179-182 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.71 (s, 1H), 7.89-7.79 
(m, 3H), 7.68–7.44 (m, 5H), 7.36 (s, 2H), 7.22-7.13 (m, 3H). 13C NMR (75 MHz, 
CDCl3+DMSO-d6) δ 163.7, 160.4, 149.2, 145.1, 138.6, 129.6, 129.5, 128.8, 128.7, 127.9, 127.9 
126.2, 121.3, 118.1, 114.5, 114.2, 112.2.; MS (ESI): m/z 355 [M+H]
+
. HRMS (ESI) calcd for 
C22H16FN4 [M+H]
+
 355.13496; found: 355.13483. 
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5-Fluoro-2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (17) 
Light brown solid, yield 79%, Mp: 189-192 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.54 (s, 1H), 7.69 
(d, J = 7.4 Hz, 2H), 7.66 – 7.60 (m, 2H), 7.52-7.41 (m, 4H), 7.33 (t, J = 7.4 Hz, 1H), 7.12 (t, J = 
8.6 Hz, 2H), 7.00 (td, J = 9.2, 2.4 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 164.4, 162.3, 160.6, 
158.7, 149.7, 139.2, 130.5, 129.6, 128.9, 128.4, 127.4, 119.2, 116.3, 116.1, 112.5, 111.2, 111.0.; 
MS (ESI): m/z 373 [M+H]
+
. HRMS (ESI) calcd for C22H15F2N4 [M+H]
+
 373.12647; found: 
373.12513. 
5-Chloro-2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (18) 
White solid, yield 77%, Mp: 198-200 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 7.75 (d, J 
= 7.7 Hz, 2H), 7.70 – 7.62 (m, 2H), 7.54 – 7.45 (m, 3H), 7.38 -7.31 (m, 2H), 7.23-7.19 (m, 2H), 
6.90 (dt, J = 16.4, 8.5 Hz, 1H); 
13
C NMR (75 MHz, CDCl3) δ 163.5, 160.2, 149.1, 145.4, 138.0, 
137.2, 135.0, 129.4, 128.6, 127.1, 126.3, 122.3, 118.0, 114.5, 113.6, 109.7; MS (ESI): m/z 389 
[M+H]
+
. HRMS (ESI) calcd for C22H15ClFN4 [M+H]
+
 389.09655; found: 389.09677. 
5-Bromo-2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (19) 
Light brown solid, yield 71%, Mp: 207-209 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 7.96 
– 7.86 (m, 2H), 7.82 (d, J = 7.4 Hz, 2H), 7.75 – 7.61 (m, 1H), 7.54-7.46 (m, 3H), 7.35 (t, J = 6.5 
Hz, 1H), 7.28 (dd, J = 8.3, 1.4 Hz, 1H), 7.13 – 7.00 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
163.5, 160.3, 149.1, 146.1, 138.4, 129.6, 129.5, 128.7, 127.7, 126.1, 124.1, 117.9, 114.3, 114.1, 
113.9, 111.6.; MS (ESI): m/z 433 [M+H]
+
. HRMS (ESI) calcd for C22H25BrFN4 [M+H]
+
 
433.04641; found: 433.04597. 
2-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-methoxy-1H-benzo[d]imidazole (20) 
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Light yellow solid, yield 77%, Mp: 213-215 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.58 (s, 1H), 
7.78 – 7.62 (m, 4H), 7.47 (t, J = 7.8 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 7.28 (s, 1H), 7.16 (t, J = 
8.6 Hz, 2H), 7.01 (s, 1H), 6.91 (dd, J = 8.8, 2.4 Hz, 1H), 3.85 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 164.8, 161.4, 156.6, 149.6, 139.1, 130.5, 130.4, 129.5, 128.71, 128.5, 127.1, 119.0, 
116.1, 115.8, 112.8, 112.3, 55.7.; MS (ESI): m/z 385 [M+H]
+
. HRMS (ESI) calcd for 
C23H18FN4O [M+H]+ 385.14507; found: 385.14507. 
2-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-methyl-1H-benzo[d]imidazole (21) 
Light brown solid, yield 65%, Mp: 185-187 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H), 7.58 
– 7.49 (m, 4H), 7.40 (d, J = 7.3 Hz, 1H), 7.34 (t, J =  7.4 Hz, 2H), 7.28 – 7.22 (m, 2H), 7.06 (dd, 
J = 8.2, 1.0 Hz, 1H), 6.98 (t, J = 8.69 Hz, 2H), 2.44 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 
164.1, 162.1, 149.8, 145.23, 139.2, 132.7, 130.4, 130.3, 129.5, 128.8, 128.4, 127.1, 124.2, 119.0, 
115.9, 115.8, 112.7, 21.6.; MS (ESI): m/z 369 [M+H]
+
. HRMS (ESI) calcd for C23H18FN4 
[M+H]
+
 369.15027; found: 369.15027. 
2-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)-1H-benzo[d]imidazole 
(22) 
Light brown solid, yield 70%, Mp: 217-219 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.78 (s, 1H), 7.98 
– 7.91 (m, 2H), 7.88-7.82 (m, 3H), 7.72-7.67 (m, 1H), 7.49 (t, J = 7.47 Hz, 2H), 7.46 (dd, J = 
8.4, 1.2 Hz, 1H), 7.35 (t, J = 7.47 Hz, 1H), 7.10 (t, J = 8.71 Hz, 2H). 
13
C NMR (75 MHz, 
CDCl3) δ 163.6, 160.3, 149.3, 147.0, 138.8, 138.2, 137.1, 129.49, 128.7, 127.3, 126.3, 125.7, 
123.6, 123.2, 122.1, 118.5, 114.2, 111.9, 110.3.; MS (ESI): m/z 423 [M+H]
+
. HRMS (ESI) calcd 
for C23H15F4N4 [M+H]
+
 423.12182; found: 423.12187. 
2-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5,6-dimethyl-1H-benzo[d]imidazole (23) 
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Light brown solid, yield 73%, Mp: 187-189 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.56 (s, 1H), 7.78 
– 7.59 (m, 4H), 7.46 (t, J = 7.8 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 7.25 (s, 1H), 7.14 (t, J = 8.6 Hz, 
2H), 2.38 (s, 6H). 
13
C NMR (75 MHz, CDCl3) δ 164.7, 161.4, 149.8, 144.7, 139.1, 131.7, 130.3, 
130.2, 129.4, 128.6, 128.4, 127.0, 118.9, 115.8, 115.5, 112.7, 20.3.; MS (ESI): m/z 383 [M+H]
+
. 
HRMS (ESI) calcd for C24H20FN4 [M+H]
+ 
383.16617; found: 383.16614. 
5,6-Dichloro-2-(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (24) 
Light brown solid, yield 79%, Mp: 203-205 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.74 – 8.60 (m, 
1H), 7.93-7.82 (m, 4H), 7.62 (s, 2H), 7.47 (t, J = 7.0 Hz, 2H), 7.39 – 7.27 (m, 1H), 7.06 (t, J = 
7.6 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 163.9, 161.9, 150.0, 148.0, 139.1, 130.3, 130.2, 
129.5, 129.3, 128.2, 127.1, 125.9, 118.8, 115.3, 112.0, 30.8, 29.5.; MS (ESI): m/z 423 [M+H]
+
. 
HRMS (ESI) calcd for C22H14ClFN4 [M+H]
+
 423.05680; found: 423.05699. 
2-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-naphtho[2,3-d]imidazole (25) 
Brown solid, yield 70%, Mp: 193-195 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.74 (s, 1H), 7.89-7.84 
(m, 3H), 7.78 – 7.69 (m, 4H), 7.47 (t, J = 7.8 Hz, 2H), 7.40 (dq, J = 6.2, 3.1 Hz, 2H), 7.35 (t, J = 
7.1 Hz, 1H), 7.25 (s, 1H), 7.20 (t, J = 8.5 Hz, 2H). 
13
C NMR (126 MHz, CDCl3) δ 163.7, 161.8, 
150.2, 150.0, 139.1, 130.5, 130.4, 130.1, 129.7, 129.4, 128.4, 127.6, 127.0, 123.4, 118.7, 115.1, 
114.9, 112.6.; MS (ESI): m/z 405 [M+H]
+
. HRMS (ESI) calcd for C26H18FN4 [M+H]+ 
405.15063; found: 405.15071. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (26) 
Light brown solid, yield 73%, Mp: 177-179 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 7.66 
(d, J = 7.7 Hz, 2H), 7.59 (d, J = 8.54 Hz, 2H), 7.56-7.52 (m, 2H), 7.42 (t, J = 7.9 Hz, 2H), 7.36 
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(d, J = 8.4 Hz, 2H), 7.31 (t, J = 7.47 Hz, 1H), 7.28 – 7.23 (m, 2H). 13C NMR (126 MHz, CDCl3) 
δ 149.6, 145.3, 139.1, 135.1, 130.7, 129.8, 129.5, 129.1, 127.3, 123.0, 119.1, 112.3.; MS (ESI): 
m/z 371 [M+H]
+
; HRMS (ESI) calcd for C22H16ClN4 [M+H]
+
 371.10567; found: 371.10580. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-fluoro-1H-benzo[d]imidazole (27) 
Light brown solid, yield 69%, Mp: 188-191 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.69 (s, 1H), 
7.91-7.80 (m, 4H), 7.60 (s, 1H), 7.52-7.46 (m, 3H), 7.36 (d, J = 7.55 Hz, 2H), 7.25 (d, J = 9.1 
Hz, 1H), 6.97 (t, J = 9.2 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 149.7, 147.8, 139.08, 134.2, 
130.7, 129.7, 129.5, 129.4, 128.3, 127.1, 125.4, 118.8, 112.2. MS (ESI): m/z 389 [M+H]
+
; 
HRMS (ESI) calcd for C22H15ClFN4 [M+H]
+
 389.09671; found: 389.09636. 
5-Chloro-2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (28) 
Light brown solid, yield 71%, Mp: 208-210 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.78 (d, J = 8.7 
Hz, 1H), 7.90 (dd, J = 16.6, 8.0 Hz, 4H), 7.72 (d, J = 11.1 Hz, 1H), 7.65 – 7.48 (m, 4H), 7.41 (d, 
J = 7.9 Hz, 2H), 7.21 (d, J = 8.3 Hz, 1H). MS (ESI): m/z 405 [M+H]
+
.; HRMS (ESI) calcd for 
C22H15Cl2N4 [M+H]
+
 405.06729; found: 405.06685. 
5-Bromo-2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (29) 
Light brown solid, yield 76%, Mp: 202-204 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.87 (s, 1H), 7.96 
(d, J = 8.5 Hz, 2H), 7.93 – 7.83 (m, 3H), 7.54 (t, J = 7.8 Hz, 2H), 7.44-7.34 (m, 4H), 7.29 (d, J = 
8.4 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ 147.9, 145.2, 137.5, 132.1, 129.5, 128.5, 128.0, 
126.5, 125.4, 123.2, 117.1, 111.0.; MS (ESI): m/z 449 [M+H]
+
. HRMS (ESI) calcd for 
C22H15BrClN4 [M+H]
+
 449.01686; found: 449.01589. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-methoxy-1H-benzo[d]imidazole (30) 
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Light brown solid, yield 75%, Mp: 191-193 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 7.70 
(d, J = 7.7 Hz, 2H), 7.61 (d, J = 8.54 Hz, 2H), 7.48-7.43 (m, 3H), 7.41 (d, J = 8.39 Hz, 2H), 
7.38-7.29 (m, 2H), 6.90 (dd, J = 8.8, 2.4 Hz, 1H), 3.84 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
155.3, 148.7, 144.4, 138.5, 133.2, 130.3, 128.9, 128.4, 127.5, 126.2, 118.0, 112.3, 110.8, 96.5, 
54.9.; MS (ESI): m/z 401 [M+H]
+
. HRMS (ESI) calcd for C23H18ClN4O [M+H]
+
 401.11680; 
found: 401.11694. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)-1H-
benzo[d]imidazole (31) 
Light brown solid, yield 71%, Mp: 216-218 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 7.71 
(d, J = 8.39 Hz, 2H), 7.60 – 7.55 (m, 3H), 7.51 (d, J = 7.78 Hz, 2H), 7.45 (t, J = 8.39 Hz, 2H), 
7.42 – 7.37 (m, 2H), 7.34 (dt, J = 7.47, 1.52 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 149.8, 148.0, 
139.0, 134.1, 130.7, 129.7, 129.6, 129.4, 128.3, 127.1, 118.8, 112.3.; MS (ESI): m/z 439 
[M+H]
+
. HRMS (ESI) calcd for C23H15ClF3N4 [M+H]
+
 439.09211; found: 439.09206. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5-methyl-1H-benzo[d]imidazole (32) 
Light brown solid, yield 67%, Mp: 176-178 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.48 (s, 1H), 7.63 
(d, J = 7.8 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.45-7.28 (m, 7H), 7.08 (d, J = 8.12 Hz, 1H), 2.46 
(s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 148.3, 144.1, 138.0, 132.6, 130.4, 130.0, 128.6, 128.3, 
127.0, 125.7, 122.3, 117.5, 111.9, 20.4.; MS (ESI): m/z 385 [M+H]
+
. HRMS (ESI) calcd for 
C23H17ClN4 [M+H]
+
 385.12185; found: 385.12093. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-5,6-dimethyl-1H-benzo[d]imidazole (33) 
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Light brown solid, yield 71%, Mp: 182-184 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.41 (s, 1H), 7.56 
(d, J = 8.08 Hz, 2H), 7.48 (t, J = 8.39 Hz, 2H), 7.36-7.30 (m, 3H), 7.26-7.21 (m, 4H), 2.34 (s, 
6H). 
13
C NMR (75 MHz, CDCl3) δ 149.7, 143.3, 134.4, 133.1, 130.0, 129.5, 129.2, 128.7, 128.4, 
127.9, 127.3, 126.9, 126.5, 119.2, 118.8, 114.3, 110.7, 109.3, 20.3.; MS (ESI): m/z 399 [M+H]
+
.; 
HRMS (ESI) calcd for C24H20ClN4 [M+H]
+
 399.13745; found: 399.13714. 
5,6-Dichloro-2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (34) 
Brown solid, yield 72%, mp: 195-197 ºC; 
1
H NMR (300 MHz, CDCl3) δ 8.39 (s, 1H), 7.92-7.80 
(m, 4H), 7.65 (s, 1H), 7.52 (t, J = 7.74 Hz, 2H) 7.4 – 7.32 (m, 4H).  MS (ESI): m/z 439 [M+H]+; 
HRMS (ESI) calcd for C22H14Cl3N4 [M+H]
+
 439.0284; found: 439.0282. 
2-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-naphtho [2,3-d]imidazole (35) 
Light brown solid, yield 75%, Mp: 184-186 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 
7.92-7.84 (m, 3H), 7.70 – 7.59 (m, 4H), 7.45 – 7.37 (m, 6H), 7.32 (t, J = 7.4 Hz, 1H), 7.25 (s, 
1H). 
13
C NMR (75 MHz, CDCl3) δ 150.0, 149.8, 139.1, 134.3, 130.8, 130.3, 129.9, 129.4, 128.4, 
127.7, 127.1, 123.5, 118.8, 112.7.; MS (ESI): m/z 421 [M+H]
+
.; HRMS (ESI) calcd for 
C26H18ClN4 [M+H]
+
 421.12184; found: 421.12176. 
2-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (36) 
Light yellow solid, yield 78%, Mp: 179-182 ºC.; 
1
H NMR (300 MHz, CDCl3+DMSO-d6) δ 8.69 
(s, 1H), 7.81 (dd, J = 8.2, 3.4 Hz, 4H), 7.56 (dd, J = 5.9, 3.1 Hz, 2H), 7.48 (t, J = 7.9 Hz, 2H), 
7.32 (t, J = 7.4 Hz, 1H), 7.23 – 7.14 (m, 2H), 6.89 (d, J = 8.8 Hz, 2H), 3.77 (s, 3H). 13C NMR 
(75 MHz, CDCl3+DMSO-d6) δ 158.6, 149.5, 145.0, 138.2, 128.5, 128.3, 128.2, 125.6, 123.8, 
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120.8, 117.5, 112.5, 111.5, 54.0.; MS (ESI): m/z 367 [M+H]
+
. HRMS (ESI) calcd for C23H19ON4 
[M+H]
+
 367.15534; found: 367.15330. 
6-Fluoro-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (37) 
Light brown solid, yield 71%, Mp: 176-179 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.64 (s, 1H), 7.73 
(d, J = 7.9 Hz, 2H), 7.63 (d, J = 8.54 Hz, 2H), 7.47-7.43 (m, 4H), 7.32 (t, J = 7.4 Hz, 1H), 7.02-
6.95 (m, 3H), 3.85 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 160.2, 159.9, 158.3, 150.7, 147.2, 
139.3, 129.6, 129.4, 128.9, 126.8, 124.6, 118.8, 113.9, 112.3, 110.4, 110.2, 55.1.; MS (ESI): m/z 
385 [M+H]
+
; HRMS (ESI) calcd for C23H18ON4F [M+H]
+
 385.1464; found: 385.1506. 
6-Chloro-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (38) 
Light brown solid, yield 75%, Mp: 188-190 ºC; 
1
H NMR (300 MHz, CDCl3) δ 8.47 (s, 1H), 7.62 
(d, J = 7.74 Hz, 2H), 7.50-7.39 (m, 4H), 7.36-7.24 (m, 3H), 7.18 (d, J = 7.6 Hz, 1H), 6.89 (d, J = 
8.5 Hz, 2H), 3.78 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 160.1, 150.7, 147.0, 139.0, 129.7, 
129.4, 128.7, 128.1, 127.1, 124.2, 123.1, 118.9, 114.2, 112.0, 55.2.; MS (ESI): m/z 401 [M+H]
+
. 
HRMS (ESI) calcd for C23H18ON4Cl [M+H]
+ 
401.11637; found: 401.11412. 
6-Bromo-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (39) 
Light brown solid, yield 78%, Mp: 194-196 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 7.81 
(d, J = 8.1 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 7.57-7.42 (m, 4H), 7.36 (t, J = 7.2 Hz, 1H), 7.11-
7.02 (m, 3H), 3.87 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 160.2, 151.1, 146.8, 139.5, 129.8, 
129.5, 128.8, 127.1, 125.6, 124.3, 119.0, 115.5, 114.3, 112.0, 55.2.; MS (ESI): m/z 445 [M+H]
+
.; 
HRMS (ESI) calcd for C23H18BrN4O [M+H]
+
 445.06593; found: 445.06581. 
6-Methoxy-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (40) 
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Light yellow solid, yield 74%, Mp: 177-179 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.69 (s, 1H), 
7.90 – 7.66 (m, 4H), 7.59-7.48 (m, 3H),  7.45 (t, J = 7.6 Hz, 2H), 7.33 (d, J = 7.2 Hz, 1H), 6.89 
(d, J = 8.5 Hz, 2H), 3.82 (s, 3H), 3.78 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 162.0, 160.0, 158.7, 
138.3, 136.1, 130.3, 129.1, 128.6, 125.7, 123.8, 118.1, 115.9, 112.5, 105.8, 101.6, 55.4, 55.3.; 
MS (ESI): m/z 397 [M+H]
+
. HRMS (ESI) calcd for C24H21O2N4 [M+H]
+
 397.16590; found: 
397.16368. 
2-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)-1H-
benzo[d]imidazole (41) 
Brown solid, yield 71%, Mp: 190-192 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 7.72 (d, J 
= 7.7 Hz, 2H), 7.57 (d, J = 8.6 Hz, 2H), 7.55-7.46 (m, 4H), 7.33 (t, J = 7.3 Hz, 1H), 7.11 (d, J = 
7.2 Hz, 1H), 6.98 (d, J = 8.6 Hz, 2H), 3.84 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 160.0, 150.8, 
147.9, 138.8, 129.4, 127.2, 123.8, 119.9, 118.9, 114.1, 110.6, 54.9. MS (ESI): m/z 435 [M+H]
+
. 
HRMS (ESI) calcd for C24H18ON4F3 [M+H]
+
 435.14272; found: 435.13945. 
2-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-6-methyl-1H-benzo[d]imidazole (42) 
Light brown solid, yield 68%, Mp: 175-177 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 7.66 
(d, J = 7.8 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 7.40 (t, J = 7.9 Hz, 2H), 7.30 (dd, J = 12.4, 5.0 Hz, 
4H), 6.94 – 6.90 (m, 2H), 3.80 (s, 3H), 2.33 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 160.2, 150.6, 
145.5, 139.3, 132.5, 130.0, 129.5, 129.2, 128.8, 128.6, 127.0, 126.4, 124.7, 124.1, 119.0, 118.7, 
114.4, 114.0, 112.8, 110.1, 55.3, 21.6.; MS (ESI): m/z 381 [M+H]
+
. HRMS (ESI) calcd for 
C24H21ON4 [M+H]
+
 381.17099; found: 381.16916. 
2-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-5,6-dimethyl-1H-benzo[d]imidazole (43) 
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Light brown solid, yield 67%, Mp: 187-189 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.93 (s, 1H), 7.65 
(d, J = 7.5 Hz, 2H), 7.45 – 7.30 (m, 4H), 7.26 – 7.11 (m, 2H), 6.78 (d, J = 8.6 Hz, 2H), 6.68-6.73 
(m, 1H), 3.71 (s, 3H), 2.33 (s, 6H); 
13
C NMR (75 MHz, CDCl3) δ 160.2, 150.5, 145.0, 139.4, 
131.5, 130.0, 129.5, 129.2, 128.7, 128.5, 126.9, 126.4, 124.7, 119.8, 119.1, 118.7, 114.3, 112.9, 
110.8, 55.3, 20.3.; MS (ESI): m/z 395 [M+H]
+
. HRMS (ESI) calcd for C25H23ON4 [M+H]+ 
395.18664; found: 395.18477. 
5,6-Dichloro-2-(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazole (44) 
Light brown solid, yield 79%, Mp: 208-210 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.73 (s, 1H), 7.82 
(d, J = 7.7 Hz, 2H), 7.78 (d, J = 8.6 Hz, 2H), 7.66 (s, 2H), 7.49 (dd, J = 10.7, 5.1 Hz, 2H), 7.33 
(t, J = 7.4 Hz, 1H), 6.95 – 6.86 (m, 2H), 3.81 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.3, 
150.3, 148.0, 138.8, 129.2, 129.1, 126.5, 124.7, 124.2, 118.2, 113.2, 111.5, 54.7.; MS (ESI): m/z 
435 [M+H]
+
. HRMS (ESI) calcd for C23H17ON4Cl2 [M+H]
+
 435.07739; found: 435.07502. 
2-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)-1H-naphtho[2,3-d]imidazole (45) 
Light brown solid, yield 76%, Mp: 211-213 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H), 
7.89-7.81 (s, 4H), 7.74 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 8.6 Hz, 2H), 7.45 (t, J = 7.9 Hz, 2H), 
7.39 (dq, J = 6.5, 3.3 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.01 (d, J = 8.6 Hz, 2H), 3.83 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 149.2, 147.2, 142.9, 139.0, 138.4, 130.9, 127.2, 123.5, 121.2, 114.1, 
110.3, 108.5, 105.7, 101.8, 101.6, 55.4.; MS (ESI): m/z 417 [M+H]
+
.; HRMS (ESI) calcd for 
C27H21N4O [M+H]
+
 417.17142; found: 417.17126. 
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4.2 Cell culture  
      MCF-7 (breast), HeLa (cervical) and A549 (lung) cancer cells were purchased from ATCC 
(Manassas, VA). The A549 cells were grown in RPMI 1640 medium (GIBCO-Invitrogen, NY) 
with 10% fetal bovine serum (FBS) and supplemented with glutamine (2 mmol/L), penicillin G 
(100 µg/mL), and streptomycin (100 µg/mL) at 37 ºC under 5% CO2. MCF-7 and HeLa cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin at 37 
o
C under 5% CO2. The culture medium was 
replaced with fresh medium every two days. After reaching 80-90% confluence, cells were 
treated with 0.25% trypsin-EDTA for further passages. Cells were used at passages 4-8 for all the 
experiments. 
4.2.1 MTT assay 
      The in vitro cytotoxicity of test compounds on MCF-7, HeLa and A549 cells was performed 
using the MTT assay. Cells under study were seeded into 96 well plates at a density of 3000-
5000 cells per well depending on their doubling times and allowed to adhere for 24 h at 37 ˚C 
and 5% CO2.  After 24 h incubation, the medium was replaced with culture medium containing 
test compounds dissolved in dimethyl sulphoxide (DMSO) and culture medium (DMSO) only 
was included as a control. After 48 h incubation, the medium containing test compounds was 
aspirated and 100 µL of culture media containing 5 mg/mL MTT (Thiazoyl blue tetrazolium 
bromide) was added to each well and cells were further incubated for 4 hours in dark at 37 ºC. 
After 4 hours incubation, the media containing MTT was removed and 100 µL DMSO was 
added to each well to solubilize the crystallized formazan product. The plates were read on a 
micro-plate reader at 570 nm and a reference wavelength of 630 nm. The per cent growth 
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inhibition was calculated as 100-[(Mean OD of treated cell x 100)/Mean OD of vehicle treated 
cells (DMSO)]. The IC50 values were calculated using Probit Software. All tests were repeated in 
at least three independent experiments.
47
 
4.2.2 In vitro cell migration assay 
      MCF-7 cells (5x10
5 
cells/well) were cultured in a 6 well plate as confluent monolayer for 24 
h. The monolayers were then scratched with 200 µL pipette tip. The wounded monolayers were 
washed twice with 150 mM PBS (pH 7.4) to remove non-adherent cells. Media containing IC50 
concentrations of the compounds 9, 17 and 28 was then added to each well. Cells which migrated 
across the inflicted wound were photographed under the phase contrast microscope microscopy 
at 0, 24 , 48 and 72 h time intervals after treatment in three or more randomly selected fields.29 
4.2.3 Colony formation inhibition assay 
      MCF-7 cells at the exponential phase were plated into 6-well culture plates at a single cell 
density (500 cells/well) and allowed to adhere for 24 h before treatment. Cells were incubated 
with culture medium containing IC50 concentrations of the compounds 9, 17 and 28. After 24 h 
the medium was replaced with fresh medium and cells were incubated for 14 days. Cells were 
then washed with 150 mM PBS (pH 7.4), fixed with 4 % paraformaldehyde and stained with 
0.5% methylene blue in 10% ethanol for 30 min and rinsed with distilled water to remove excess 
dye. Plates were photographed with a digital camera.
30
 
4.2.4 Cell cycle analysis 
      MCF-7 Cells (1x10
6
 cells/well) were seeded in 6 well plates and incubated overnight. Cells 
were treated with IC50 concentrations of compounds 9, 17 and 28 for 24 h. Vehicle (DMSO) 
treated cells were used as controls. After 24 h treatment, both floating and adherent, trypsinzed 
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cells were collected and washed with 150 mM PBS (pH 7.4). The pellet was resuspended in 1 
mL of 150 mM PBS  at room temperature  and all suspended cells added to 9 ml of 70% ethanol 
by pipetting the cell suspension slowly in to ethanol, while and then vortexing at high speed.  
Cells were kept at 4 ºC. After 30 min, ethanol was removed by centrifuging the cells. After 
tapping the tube to loosen the pellet, 5 mL 150 mM PBS was added at room temp. Cells were 
allowed to rehydrate for 15 min and then centrifuged. The cell pellet was resuspended in 
propidium iodide staining buffer (PI (200 µg), 0. 1% (v/v) Triton X-100, 2 mg DNAse-free 
RNAse A (Sigma) in 10 mL PBS), and incubated for 15 min at room temp in dark. The samples 
were analysed for PI fluorescence from 10000 events in a FACScanto -II flow cytometer (BD), 
using a linear scale for the cell cycle and a logarithmic scale to determine the sub- G1 fraction. 
Results were analysed with FlowJo software (v 7.6.5, Tree Star, Inc.).
48
 
4.2.5 Hoechst staining 
      MCF-7 cells were seeded at a density of 5X10
4
 cells/well in 12 well tissue culture plates and 
incubated for 24 h. The culture medium was then replaced with media containing IC50 
concentrations of the compounds 9, 17 and 28 and incubated for 24 h. After 24 h treatment, cells 
were fixed with 4% para formaldehyde and stained with Hoechst 33242 (5 µg/mL) for 30 min at 
room temp. Excess dye was removed by washing the cells twice with 150 mM PBS (pH 7.4). 
Images of stained nuclei from each well were captured from randomly selected fields under 
fluorescence microscopy (filters, excitation 350 nm and emissions 460 nm) to detect apoptotic 
cells.
48 
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4.2.6 DNA fragmentation assay 
      MCF-7 Cells were seeded (1X10
6 
cells/well) in six-well plates. After incubation for 24 h, 
cells were treated with IC50 concentrations of compounds 9, 17 and 28 for 24 h. Cells were 
harvested by trypsinisation and centrifuged at 2500 rpm for 5 min at 4 ºC. The pellet was 
collected and washed with phosphate buffered saline (150 mM PBS; pH 7.4). 250 µL of lysis 
buffer (100 mM NaCl, 5 mM EDTA, 10 mM Tris HCl pH 8.0, 0.25% SDS) containing 400 
µg/mL DNase free RNase A was added and incubated at 37 
º
C for 90 min, followed by 
incubation with proteinase K (200 µg/mL) at 50 
o
C for 1 h. Samples were centrifuged at 3000 
rpm for 5 min at 4 
º
C and supernatant collected. 65 µL of 10 M ammonium acetate and 500 µL 
of ice cold ethanol was added and mixed well. These samples were incubated at -80 
o
C for 1 h. 
After incubation, samples were centrifuged at 12000 rpm for 20 min at 4 
o
C and the pellet 
washed with 80% ethanol and air- dried for 10 min at room temperature. The pellet was 
dissolved in 50 µL of TBE buffer and DNA laddering was visualised by using 1.5% agarose gel 
electrophoresis in TBE Buffer followed by ethidium bromide staining and photography. 
4.2.7 Measurement of mitochondrial membrane potential 
      MCF-7 cells (5X10
5
 cells/mL) were seeded in 6 well plates and allowed to adhere overnight. 
Cells were treated with IC50 concentrations of compounds 9, 17 and 28. After 24 h treatment, 
cells were harvested by trypsinisation, washed with 150 mM PBS (pH 7.4) and resuspended in a 
solution of rhodamine 123 (5 µg/mL). The cells were washed twice with 150 mM PBS followed 
by 30 min incubation at room temperature then resuspended in 150 mM PBS. Samples were then 
subjected to flow cytometric analysis on a FACScan (Becton Dickinson) to detect loss of 
mitochondrial membrane potential. For qualitative analysis, cells were observed under a 
fluorescence microscope (Nikon, 10X Magnification).
48 
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4.2.8 Measurement of reactive oxygen species (ROS) levels 
      MCF-7 cells were plated in 6 well plates at a density of 1x10
5
 cells/mL and allowed to 
adhere overnight. Cells were then treated with IC50 concentrations of compounds 9, 17 and 28 
for 24 h. After 24 h treatment, the medium was replaced with culture medium containing 
carboxy-DCFDA (10 µM) and further incubated for 30 min at room temperature in dark. Cells 
were collected, washed twice with 150 mM PBS (pH 7.4) and resuspended at a density of 5x10
4
 
cells/mL. The fluorescence intensity from each sample was analysed by spectrofluorometry at 
excitation and emission wavelengths of 488 and 525 nm, respectively. Qualitative cellular 
fluorescence images were captured by using a Nikon ECLIPSETE2000-S fluorescence 
microscope.
48 
 
4.2.9 RNA extraction 
      MCF-7 cells (1X10
6
 cells/ well) were plated in 6-well plates and allowed to adhere for 24h. 
After 24 h, cells were treated with IC50 concentrations of compounds 9, 17 and 28. After 24h 
incubation time, total RNA was extracted using TRIZOL reagent (Life Technologies, Carlsbad, 
CA, 12183-555) according to the manufacturer’s instructions. Briefly, cells were washed twice 
with 2 mL cold 1 x PBS followed by addition of 1 mL of Trizol. Cell lysis was performed by 
incubating the cells with Trizol for 5 min at room temperature, samples transferred to 1.5 mL 
eppendorf centrifuge tubes and 0.12 mL of chloroform added. Tubes were then inverted 
vigorously for 15 seconds and incubated on ice for 10 min followed by centrifugation at 12000 
rpm for 15 min at 4 
o
C. The aqueous phase was withdrawn and transferred to new 1.5 mL 
eppendrof tubes. 0.3 mL of isopropanol was added to the aqueous phase and RNA precipitated. 
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Samples were centrifuged at 8000 rpm for 30 min at 4 
o
C. The supernatant was removed and the 
resulting pellet washed with 0.6 mL of 75% ethanol. Samples were then centrifuged at 8000 rpm 
for 20 min at 4 
o
C, the supernatant was discarded and the pellet was air-dried then resuspended in 
20 µL of DEPC water. RNA was stored at −80 °C. RNA concentration was determined with a 
Nano drop (Thermo Scientific, USA). This method yielded an average of 40 µg total RNA from 
10
6 
cells.
49
 
4.2.10 cDNA Synthesis 
      cDNA synthesis from RNA was carried out in a volume of 20 µL reaction mixture containing 
1 µg of RNA in 10 µL nuclease free water, 2 µL of 10X RT buffer, 0.8 µL of 25X dNTP mix 
(100 mM), 2 µL of 10X random primers and 3.2 uL of nuclease free water. The thermal PCR 
cycles used in thermal cycler for reverse transcription were: 25 
º
C for 10 min followed by 37 ºC 
for 2 h, 85 ºC for 5 min and finally hold at 4 ºC. The resulting cDNA was stored at −20 °C until 
use.
49
 
4.2.11 Real Time PCR 
      Fold change in mRNA expression levels were determined by the comparative CT method. 
Each 10 µL PCR reaction in PCR fast reaction tubes (Applied Biosystems) contained 2.5 µL of 
De Ionised water, 5 µL of TaqMan Universal Master Mix (Applied Biosystems), 0.5 µL (300 
nM) of assay primers (Eurofins, Germany) and 2 µL of cDNA. Samples were subjected to real-
time quantitative PCR (Applied Biosystems-7500 Fast, USA). Specific gene primers (Bax, BCl-
2, CASP-3, CASP-7, E-cadherin and the internal control gene β-actin) were used to amplify the 
target genes. The sequences of the human genome based primers used for RT-PCR were 
E-cadherin (CGCGTCCTGGGCAGAGTGAATTTTG) 
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β-catenin (CGCCAGGATGATCCTAGCTATCGTT),  
cyclin-D1 (CTCTGTGCCACAGATGTGAAGTTCA),  
Bax (CTGGTGCTCAAGGCCCTGTGCACCA),  
Bcl-2 (CGGAGGCTGGGATGCCTTTGTGGAA),    
caspase-3 (CATAAAAGCACTGGAATGACATCTC),   
caspase-7 (TATTCCACGGTTCCAGGCTATTACT),  
β-actin (CCTTTGCCGATCCGCCGCCCGTCCA),  
      Each reaction was performed in triplicate and threshold cycle numbers (CT) determined 
using the Applied Biosystems-7500 Fast software and the mean CT of triplicate reactions 
determined. Expression levels of specific genes were normalized to β-actin levels. The levels of 
the target gene expression can be expressed as 2
ΔΔCT
 fold, where ΔΔCT = (CT.target – CT.actin)Time 24 
h – (CT.target – CT.actin)Time 0 h. The ΔCT value is inversely proportional to the levels of mRNA 
expression of the samples in this formula. The PCR cycles used were: 1 cycle of 95 
o
C for 3 min, 
followed by 40 cycles of 95 
o
C for 1 second (denaturation) and 60 
o
C for 20 seconds (annealing 
and extension). The PCR products were separated on a 1.5 % agarose gel containing ethidium 
bromide and viewed under UV light. Signal intensities for the PCR products were analysed using 
Quantiscan software (Biosoft, Cambridge, MA, USA).
49
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NMR and Mass spectra of selected compounds 
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HRMS spectrum of compound 9 
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Chapter-VI 
Synthesis and biological evaluation of pyrazolo-triazole 
hybrids as cytotoxic and apoptosis inducing agents 
      
Abstract 
A series of pyrazolo-triazole hybrids were designed and synthesized by combining the 1,3-
diphenyl pyrazole and triazole scaffolds to obtain (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-
diphenyl-1H-pyrazol-4-yl)methanones. All the synthesized compounds were screened for 
their anticancer activity against four tumor cell lines HT-29 (colon), PC-3 (prostate), A549 
(lung), U87MG (glioblastoma) cancer cell lines employing MTT assay. Most of the tested 
compounds showed moderate to potent cell growth inhibition on different cancer cells, in 
particular the compounds 17, 23, and 29 exhibited promising cytotoxicity against these cell 
lines with the IC50 values in the range of 0.86-3.72 µM. In addition, the mechanism of cell 
growth inhibition and apoptotic induction by these compounds was preliminarily investigated 
in U87MG cancer cells by wound healing assay, flow cytometry, Hoechst 33242 staining, 
acridine orange/ethidium bromide staining, Rhodamine 123 staining, and DCFDA staining. 
These compounds induce apoptosis in U87MG cells via mitochondrial pathway through up 
regulation of proapoptotic genes such as Bax and down regulation of anti-apoptotic proteins, 
like Bcl-2. Based on these studies, three compounds 17, 23 and 29 were identified as 
promising new molecules that have the potential to be developed as leads. 
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6.1 Introduction 
      Cancer is a disease of uncontrolled cell proliferation and is one of the second leading 
causes of death worldwide after heart diseases.
1 
Many of the currently existing anticancer 
drugs are limited by their toxicity to normal rapidly growing cells and may develop 
resistance.
2 
The enormous incidence and mortality rate of cancer patients increases the search 
for safer and effective anticancer agents that show potent and broad spectrum of anticancer 
activity. Apoptosis or programmed cell death is a critical cellular process for the maintenance 
of tissue homeostasis and normal development of multicellular organisms. In appropriate 
regulation of apoptosis signaling pathways may lead to several diseases including cancer.
3
 In 
tumor cells, the pathways that lead to apoptosis are disrupted or impaired due to which cells 
undergo malignant transformation. Therefore, targeting critical apoptosis regulators with a 
goal to induce apoptosis in cancer cells has emerged as an attractive strategy in cancer 
chemotherapy.
4
 
      Pyrazole is an important heterocyclic structural motif which is known to exhibit extensive 
range of biological activities such as analgesic anti-pyretic, anti-inflammatory, anti-oxidant, 
anti-bacterial and anticancer activities.
5-8 
Pyrazole-based compounds are reported to exert 
their anticancer activity through inhibition of various targets such as EGFR, tumor growth 
factor (TGF), fibroblast growth factor (FGF), telomerase and different kinases which are 
significant for the management of cancer.
9-11
 Among the pyrazoles, 1,3-diphenylpyrazoles are 
known for their potent  anticancer activity, including cytotoxicity against different cancer 
cells, induction of cell-cycle arrest  and induction of apoptosis.
12-13
 Moreover, it has been 
reported that pyrazole-based molecules have excellent drug-like properties and high oral 
bioavailability.
14
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      On the other hand, 1,2,3-triazoles are very important heterocyclic structural motifs in 
organic as well as medicinal chemistry due to their ease of synthesis by click chemistry and 
wide range of pharmacological activities with potent anticancer properties.
15-18
 1,2,3- 
Triazoles are highly stable under different acidic or basic conditions and are capable of 
forming hydrogen bonds with the biological targets.
19
 Many of the 1,2,3-triazole containing 
drugs such as cefatrizine, tazobactam, carboxyamidotriazole are available in the market.
20
 
      Pharmacophore hybridization is an effective tool to design highly active new chemical 
entities by covalently combining two or more active pharmacophores in to a single molecule. 
These merged pharmacophores may act on multiple targets and offer the possibility of 
circumventing drug resistance, and in addition, hybrids may also often show synergetic 
action. In view the above considerations and inspired by the promising anticancer activity of 
pyrazoles and 1,2,3-triazoles, we designed a series of various pyrazolo-triazole hybrids  
 To generate new hybrid molecules of 1,3-diphenyl pyrazoles with 1,2,3-triazoles via 
click chemistry  
 To make new hybrids that show higher activities than their parent individual 
molecules 
 To produce promising anticancer agents with strong growth inhibition on cancer cells 
 To establish structure activity relationship studies for the new hybrid scaffold. 
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Scheme. 6.1 
 
Scheme 6.1 General synthesis of (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-
4-yl)methanone (7-36). Reagents and conditions: (a) ethanol, 50–60 ºC, 3 h; (b) DMF, POCl3, 
50–60 ºC, 5 h; (c) ethynylmagnesium bromide, THF, 0°C-rt, 8-9 h, 60-70%; (d) 2-
iodoxybenzoic acid, DMSO, rt, 5 h, 70-72%; (e) different substituted aliphatic azides, CuSO4 
5H2O, sodium ascorbate, tBuOH/H2O (1:2), rt, 8 h. See Table. 6.1 for structures of final 
compounds (64-90%). 
6.2 Results and discussion 
6.2.1 Chemistry 
      The synthetic route for (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-
yl)methanone derivatives is illustrated in Scheme 1.
21
 Condensation of the different 
substituted acetophenones (1a-e) with phenyl hydrazine (2) in ethanol produces the 
corresponding acetophenone phenyl hydrazones (3a-e) which on cyclization with DMF-
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POCl3 (Vilsmeier–Haack reaction) afforded the corresponding 1,3-diphenyl pyrazole 
carboxaldehydes (4a-e). Their spectroscopic and analytical data were similar to those 
reported in the literature.
21
 Reaction of the aryl aldehyde intermediates with ethynyl 
magnesium bromide in dry tetrahydrofuran (THF) at 0 °C to room temperature, yielded 
alcohol substituted compounds 5a-e which upon oxidation with 2-iodoxybenzoic acid (IBX) 
in the presence of dimethylsulfoxide (DMSO) gave 1-(1,3-diphenyl-1H-pyrazol-4-yl)prop-2-
yn-1-one derivatives (6a-e). These terminal alkyne substituted intermediates were allowed to 
react with various synthesized benzyl azides, in the presence of CuSO4.5H2O and sodium 
ascorbate, in t-butyl alcohol and water (1:2) at room temperature to afford the pyrazolo 
triazole hybrids (7-36) in good to excellent yields (64-90%). All the structures of these 
hybrids were confirmed by spectral data (
1
H and 
13
C NMR and MS and HRMS).  
6.2.2 In vitro cytotoxicity 
      All the synthesized compounds (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-
pyrazol-4-yl)methanone, 7-36 were evaluated for their anticancer activity against four human 
tumor cell lines HT-29 (colon), PC3 (prostate), A549 (lung) and U87MG (brain), by using 
standard MTT assay. The concentrations that cause 50% inhibition of cancer cell growth are 
expressed as IC50 values. The IC50 values of the compounds in comparison to standard drug 
5-fluorouracil are presented in Table.6.1. Results from the MTT assay revealed that most of 
the compounds showed moderate to potent cell growth inhibition on U87MG cells 
selectively. Some of the synthesized compounds such as 11, 16, 17, 18, 23, 24, 29, 30, 35 and 
36 displayed potent and broad spectrum of growth inhibition against the cell lines tested and 
were superior or comparable to the positive standard (5-fluorouracil). The highest growth 
inhibitory activity was observed with the compounds 23 (IC50-0.86 µM) followed by the 
compounds 29 (IC50-0.97 µM), 17 (IC50-1.14 µM) against the U87MG cancer cell line. The 
other three remaining cell lines also showed maximum sensitivity towards these three 
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compounds with not more than IC50 values of 3.71 μM concentration. Compound 22 was 
highly active on colon cancer HT-29 cell line (IC50-1.78 µM), while the compounds 16 and 
35 showed selective potency against, lung cancer (A549) cell line (IC50-2.13 µM) and 
prostate cancer (PC-3) cell line (IC50-2.32 µM) respectively. 
Table 6.1 Anti-proliferative activities (
a
IC50-µM) of the (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-
diphenyl-1H-pyrazol-4-yl)methanone derivatives (7-36) 
Compound R R1 HT29 
(Colon) 
PC3 
(Prostate)   
A549 
(Lung) 
U87MG 
(brain) 
7 H F 22.4±2.6 >50 7.07±0.6 6.45±1.3 
8 H Cl >50 >50 >50 >50 
9 H CF3 >50 >50 >50 >50 
10 H OMe 5.71±1.8 4.21±0.7 7.21±1.3 8.87±0.9 
11 H 3,4 OMe 2.92±0.3 2.69±0.7 4.69±1.7 3.57±0.3 
12 H 3,4,5-OMe 4.63±0.7 6.81±1.3 5.56±1.6 7.85±2.1 
13 F F 14.48±2.6 17.87±0.6 5.92±0.2 4.76±0.7 
14 F Cl 15.92±2.3 16.04±2.7 8.5±1.9 9.43±2.9 
15 F CF3 >50 >50 >50 24.76±0.2 
16 F OMe 2.54±0.6 5.87±1.1 2.13±0.4 3.76±0.5 
17 F 3,4 OMe 2.48±1.2 3.34±0.2 2.3±0.8 1.14±0.8 
18 F 3,4,5OMe 3.09±0.02 4.4±0.2 3.8±1.01 5.3±1.01 
19 Cl F 12.59±1.7 >50 4.98±0.5 8.91±1.3 
20 Cl Cl 9.92±0.4 11.05 ±1.6 6.04±0.9 4.24±0.7 
21 Cl CF3 12.9±2.3 13.4±1.1 5.72±1.2 6.54±0.4 
22 Cl OMe 1.78±0.2 6.3±0.8 5.3±0.6 3.3±0.5 
23 Cl 3,4 OMe 2.42±1.4 3.71±1.0 1.93±0.5 0.86±0.3 
Chapter-VI 
 
282 | P a g e  
 
24 Cl 3,4,5-OMe 3.5±1.2 5.62±0.45 2.42±0.1 3.95±0.03 
25 OMe F 14.7±2.6 9.7±1.7 13.7±2.3 15.5±3.8 
26 OMe Cl 7.22±1.1 >50 11.21±4.1 5.89±1.0 
27 OMe CF3 29.11±1.8 >50 14.5±1.0 4.24±0.6 
28 OMe OMe 6.99±0.09 7.84±1.2 4.84±1.2 3.63±0.8 
29 OMe 3,4 OMe 1.78±1.0 3.52±0.3 2.24±0.1 0.97±0.3 
30 OMe 3,4,5-OMe 4.4±0.7 5.65±0.9 5.32±1.2 1.15±0.4 
31 3,4,5-OMe F 28.6±1.9 >50 >50 18.9±2.6 
32 3,4,5-OMe Cl 24.1±2.6 >50 >50 26.7±3.5 
33 3,4,5-OMe CF3 14.72±0.5 >50 >50 8.25±1.1 
34 3,4,5-OMe OMe 4.39±0.3 >50 5.5±0.5 2.47±0.9 
35 3,4,5-OMe 3,4 OMe 2.6±0.1 2.32±0.3 3.47±0.9 3.61±0.5 
36 3,4,5-OMe 3,4,5-OMe 3.89±0.8 5.6±0.5 6.45±0.7 3.81±1.2 
5-Fluorouracil 2.6±0.1 2.32±0.3 3.47±0.9 3.61±0.5 
a
IC50 values are  the concentrations that cause 50 % inhibition of cancer cell growth.  Data 
represent the mean values plus standard deviation of three independent experiments 
performed in triplicate. 
      Herein, we investigated structure activity relationship by examining the effect of nature of 
substituents such as fluorine, chlorine, trifluoromethyl, and methoxy in A and B phenyl rings 
of these derivatives on inhibitions cancer cell proliferation. Firstly, the best substituent on the 
B ring is the electron donating 3, 4-dimethoxy, as all the 3,4 dimethoxy substituted hybrids 
11, 17, 23, 29 and 35 showed remarkable growth inhibition values on all the tested cancer 
cells with specificity towards U87MG cancer cells. Moreover, the other electron donating 
groups like methoxy (10, 16, 22, 28, and 34) and trimethoxy (12, 18, 24, 30, and 36) 
substitutions on the B ring produces derivatives with moderate to significant growth 
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inhibition of cancer cells. It is worth noting that, derivatives having electron withdrawing 
groups like fluoro, chloro, trifuromethyl on B ring displayed dramatic loss of potency. The 
anticancer activity was also influenced by the presence of various substituents on A ring. For 
instance, hybrids having fluoro (13-18) and chloro (19-24) group on A ring, showed 
increased sensitivity towards cancer cells when compared to unsubstituted hybrids (7-12). 
Similarly the methoxy (25-30) and trimethoxy (30-36) substitutions at the same position, 
resulted in moderate growth inhibition values. Overall, these SAR studies indicate that 
electron withdrawing groups on A ring and electron donating groups on B ring are favorable 
for cytotoxic activity of such hybrids. In view of the promising anti-proliferative activity of 
the compounds 17, 23 and 29, it was considered of interest to pursue some detailed studies 
with a view to understand the cell growth inhibition mechanisms in such hybrids. 
6.2.3 In vitro cell migration assay 
      As migration of cancer cells is a key step of tumor metastasis, cell migration assay
22 
was 
used to investigate the effect of 17, 23 and 29 on the migration potential of U87MG cancer 
cells. As shown in figure.6.1, cells migrated to the wound area decreased significantly after 
treatment with these hybrids in comparison to the control (untreated group) and showed 40-
57 % of migration in the inhibition of U87MG cancer cells. These results indicate that the 
migration of U87MG cancer cells was significantly suppressed by these pyrazolo-triazole 
hybrids. 
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Figure 6.1A 
 
Figure 6.1B 
Figure 6.1A).Effect of compounds17, 23, and 29 on U87MG cells migration in vitro.U87MG 
cells were treated with the compounds 17, 23 and 29 and wounds were induced with 200 µL 
pipette. The edges of wound were captured immediately (0 h) and 24 h after treatment. 6.1B) 
No. of cells migrated into the wound area was counted manually. The data are representative 
of three independent experiments and viewed at 4X magnification. 
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6.2.4 Cell cycle analysis 
      Cell cycle analysis was performed to determine whether the compounds have any effect 
on the cell cycle progression of U87MG cells. U87MG cells were treated with the 
compounds 17, 23 and 29 with their IC50 concentrations for 24 h and stained with propidium 
iodide. As shown in the figure 6.2, the compound treatment increases the cells in the G0/G1 
phase and concomitantly decreasing the cells in the S and G2/M phases. The control cells 
exposed to DMSO showed 59.4 % cells in G0/G1 phase, whereas compound treatment results 
in 74 to 86 % cells in G0/G1 phase. In particular, compound 29 increases G0/G1 population 
of U87MG cells to 86%. Moreover, the percentage of cells in S and G2/M phases was 
decreased significantly in compound treated cells compared to the control. These results 
indicated that the compound treatment of U7MG cells resulted in G0/G1 phase of the cell 
cycle arrest. 
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Figure.6. 2 Effect of compounds 17, 23 and 29 on cell cycle arrest. (6.2A) U87MG cells 
treated with the IC50 concentrations of the compounds or vehicle control were harvested after 
24 h. The cells were fixed and stained with propidium iodide and analyzed by BD FACS 
Canto-II. For each sample, 10,000 cells were used for sorting.  
 
Figure 6.2B. The percentage of cells in each phase was quantified bu using Flowjo Software.  
6.2.5 Apoptosis detection assays 
      Several members of the pyrazole and triazole derivatives were found to induce apoptosis 
and/or reduce cell proliferation in different cancer cell lines they inducing apoptosis.
23-24 
Hence it was considered of interest to investigate the apoptotic inducing effect of these 
potential hybrids in U87MG cancer cells. 
6.2.5.1 Hoechst staining 
      To investigate the apoptotic inducing effect of these hybrids (17, 23 and 29), Hoechst 
staining assay was carried out on U87MG cells. Hoechst 33242 is a cell membrane permeable 
nuclear staining dye which emits blue fluorescence and stains the live cell nuclei as light blue 
and while the apoptotic cell nuclei as bright blue due to chromatin condensation. U87MG 
cells were treated with 17, 23 and 29 at their IC50 concentrations for 24 h and stained with 
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Hoechst. The results from figure 6.3A indicate that in the control group, the cells (vehicle 
treated cells) did not show obvious morphological changes (all the cells exhibited uniform 
rounded cell morphology), however in compound treated group, 25-34 % of the cells 
exhibited typical apoptotic morphology such as highly condensed nuclei (brightly stained) as 
indicated by arrows in the figure 6.3B. This observation demonstrates that all the three 
hybrids 17, 23 and 29 are able to induce apoptosis in U87MG cells. 
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Figure 6.3B 
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Figure 6.3A) Compounds 17, 23 and 29 induced nuclear morphological changes of U87MG 
cells.6.3B) Quantitative analysis of apoptosis induced by the compounds 17, 23 and 29. Data 
are mean ± SD from three independent experiments. 
6.2.5.2 Acridine orange / Ethidium bromide (AO/EB) staining 
       To further address the apoptosis inducing effect of these hybrids, AO/EB staining assay 
was carried out. Acridine orange stains the nucleus of the both intact and damaged cell 
membrane and emits green fluorescence; whereas ethidium bromide (EB) only stains the 
nucleus of the damaged cell membrane and emits red fluorescence. Therefore viable cells can 
be observed as having uniform green nucleus and orange cytoplasm. Early apoptotic cells 
exhibit bright green nuclei because of condense chromatin and late apoptotic cells show 
bright orange areas of condensed chromatin in the nucleus. U87MG cells treated with the 
compounds at their IC50 concentration for 24 h and stained with AO/EB, and cells treated 
with DMSO were used as control. Results shown in figure 6.4 indicated that, control cells 
appeared uniformly green and did not take up the EB, while cells treated by these hybrids 17, 
23 and 29 showed apoptotic characters (chromatin condensation) and appeared as intense 
green and orange. These results clearly indicate that the pyrazolo-triazole hybrids 17, 23 and 
29 induce apoptosis in U87MG cells. 
 
Chapter-VI 
 
289 | P a g e  
 
Figure 6.4 AO/EB staining assay. U87MG cells were treated with compounds 17, 23 and 29 
for 24 h and stained with AO/EB. Images were captured with fluorescence microscope 
(Nikon) using green and red filter. Green colour (live cells); intense green (early apoptotic); 
intense yellow or orange (late apoptotic)  
6.2.5.3 DNA fragmentation assay 
      During apoptosis endonucleases cleave the DNA into smaller fragments and these 
fragments can be detected by gel electrophoresis as ladders. This ladder-like pattern is 
regarded as the biochemical hallmark of apoptosis.
25 
In order to further test the apoptosis 
inducing effect of these hybrids, DNA fragmentation assay was carried out. The 
chromosomal DNA extracted from the cells that were treated with IC50 concentrations of 
these hybrids (17, 23 and 29) after 24 h treatment, these extracts were used for agarose gel 
electrophoresis. As shown in figure 6.5, the exposure of U87MG cells to 17, 23 and 29 
resulted in DNA breaks (fragments), which then led to the formation of the DNA ladder. 
These breakages were extensive in case of 17 and 23, and further illustrate the activation of 
cell death pathways upon treatment by such hybrids. 
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Figure 6.5 DNA fragmentation in U87MG cells induced by the pyrazolo-triazole derivatives. 
U87MG cells were treated with the IC50 concentrations of the compounds17, 23 and 29 for 24 
h. The DNA was analyzed by agarose gel electrophoresis at 75 V for 1.5 h. Lane 1: Control; 
Lane 2–4: U87MG cells treated with compounds 17, 23 and 29 respectively. ‘M’ is Marker. 
6.2.5.4 Measurement of mitochondrial membrane potential (DΨm) 
      Previous reports have suggested that, the loss of mitochondrial membrane potential leads 
to apoptosis.
26
 In order to further investigate the apoptosis-inducing effect of target 
compounds, changes in mitochondrial membrane potential was measured after staining with 
rhodamine 123. Mitochondria that maintain normal DΨm can retain the rhodamine 123, 
which give strong green fluorescence. Disruption of mitochondrial membrane potential 
(DΨm) was associated with a decrease in green fluorescence due to a lack of rhodamine 123 
retention.
27 
Thus the relationship between (DΨm) and rhodamine 123 fluorescence is 
considered as linear. U87MG cells were treated with these hybrids 17, 23 and 29 at their IC50 
concentrations, stained with rhodamine 123 and the intensity of rhodamine 123 fluorescence 
was measured by spetrofluorometer. The results from the figure 6.6 revealed that these 
compounds induce 40-60 % loss of mitochondrial membrane potential (DΨm) in U87MG 
cells. Compound 23 is more potent in causing drop in DΨm which showed 60 % of collapse 
of MMP followed by the compounds 29 and 17 which induces 53 and 40 % loss of DΨm 
respectively. These results demonstrate that they induce apoptosis in U87MG cells through 
changes in DΨm. 
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Figure 6.6 Compounds 17, 23 and 29 induced loss of mitochondrial membrane potential 
(DΨm) in U87MG cells analyzed using Rhodamine 123 staining. The loss in intensity of 
fluorescence was measured by spetrofluorometer. Data are mean ± SD from three 
independent experiments. 
6.2.5.5 Measurement of reactive oxygen species (ROS) levels 
      Loss of mitochondrial membrane potential and elevation of intracellular reactive oxygen 
species (ROS) levels are two closely related events that occur during apoptosis.
28
 The levels 
of ROS were measured in U87MG cells by using a fluorescent probe, Carboxy-2’,7’-
dichlorofluorescein diacetate (DCFDA) to examine whether the drop in mitochondrial 
membrane potential was on account of the production of ROS.
29 
The non-fluorescent 
Carboxy-DCFDA was oxidized to green fluorescent DCF by intracellular esterase’s when it 
diffuses into cells. Thus, the intracellular ROS levels can be expressed as mean fluorescence 
intensity (MFI) of DCF. As shown in figure 6.7A, U87MG cells treated with hybrids 17, 23 
and 29 showed increase in green fluorescence compared to the control (untreated cells). The 
results from quantitative analysis show that they cause elevation of ROS levels by 1.5 to 3.5 
times compared to the control cells. Compound 29 showed marked increase in ROS levels 
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(3.5 times) and was found to be most potent ROS inducer (figure 6.7B). Hence, it could be 
concluded that these hybrids significantly elevate the intracellular ROS levels. 
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Figure 6.7A) Effect of compounds 17, 23 and 29 on the intracellular levels of ROS. U87MG 
cells were treated with compounds 17, 23 and 29 for 24 h and stained with Carboxy DCFDA. 
Images were captured by a fluorescence microscope (Nikon). 6.7B) The intensity of DCFDA 
fluorescence was measured by spetrofluorometer using an excitation wavelength of 485 nm 
and an emission wavelength of 535 nm. 
6.2.5.6 Effect on the mRNA expression of Bcl-2 and Bax 
      Bcl-2 family of proteins play an important role in inducing or inhibiting the apoptosis
30
 
and maintain the homeostasis by regulating the mitochondrial membrane potential, 
cytochrome c release and caspase activation.
31 
Therefore, we investigated the effect of these 
hybrids on Bcl-2 and Bax mRNA expressions through RT-PCR. The results from the 
experiment revealed that these hybrids have significant effect on the expression of Bax and 
Bcl-2, in U87MG cells. As shown in the figure 6.8, they induce the expression of 
proapoptotic gene Bax (1.8, 1.5, 2.16 times respectively) after 24 h exposure. Expression of 
anti-apoptotic gene Bcl-2 was down regulated 0.31-0.69 times by these compounds. 
Moreover, the Bcl-2/Bax ratio in U87MG cells was also determined and found as 2.95 (17), 
3.89 (23), 4.07 (29) in comparison to the control (1.00). This increase in the ratio of Bax/Bcl-
2 stimulates the release of cytochrome-c from mitochondrion to cytosol that leads to the 
activation of caspases causing cell death. They dramatically increase the ratio from 1 to 4.07, 
indicating their significant apoptotic behavior. These results suggest that U87MG induced 
cell apoptosis by these hybrids associated with the mitochondrial pathway. 
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Figure 6.8 Effect of compounds 17, 23 and 29 on the mRNA expression of apoptotic 
signaling molecules (Bax and Bcl-2) in U87MG cells. Cells were treated with IC50 
concentration of the compounds for 24 h. The mRNA expression levels of Bax and Bcl-2 
were analyzed by real-time PCR. Target gene expression is normalized to β-actin. PCR 
products were run on a 1.5 % agarose gel containing ethidium bromide and viewed under UV 
light. 
6.3 Conclusion 
      In summary, a series of new pyrazolo-triazole hybrids (7-36) have been prepared and 
evaluated for their cytotoxic activity against four human tumor cell lines. The results showed 
that most of these hybrids exhibited remarkable cell growth inhibition activities on different 
cancer cells. Some of the hybrids like 17, 23 and 29 exhibited potent broad spectrum of 
cytitoxic activity against all the tested cancer cells and were superior to the standard 5- 
fluorouracil. Their exposure to the U87MG cells resulted in inhibition of in vitro cell 
migration. Flow cytometry analysis results indicate that they induce cell cycle arrest at G1 
phase. In addition, they induce apoptosis in U87MG cells by causing collapse of 
mitochondrial membrane potential, elevation of ROS production, inducing DNA breaks and 
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changes in Bax, as well as BCl-2 gene expressions. Overall these results demonstrate that the 
pyrazolo-triazole hybrids have the potential to be developed as leads and their further 
structural modifications may produce promising anticancer agents for U87MG cancer cells. 
6.4 Experimental section 
General procedure for the synthesis of 1, 3 diphenyl pyrazole carboxaldehydes (4a-e) 
      The 1,3-diphenyl-1H-pyrazole-4-carboxaldehydes (4a-e) were synthesized based on a 
literature method.
13,32
 as following: para-substituted acetophenones (1a-e, 20 mmol) interact 
with phenyl hydrazine (2, 25 mmol)  in anhydrous ethanol to form acetophenone 
phenylhydrazones, which were added to a cold solution of DMF (25 mL) and POCl3 (5 mL), 
stirred at 50–60 ºC for 6 h. The resulting mixture was poured into ice-cold water; a saturated 
solution of sodium bi carbonate was added to neutralize the mixture, extracted with ethyl 
acetate and concentrated in vacuo. The obtained residue was purified by column 
chromatography using EtoAc/hexane as eluent to afford pure 1,3-diphenyl-1H-pyrazole-4-
carbaldehydes (4a-e) in good yields. The spectroscopic data of the obtained aldehyde 
compounds was in agreement with the reported data. 
General Procedure for the synthesis of 1-(1,3-diphenyl-1H-pyrazol-4-yl)prop-2-yn-1-ol 
derivatives (5a-e) 
      To a stirred solution of aldehydes (4a-e, 5 mmol) in dry tetrahydrofuran (THF) was added 
ethynylmagnesium bromide in THF (0.5 M solution, 7.5 mmol) at 0 °C and stirred at same 
temperature for 1 h. Then the reaction mixture was warmed to room temperature and stirred 
for another 6−7 h. Saturated aqueous ammonium chloride solution 5 mL was added and 
partitioned between ethyl acetate and saturated ammonium chloride solution. The organic 
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layer was washed with brine, dried over anhydrous Na2SO4, and evaporated in vacuo to get 
pure compounds and were used for next step without further purification.
33
 
General procedure for the synthesis of 1-(1,3-Diphenyl-1H-pyrazol-4-yl)prop-2-yn-1-
one derivatives (6a-e) 
      A solution of 2-iodoxy-benzoic acid (IBX) (12.5 mmol) in dimethyl sulfoxide (DMSO) 
(90 mL) was stirred for 5 min at room temperature until homogeneous. A solution of different 
substituted secondary alcohols (5a-e, 5 mmol) in DMSO (5 mL) was added, and the mixture 
was stirred for 5 h. Water (10 mL) was added, and the mixture was stirred at room 
temperature for 10 min, cooled in ice, and partitioned between water and EtOAc (50 mL). 
The mixture was filtered through celite, and the aqueous layer was further extracted with 
EtOAc (3x30 mL). The organic extracts were combined, washed with water followed by 
saturated sodium bicarbonate solutions and brine, dried over sodium sulfate, and evaporated 
in vacuo to get the pure product and was used for next step without further purification.
33
 
1-(1,3-Diphenyl-1H-pyrazol-4-yl)prop-2-yn-1-one (6a) 
Light yellow solid, yield 79%, Mp: 145-147 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 
7.99 – 7.90 (m, 2H), 7.82 (dt, J = 3.4, 2.1 Hz, 2H), 7.58 – 7.36 (m, 6H), 3.25 (s, 1H); 13C 
NMR (75 MHz, CDCl3) δ 169.3, 153.5, 138.8, 135.2, 131.4, 129.7, 129.3, 129.2, 128.0, 
127.9, 122.5, 119.7, 81.6. MS (ESI): 273 [M+H]
+
;  HRMS (ESI) calcd for  C18H13ON2 
[M+H]+ 273.1027; found: 273.1018 and C18H13ON2 Na[M+Na]
+
 295.0867 
1-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)prop-2-yn-1-one (6b) 
Light brown solid, yield 75%, Mp: 159-162 ºC; 
1
H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 
7.89 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.1 Hz, 2H), 7.53 (t, J = 7.7 Hz, 2H), 7.47-7.35 (m, 3H), 
3.26 (s, 1H); 
13
C NMR (75 MHz, CDCl3) δ 168.0, 159.8, 150.6, 137.1, 134.7, 129.8, 129.3, 
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128.2, 126.5, 120.8, 118.1, 117.9, 113.8, 113.3, 80.0, 79.0.; MS (ESI): 291[M+H]
+
;  HRMS 
(ESI) calcd for  C18H12FN2O [M+H]
+
 291.0934; found: 291.0886.  
1-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)prop-2-yn-1-one (6c) 
Light brown solid, yield 71%, Mp: 163-165 ºC; 
1
H NMR (300 MHz, CDCl3) δ 8.65 (s, 1H), 
7.87 (d, J = 8.3 Hz, 2H), 7.81 (d, J = 8.1 Hz, 2H), 7.52-7.36 (m, 4H), 3.27 (s, 1H); 
13
C NMR 
(75 MHz, CDCl3) δ 167.7, 159.1, 151.1, 137.2, 135.4, 130.2, 129.3, 128.1, 126.6, 120.5, 
118.2, 117.9, 113.5, 80.1, 78.8.; MS (ESI): 307 [M+H]
+
;  HRMS (ESI) calcd for  
C18H12ClN2O [M+H]
+
 307.0638; found: 307.0595. 
1-(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)prop-2-yn-1-one (6d) 
Light yellow solid, yield 76%, Mp: 153-155 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 
7.92 (d,  J = 8.1 Hz, 2H), 7.81 (d, J = 8.0 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.41 (t, 1H),  6.96 
(d, 2H), 3.87 (s, 3H), 3.25 (s, 1H);
 13
C NMR (75 MHz, CDCl3) δ 169.3, 161.0, 153.6, 139.2, 
135.2, 131.3, 129.6, 127.9, 123.9, 122.3, 119.5, 113.5, 81.5, 55.3; MS (ESI): 303 [M+H]
+
;  
HRMS (ESI) calcd for  C19H15O2N2 [M
+
]
+
 303.1133; found: 303.1178. 
1-(1-Phenyl-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-4-yl)prop-2-yn-1-one (6e) 
Light yellow solid, yield 78%, Mp: 147-149 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 8.61 (s, 1H), 
7.73 (d, J = 7.9 Hz, 2H), 7.45 (t, J = 7.8 Hz, 2H), 7.33 (t, J = 7.4 Hz, 1H), 7.18 (d, J = 5.3 Hz, 
1H), 7.09 (d, J = 13.7 Hz, 1H), 3.86 (s, 6H), 3.83 (s, 3H), 3.21 (s, 1H); 
13
C NMR (75 MHz, 
CDCl3) δ 169.3, 153.1, 152.8, 139.0, 138.7, 135.9, 129.7, 128.1, 126.6, 122.3, 119.8, 106.6, 
81.7, 60.9, 56.2. MS (ESI): 363 [M+H]
+
;  HRMS (ESI) calcd for  C21H18O4N2 [M+]
+ 
362.1266; found: 362.1370. 
General procedure for the synthesis of pyrazole-triazole hybrids (7-36) 
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To a solution of compounds (6 a-e, 2.0 mmol) and corresponding benzyl azides (2.0 mmol) in 
a mixture of t-BuOH/H2O 1:2 (8 ml) was added CuSO4·5H2O (2.0 mmol) and sodium 
ascorbate (10.0 mmol). The reaction mixture was stirred at room temperature overnight. After 
completion of the reaction, the mixture was diluted with 80 mL of H2O and extracted with 
CHCl3 (2X20 mL). The combined extracts were dried over Na2SO4, and evaporated in vacuo. 
The crude product was purified by column chromatography using EtOAc/hexane as eluent.
23
 
(1,3-Diphenyl-1H-pyrazol-4-yl)(1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methanone (7) 
Light brown solid, yield 69%, Mp: 179-181 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.58 (s, 1H), 
8.12 (s, 1H), 7.87 (d, J = 7.9 Hz, 2H), 7.82 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.35-
7.45 (m, 4H), 7.27-7.33 (m, 2H), 7.08 (t, J = 8.3 Hz, 2H), 5.55 (s, 2H). 
13
C NMR (75 MHz, 
DMSO-d6) δ 177.4, 163.5, 160.2, 153.7, 138.2, 133.6, 131.7, 129.5, 128.7, 128.4, 127.7, 
126.9, 126.6, 118.6, 115.2, 52.4.; MS (ESI): 424 [M+H]
+
;  HRMS (ESI) calcd for  
C25H19ON5F [M+H]
+
 424.15681; found: 424.15679. 
(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-yl)methanone (8) 
Brown solid, yield 74%, Mp: 185-187 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 8.16 
(s, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.82 (d, J = 6.4 Hz, 2H), 7.50 (t, J = 7.3 Hz, 2H), 7.45 – 
7.32 (m, 6H), 7.22 (d, J = 7.9 Hz, 2H), 5.51 (s, 2H). 
13
C NMR (75 MHz, DMSO-d6) δ 177.7, 
154.1, 148.5, 138.6, 134.2, 133.9, 132.0, 128.9, 128.7, 128.0, 127.2, 127.0, 119.0, 118.7, 
52.9.; MS (ESI): 440 [M+H]
+
; HRMS (ESI) calcd for  C25H19ON5Cl [M+H]
+
 440.12726; 
found: 440.12755. 
(1,3-Diphenyl-1H-pyrazol-4-yl)(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-
yl)methanone (9) 
Chapter-VI 
 
299 | P a g e  
 
Light brown solid, yield 71%, Mp: 170-172 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.58 (s, 1H), 
8.23 (s, 1H), 7.88-7.71 (m, 4H), 7.63 (d, J = 7.2 Hz, 2H), 7.50 (t, J = 7.7 Hz, 2H), 7.45 – 7.33 
(m, 6H), 5.58 (s, 2H). 
13
C NMR (75 MHz, CDCl3) δ 178.1, 139.2, 137.6, 132.6, 131.6, 131.1, 
129.5, 129.4, 128.8, 128.5, 127.9, 127.6, 126.3, 119.8, 52.3.; MS (ESI): 474 [M+H]
+
; HRMS 
(ESI) calcd for C26H19ON5F3 [M+H]
+
 474.15362; found: 474.15319. 
(1,3-Diphenyl-1H-pyrazol-4-yl)(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methanone 
(10) 
Light brown solid, yield 69%, Mp: 202-204 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.57 (s, 1H), 
8.07 (s, 1H), 7.91 – 7.77 (m, 4H), 7.51 (t, J = 7.8 Hz, 2H), 7.46 – 7.33 (m, 4H), 7.29 – 7.20 
(m, 2H), 6.90 (d, J = 8.7 Hz, 2H), 5.50 (s, 2H), 3.79 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ 
178.3, 160.1, 155.0, 149.2, 139.2, 134.6, 132.5, 129.9, 129.4, 129.3, 128.6, 127.8, 127.4, 
127.2, 125.4, 119.7, 119.2, 114.6, 55.3, 54.1.; MS (ESI): 436 [M+H]+; HRMS (ESI) calcd 
for C26H22O2N5 [M+H]
+ 
436.1773; found: 436.1792. 
(1-(3,4-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-
yl)methanone (11) 
Light brown solid, yield 71%, Mp: 142-144 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.58 (s, 1H), 
8.10 (s, 1H), 7.87 (d, J = 7.62 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.50 (t, J = 8.0 Hz, 2H), 7.45 
– 7.39 (m, 3H), 7.37 (t, J = 7.4 Hz, 1H), 6.90 (dd, J = 8.2, 1.9 Hz, 1H), 6.85 (d, J = 8.2 Hz, 
1H), 6.82 (d, J = 1.9 Hz, 1H), 5.48 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H); 
13
C NMR (75 MHz, 
CDCl3) δ 178.3, 55.1, 149.7, 149.6, 139.2, 134.6, 132.5, 129.5, 129.4, 128.7, 127.9, 127.5, 
125.9, 121.2, 119.8, 119.2, 111.4, 56.3, 54.6.; MS (ESI): 466 [M+H]
+
; HRMS (ESI) calcd for  
C27H24O3N5 [M+H]
+
 466.18737; found: 466.18704. 
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(1,3-Diphenyl-1H-pyrazol-4-yl)(1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-triazol-4-
yl)methanone (12) 
Light brown solid, yield 79%, Mp: 175-177 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.60 (s, 1H), 
8.13 (s, 1H), 7.88 (d, J = 8.1 Hz, 2H), 7.85 – 7.80 (m, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.35-7.45 
(m, 4H), 6.54 (s, 2H), 5.47 (s, 2H), 3.84 (s, 9H). 
13
C NMR (126 MHz, CDCl3) δ 178.4, 155.2, 
153.8, 149.3, 139.2, 138.6, 134.7, 132.5, 129.4, 129.1, 128.7, 127.9, 127.6, 119.8, 119.2, 
105.6, 60.9, 56.2, 54.8.; MS (ESI): 496 [M+H]
+
; HRMS (ESI) calcd for C28H26O4N5 [M+H]
+
 
496.19793; found: 496.19797. 
(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-
yl)methanone (13) 
Light brown solid, yield 80%, Mp: 163-165 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.59 (s, 1H), 
8.13 (s, 1H), 7.89 – 7.79 (m, 4H), 7.51 (t, J = 7.8 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 7.31 (dd, 
J = 8.4, 5.2 Hz, 2H), 7.16 – 7.02 (m, 4H), 5.55 (s, 2H). 13C NMR (75 MHz, CDCl3) δ 178.1, 
164.8, 161.5, 154.1, 139.1, 134.8, 131.4, 131.2, 130.2, 130.1, 129.5, 128.6, 127.6, 127.4, 
119.7, 119.1, 116.5, 116.2, 114.9, 114.6, 53.7.; MS (ESI): 442 [M+H]
+
; HRMS (ESI) calcd 
for C25H18ON5F2 [M+H]
+
 442.14739; found: 442.14725. 
(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-
yl)methanone (14) 
Light brown solid, yield 77%, Mp: 184-186 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.60 (s, 1H), 
8.15 (s, 1H), 7.86 (m, 4H), 7.53 (t, J = 7.8 Hz, 2H), 7.40 (m, 3H), 7.26 (d, J = 8.5 Hz, 2H), 
7.13 (t, J = 8.8 Hz, 2H), 5.56 (s, 2H). 
13
C NMR (75 MHz, CDCl3) δ 178.2, 164.8, 161.5, 
154.1, 149.5, 139.1, 135.2, 134.8, 132.1, 131.4, 131.2, 129.5, 127.6, 127.4, 119.7, 119.0, 
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115.0, 114.7, 53.4.; MS (ESI): 458 [M+H]
+
; HRMS (ESI) calcd for C25H18ON5ClF [M+H]
+
 
458.11784; found: 458.11831 
(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-
triazol-4-yl)methanone (15) 
Brown solid, yield 75%, Mp: 188-190 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.60 (s, 1H), 8.19 
(s, 1H), 7.91 – 7.76 (m, 4H), 7.66 (d, J = 8.0 Hz, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.46 – 7.32 
(m, 3H), 7.11 (t, J = 8.6 Hz, 2H), 5.65 (s, 2H). 
13
C NMR (75 MHz, CDCl3+DMSO-d6) δ 
177.9, 164.3, 161.1, 153.6, 149.0, 138.7, 137.6, 134.4, 130.9, 129.2, 128.2, 127.6, 127.3, 
125.8, 119.3, 118.7, 114.5, 53.3.; MS (ESI): 492 [M+H]
+
; HRMS (ESI) calcd for 
C26H18ON5F4 [M+H]
+ 
492.14420; found: 492.14413 
(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-
yl)methanone (16) 
Light brown solid, yield 77%, Mp: 199-201 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.61 (s, 1H), 
8.08 (s, 1H), 7.93 – 7.79 (m, 4H), 7.53 (t, J = 7.8 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.33 – 
7.24 (m, 2H), 7.13 (t, J = 8.8 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 5.53 (s, 2H), 3.83 (s, 3H). 
13
C 
NMR (126 MHz, CDCl3) δ 178.6, 164.4, 162.1, 160.1, 154.4, 149.4, 139.2, 135.2, 131.3, 
129.5, 128.7, 127.6, 125.5, 119.8, 119.1, 114.7, 55.1, 53.7.; MS (ESI): 454 [M+H]+; HRMS 
(ESI) calcd for C26H21O2N5F [M+H]
+
 454.16738; found: 454.16706. 
(1-(3,4-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-fluorophenyl)-1-phenyl-1H-
pyrazol-4-yl)methanone (17) 
Brown solid, yield 73%, Mp: 169-171 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.60 (s, 1H), 8.10 
(s, 1H), 7.90 – 7.80 (m, 4H), 7.51 (t, J = 7.8 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 7.11 (t, J = 8.8 
Hz, 2H), 6.88 (m, 3H), 5.51 (s, 2H), 3.89 (s, 3H), 3.86 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
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178.4, 164.8, 161.5, 154.3, 149.6, 139.2, 134.8, 131.4, 129.5, 127.6, 125.9, 121.2, 119.7, 
114.9, 111.4, 55.9, 54.6.; MS (ESI): 484 [M+H]
+
;  HRMS (ESI) calcd for C27H22O3N5FNa 
[M+Na]
+
 506.15989; found: 506.16105. 
 (3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-
triazol-4-yl)methanone (18) 
Light brown solid, yield 71%, Mp: 180-182 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.63 (s, 1H), 
8.16 (s, 1H), 7.92 – 7.80 (m, 4H), 7.53 (t, J = 7.8 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.11 (q, J 
= 8.8 Hz, 2H), 6.56 (s, 2H), 5.49 (s, 2H), 3.87 (s, 6H) 3.83 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 178.3, 164.1, 162.3, 154.2, 153.8, 149.3, 139.2, 138.6, 134.8, 131.3, 129.6, 129.0, 
128.6, 127.5, 119.8, 119.1, 114.9, 105.6, 60.9, 56.2, 54.9.; MS (ESI): 514 [M+H]
+
; HRMS 
(ESI) calcd for C28H25O4N5F [M+H]
+
 514.18851; found: 514.18922. 
(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-
yl)methanone (19) 
Light yellow solid, yield 69%, Mp: 188-190 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.59 (s, 1H), 
8.13 (s, 1H), 7.85 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.3 Hz, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.39 
(d, J = 8.3 Hz, 2H), 7.31 (dd, J = 8.3, 5.2 Hz, 2H), 7.27-7.08 (m, 3H), 5.55 (s, 2H). 
13
C NMR 
(75 MHz, CDCl3) δ 178.2, 164.7, 161.4, 153.9, 139.1, 134.8, 131.0, 130.7, 130.1, 129.5, 
128.0, 127.7, 127.4, 119.7, 119.2, 116.5, 116.2, 54.1.; MS (ESI): 458 [M+H]
+
; HRMS (ESI) 
calcd for  C25H18ON5ClF [M+H]
+
 458.11784; found: 458.11728. 
(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-
yl)methanone (20) 
Light yellow solid, yield 76%, Mp: 207-209 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.58 (s, 1H), 
8.15 (s, 1H), 7.85 (d, J = 7.7 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.43 
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– 7.34 (m, 5H), 7.27 – 7.21 (m, 2H), 5.54 (s, 2H). 13C NMR (75 MHz, CDCl3+DMSO-d6) δ 
177.8, 153.2, 148.6, 138.6, 134.3, 132.1, 130.7, 130.3, 129.2, 128.9, 127.5, 127.2, 119.2, 
118.8, 53.1.; MS (ESI): 474 [M+H]
+
; HRMS (ESI) calcd for  C25H18ON5Cl2 [M+H]
+
 
474.08829; found: 474.08920. 
(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-
triazol-4-yl)methanone (21) 
Light yellow solid, yield 71%, Mp: 211-213 ºC.; 
1
H NMR (300 MHz, CDCl3+DMSO-d6) δ 
9.14 (s, 1H), 8.63 (s, 1H), 7.86 (s, 1H), 7.62 (d, J = 7.7 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 
7.38 (d, J = 8.2 Hz, 2H), 7.24 (dd, J = 14.7, 7.7 Hz, 4H), 7.09 (dd, J = 13.2, 7.9 Hz, 2H), 5.50 
(s, 2H). 
13
C NMR (75 MHz, CDCl3) δ 176.5, 150.6, 146.0, 137.8, 136.9, 132.8, 131.7, 129.3, 
128.8, 127.7, 126.9, 126.0, 125.7, 123.8, 117.5, 50.8.; MS (ESI): 508 [M+H]
+
; HRMS (ESI) 
calcd for C26H18ON5ClF3 [M+H]
+
 508.11465; found: 508.11503. 
(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-
yl)methanone (22) 
Brown solid, yield 73%, Mp: 157-159 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.58 (s, 1H), 8.07 
(s, 1H), 7.85 (d, J = 7.9 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.39 (d, J 
= 8.5 Hz, 2H), 7.23 (d, J = 2.26 Hz, 2H), 7.13 (t, J = 8.8 Hz, 1H),  6.91 (d, J = 8.6 Hz, 2H), 
5.51 (s, 2H), 3.76 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 178.3, 160.2, 153.9, 139.1, 134.8, 
130.8, 129.9, 129.5, 128.0, 127.6, 127.3, 125.4, 120.0, 119.2, 114.7, 113.9, 55.2, 54.1.; MS 
(ESI): 470 [M+H]
+
; HRMS (ESI) calcd for  C26H21O2N5Cl [M+H]
+
 470.13783; found: 
470.13810. 
(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(3,4-dimethoxybenzyl)-1H-1,2,3-
triazol-4-yl)methanone (23) 
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Light brown solid, yield 71%, Mp: 215-217 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.62 (s, 1H), 
8.11 (s, 1H), 7.88 (d, J = 7.8 Hz, 2H), 7.82 (d, J = 8.5 Hz, 2H), 7.53 (t, J = 7.8 Hz, 2H), 7.42-
7.29 (m, 3H), 6.98 – 6.89 (m, 2H), 6.87 (d, J = 5.8 Hz, 1H), 5.54 (s, 2H), 3.91 (s, 3H), 3.88 
(s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 178.3, 154.0, 149.7, 149.2, 139.2, 134.8, 130.8, 129.5, 
127.9, 127.3, 125.9, 121.2, 119.8, 111.6, 56.0, 54.5.; MS (ESI): 500 [M+H]
+
;  HRMS (ESI) 
calcd for C27H23O3N5Cl [M+H]
+
 500.14839; found: 500.14937. 
(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-
triazol-4-yl)methanone 
Light brown solid, yield 81%, Mp: 193-195 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.61 (s, 1H), 
8.15 (s, 1H), 7.88 – 7.84 (m, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.51 (t, J = 7.3 Hz, 2H), 7.42 – 
7.38 (m, 3H), 6.54 (s, 2H), 5.49 (s, 2H), 3.86 (s, 6H), 3.84 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 187.4, 160.9, 159.7, 152.9, 150.6, 148.9, 134.4, 133.5, 132.2, 131.06, 130.3, 129.0, 
128.4, 127.2, 123.6, 122.5, 122.0, 120.7, 114.8, 114.2, 110.4, 109.8, 55.9, 55.3.; MS (ESI): 
530 [M+H]
+
; HRMS (ESI) calcd for C28H25O4N5Cl [M+H]
+
 530.15996; found: 530.15994. 
(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-
yl)methanone (25) 
Light yellow solid, yield 81%, Mp: 171-173 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.59 (s, 1H), 
8.13 (s, 1H), 7.89 (d, J = 7.7 Hz, 2H), 7.83 (d, J = 8.8 Hz, 2H), 7.52 (t, J = 7.8 Hz, 2H), 7.40 
(d, J = 7.4 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.11 (t, J = 8.6 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 
5.57 (s, 2H), 3.87 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO) δ 177.5, 163.4, 160.2, 159.1, 
153.4, 148.1, 138.2, 133.6, 129.7, 129.5, 128.6, 127.1, 126.6, 124.1, 118.6, 118.2, 115.2, 
112.3, 54.3, 52.4.; MS (ESI): 454 [M+H]
+
; HRMS (ESI) calcd for C26H21O2N5F [M+H]
+ 
454.16738; found: 454.16706. 
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(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-
yl)methanone (26) 
Light yellow solid, yield 77%, Mp: 182-184 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 
8.12 (s, 1H),  7.84 (d, J = 8.45 Hz, 2H), 7.80 (d, J = 8.85 Hz, 2H), 7.51 (t, J = 7.9 Hz, 2H), 
7.40 – 7.36 (m, 3H), 7.27 – 7.23 (m, 2H), 6.96 (d, J = 8.7 Hz, 2H), 5.55 (s, 2H), 3.85 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO) δ 177.5, 159.1, 153.5, 148.3, 138.3, 133.7, 132.1, 129.8, 
128.9, 128.4, 127.2, 126.8, 124.1, 118.7, 118.3, 112.4, 54.4, 52.5.; MS (ESI): 470 [M+H]
+
; 
HRMS (ESI) calcd for C26H21O2N5Cl [M+H]
+
 470.13783; found: 470.13810. 
(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(4-(trifluoromethyl)benzyl)-1H-
1,2,3-triazol-4-yl)methanone (27) 
Light yellow solid, yield 79%, Mp: 172-174 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.60 (s, 1H), 
8.19 (s, 1H), 7.89 (d, J = 7.9 Hz, 2H), 7.83 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.53 
(t, J = 7.6 Hz, 2H), 7.43-7.32 (m, 3H), 6.98 (d, J = 8.4 Hz, 2H), 5.66 (s, 2H), 3.87 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3+DMSO) δ 177.7, 159.3, 153.8, 138.5, 137.7, 133.9, 130.0, 128.9, 
127.9, 127.5, 126.8, 125.3, 124.3, 118.9, 118.4, 112.6, 54.6, 52.8.; MS (ESI): 504 [M+H]
+
; 
HRMS (ESI) calcd for C27H21N5O2F3 [M+Na]
+
 504.16356; found: 504.16388. 
(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-
4-yl)methanone (28) 
Light brown solid, yield 73%, Mp: 165-167 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.57 (s, 1H), 
8.06 (s, 1H), 7.86 (d, J = 7.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.50 (t, J = 7.8 Hz, 2H), 7.36 
(t, J = 7.4 Hz, 1H), 7.30 – 7.23 (m, 4H), 7.06-6.94 (m, 2H), 5.51 (s, 2H), 3.85 (s, 3H), 3.81 (s, 
3H). 
13
C NMR (126 MHz, CDCl3) δ 178.4, 160.2, 154.8, 149.4, 139.3, 134.7, 130.7, 129.9, 
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129.5, 127.4, 125.6, 125.0, 119.7, 119.0, 114.6, 113.3, 55.3, 54.0.; MS (ESI): 466 [M+H]
+
; 
HRMS (ESI) calcd for  C27H24O3N5 [M+H]
+ 
466.18737; found: 466.18702. 
(1-(3,4-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)(3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazol-4-yl)methanone (29) 
Light brown solid, yield 76%, Mp: 181-183 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.57 (s, 1H), 
8.10 (s, 1H), 7.90 – 7.77 (m, 4H), 7.50 (t, J = 7.8 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 6.96 (d, J 
= 8.8 Hz, 2H), 6.90 – 6.80 (m, 3H), 5.49 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.84 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 178.4, 160.1, 154.8, 149.6, 139.3, 134.7, 130.7, 129.5, 127.3, 
126.0, 125.0, 121.2, 119.7, 119.1, 113.3, 111.5, 56.0, 55.2, 54.4.; MS (ESI): 496 [M+H]+; 
HRMS (ESI) calcd for  C28H26O4N5 [M+H]
+ 
496.19793; found: 496.19768. 
(3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)(1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-
triazol-4-yl)methanone (30) 
Light yellow solid, yield 71%, Mp: 175-177 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 9.60 (s, 1H), 
8.15 (s, 1H), 7.87 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.51 (t, J = 7.4 Hz, 2H), 7.37 
(t, J = 7.4 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.54 (s, 2H), 5.46 (s, 2H), 3.87 (s, 6H), 3.83 (s, 
6H). 
13
C NMR (75 MHz, CDCl3) δ 178.3, 160.1, 154.9, 153.8, 149.5, 139.3, 139.3, 138.6, 
135.4, 134.7, 130.8, 129.5, 129.0, 127.4, 125.0, 119.7, 119.0, 113.3, 105.6, 60.8, 56.2, 55.3, 
54.2.; MS (ESI): 526 [M+H]
+
; HRMS (ESI) calcd for C29H28O5N5 [M+H]
+ 
526.20850; found: 
526.20865. 
(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)(1-phenyl-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-4-yl)methanone (31) 
Light yellow solid, yield 70%, Mp: 161-163 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.58 (s, 1H), 
8.16 (s, 1H), 7.93 – 7.83 (m, 2H), 7.53 (t, J = 7.8 Hz, 2H), 7.40 (d, J = 7.4 Hz, 1H), 7.38 – 
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7.32 (m, 2H), 7.19 (s, 2H), 7.10 (t, J = 8.6 Hz, 2H), 5.56 (s, 2H), 3.92 (s, 6H), 3.90 (s, 3H). 
13
C NMR (75 MHz, CDCl3+DMSO) δ 177.5, 163.4, 160.2, 159.1, 153.4, 148.1, 138.2, 133.6, 
129.7, 129.5, 128.6, 127.1, 126.6, 124.1, 118.6, 118.2, 115.2, 112.3, 54.3, 52.4.; MS (ESI): 
514 [M+H]
+
; HRMS (ESI) calcd for C28H25O4N5F [M+H]
+
 514.18851; found: 514.18805. 
(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)(1-phenyl-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-4-yl)methanone (32) 
Light yellow solid, yield 78%, Mp: 173-175 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.57 (s, 1H), 
8.17 (s, 1H), 7.88 (d, J = 7.8 Hz, 2H), 7.53 (t, J = 7.8 Hz, 2H), 7.43 – 7.35 (m, 3H), 7.29-7.23 
(m, 2H), 7.19 (s, 2H), 5.55 (s, 2H), 3.92 (s, 6H), 3.90 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
178.2, 154.7, 152.7, 139.1, 138.6, 135.2, 134.9, 132.2, 129.7, 129.5, 127.9, 127.6, 119.8, 
119.2, 106.8, 60.8, 56.2, 53.7.; MS (ESI): 530 [M+H]
+
; HRMS (ESI) calcd for C28H25O4N5Cl 
[M+H]
+
 530.15896; found: 530.15909. 
 (1-Phenyl-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-4-yl)(1-(4-(trifluoromethyl)benzyl)-
1H-1,2,3-triazol-4-yl)methanone (33) 
Light yellow solid, yield 75%, Mp: 202-204 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.59 (s, 1H), 
8.22 (s, 1H), 7.89 (d, J = 7.6 Hz, 2H), 7.67 (d, J = 8.1 Hz, 2H), 7.53 (t, J = 7.8 Hz, 2H), 7.41 
(m, 3H), 7.19 (s, 2H), 5.66 (s, 2H), 3.92 (s, 6H), 3.90 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
178.0, 154.6, 152.7, 149.6, 139.2, 138.8, 137.7, 134.9, 129.5, 128.5, 127.6, 126.3, 119.8, 
119.2, 107.0, 60.8, 56.2, 53.7.; MS (ESI): 564 [M+H]
+
; HRMS (ESI) calcd for C29H25O4N5F3 
[M+H]
+
 564.18532; found: 564.18579. 
(1-(4-Methoxybenzyl)-1H-1,2,3-triazol-4-yl)(1-phenyl-3-(3,4,5-trimethoxyphenyl)-1H-
pyrazol-4-yl)methanone (34) 
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Light brown solid, yield 75%, Mp: 196-198 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.57 (s, 1H), 
8.10 (s, 1H), 7.88 (d, J = 7.9 Hz, 2H), 7.59 – 7.46 (m, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.33 – 
7.24 (m, 2H), 7.19 (s, 2H), 6.93 (d, J = 8.6 Hz, 2H), 5.53 (s, 2H), 3.92 (s, 6H), 3.91 (s, 3H), 
3.82 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 178.3, 160.1, 154.8, 152.6, 149.2, 139.1, 138.5, 
134.9, 130.0, 129.5, 127.6, 127.3, 125.5, 119.7, 119.2, 114.7, 106.7, 60.8, 56.1, 55.3, 54.0.; 
MS (ESI): 526 [M+H]
+
; HRMS (ESI) calcd for C29H28O5N5 [M+H]
+
 526.20850; found: 
526.20848. 
(1-(3,4-Dimethoxybenzyl)-1H-1,2,3-triazol-4-yl)(1-phenyl-3-(3,4,5-trimethoxyphenyl)-
1H-pyrazol-4-yl)methanone (35) 
Light brown solid, yield 71%, Mp: 170-172 ºC.; 
1
H NMR (300 MHz, CDCl3) δ 9.57 (s, 1H), 
8.11 (s, 1H), 7.84 (t, J = 15.4 Hz, 2H), 7.56 – 7.44 (m, 2H), 7.43 – 7.33 (m, 2H), 7.19 (s, 2H), 
6.98 (d, J = 8.2 Hz, 1H), 6.94 - 6.89 (m, 1H), 5.52 (s, 2H), 3.94 (s, 3H), 3.91 (s, 6H), 3.89 (s, 
3H), 3.86 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 190.9, 178.4, 154.8, 152.7, 149.6, 139.2, 
134.9, 129.5, 127.6, 125.9, 121.3, 119.8, 119.3, 111.5, 110.4, 109.1, 106.9, 60.7, 56.0, 54.5.; 
MS (ESI): 556 [M+H]
+
; HRMS (ESI) calcd for C30H30O6N5 [M+H]
+
 556.21906; found: 
557.19275. 
(1-Phenyl-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-4-yl)(1-(3,4,5-trimethoxybenzyl)-1H-
1,2,3-triazol-4-yl)methanone (36) 
Light yellow solid, yield 71%, Mp: 162-164 ºC.; 
1
H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 
7.77 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 9.1 Hz, 2H), 7.35 (t, J = 7.2 Hz, 1H), 7.27 (dd, J = 11.1, 
8.9 Hz, 1H), 6.98 (s, 2H), 6.28 (s, 2H), 5.52 (s, 2H), 3.94 (s, 6H), 3.91 (s, 3H), 3.86 (s, 6H), 
3.81 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 178.3, 154.8, 153.8, 152.7, 149.4, 139.2, 138.7, 
135.0, 129.5, 127.6, 119.8, 119.3, 106.9, 105.6, 60.1, 56.2, 54.8.; MS (ESI): 586 [M+H]
+
 and 
[M+Na] 608; HRMS (ESI) calcd for C31H32O7N5 [M+H]
+ 
586.2301; found: 586.2314. 
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Cell culture  
      HT-29 (colon), PC-3 (prostate), A549 (lung) and U87MG (brain) cancer cells were 
purchased from ATCC (Manassas, VA). The PC-3 and A549 cells were grown in RPMI 1640 
medium (GIBCO-Invitrogen, NY) with 10% fetal bovine serum (FBS) and supplemented 
with glutamine (2 mmol/L), penicillin G (100 µg/mL), and streptomycin (100 µg/mL) at 37 
ºC under 5% CO2. HT-29 and U87MG cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin/ streptomycin at 
37 ºC under 5% CO2. The medium was changed every two days. After reaching 80 - 90% 
confluency, cells were treated with 0.25% trypsin-EDTA for further passage.  For all the 
experiments cells were used at passages 4–10.  
MTT Assay 
      MTT assay was carried out on HT-29, U87MG, A549 and PC-3 cells to test the 
cytotoxicity of the synthesized pyrazolo-triazole compounds (7-36). The cells under study 
were harvested, counted and seeded into a 96 well plate at a density of 3000-5000 cells per 
well depending on their doubling times. The cells were allowed to adhere for 24 h at 37˚C 
and 5 % CO2.  After 24 h incubation, the culture media was removed, 100 µL of test chemical 
dissolved in dimethyl sulphoxide (DMSO) and culture medium was added to the cells, culture 
medium containing 0.001 % DMSO only (without test compounds) was used for the control 
cells. Then, the cells were incubated with compounds for 48 h under the same conditions. 
After 48 h, the culture medium containing compounds was removed and 100 µL of culture 
media containing 5 mg/mL MTT (Thiazoyl blue tetrazolium bromide) was added to each well 
and cells were further incubated for 4 hours. After 4 hours incubation the media containing 
MTT was aspirated and 100 µL DMSO was added to each well to solubilize the crystallized 
formazan product. The plates were read on a plate reader at 570 nm and a reference 
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wavelength of 630 nm. The absorbance readings for 630 nm were subtracted from the 570 nm 
readings and the results were adjusted by dividing the average by the 0.001 % DMSO control 
to adjust for any toxicity that may have occurred in this control treatment set. The Percentage 
inhibition was calculated as 100-[(Mean OD of treated cell x 100)/Mean OD of vehicle 
treated cells (DMSO)]. The IC50 Values were calculated using Probit Software. All the tests 
were repeated in at least three independent experiments.
34
 
In vitro migration Assay 
      The wound-healing assay is a proven method to study astrocyte cell migration. U87MG 
cells (5x10
5
 cells/well) were cultured in 6 well plates as confluent monolayers for 24 h. The 
monolayers were then scratched with 200 µL pipette tip. The wounded monolayers were 
washed twice with 150 mM PBS to remove non-adherent cells. Then, media containing the 
test compounds 17, 23 and 29 at their IC50 concentrations were added to each well. Cells 
which migrated across the inflicted wound were photographed under the Phase contrast 
microscope (Nikon) at 0 h and 24 h time interval after treatment in three or more randomly 
selected fields. The cells that migrated to the wounded areas were counted and the percentage 
of migrated cells in each experimental condition was calculated in comparison to control 
cells.
35
 
Cell cycle analysis 
      U87MG cells (1x106 cells /well) in 6 well plate were treated with IC50 concentrations of 
the compounds 17, 23 and 29. After 24 h treatment, both floating and trypsinised cells were 
harvested and washed with 150 mM PBS. The cells were fixed with 70 % ethanol for 30 min 
at 4 ºC. After fixation, cells were washed with 150 mM PBS and stained with Propidium 
Iodide staining buffer (PI (200 µg), 0. 1 % (v/v) Triton X-100, 2 mg DNAse-free RNAse A 
(Sigma) in 10 mL 150 mM PBS) for 15 min at room temp in dark. The samples were then 
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analyzed for Propidium Iodide-DNA fluorescence from 10000 events by flow cytometry 
using FACS Canto-II (Becton Dickinson, USA).
36
 
Hoechst staining 
      Human Brain cancer U87MG cells (5X10
4
 cells/well) at their growth phase were seeded 
in 12 well plates and allowed to adhere for 24 h. The culture medium containing the test 
compounds 17, 23 and 29 at their IC50 concentration were added to the cells and incubated 
for 24 h at 37 ºC. After 24 h, culture medium was removed; cells were washed with 150 mM 
PBS and fixed with 4 % para formaldehyde solution at 4 ºC for 10 min. The cells were 
washed twice with 150 mM PBS and stained with Hoechst 33242 (5 µg/mL) for 30 min at 
room temp. The excess dye was removed by washing twice with 150 mM PBS and cells were 
examined for morphological changes under fluorescence microscope using 350 nm excitation 
and 460 nm emission (Nikon, magnification 10X).
36 
 
Acridine orange/Ethidium bromide (AO/EB) staining 
      U87 MG cells were grown in 24 well plates (50,000 cells/well) for 24 h and were treated 
with and without IC50 concentration of compounds 17, 23 and 29 for 24 h. After treatment, 
cells were washed twice with phosphate buffer saline (150 mM PBS) and fixed with 4 % para 
formaldehyde at 4 ºC for 10 min. Then, the cells were incubated with 0.5 mL of 150 mM 
PBS solution containing mixture of Acridine Orange and Ethidium Bromide (1:1, 100 
µg/mL) in dark for 10 min at 37 ºC. The stained cells were washed with PBS to remove the 
excess dye and the cells were observed immediately under fluorescence microscope 
(Nikon).
36  
 
 
 
Chapter-VI 
 
312 | P a g e  
 
DNA fragmentation assay 
U87MG cells were grown in presence or absence of compounds 17, 23 and 29 with their IC50 
conc for 24 h. Cells were harvested and genomic DNA was extracted using standard protocol. 
DNA was resuspended in 50 µL of TBE buffer. The DNA samples were electrophoresed on 
1.5% agarose gel and visualized by ethidium bromide staining and photographed by 
ChemiDoc (BioRad, Milano, Italy).
37
 
Measurement of mitochondrial membrane potential (MMP) 
      U87MG cells were cultured in 6 well plates at a density of 5x10
5
 cells/mL and allowed to 
grow over night. The cells were treated with the test compounds 17, 23 and 29 with their IC50 
concentration for 24 h. After 24 h treatment, the adherent cells were collected by 
trypsinsation, washed with 150 mM PBS and resuspended in solution of 150 mM PBS 
containing Rhodamine-123 (10 µg/mL). After incubation for 30 min at room temp, cells were 
washed twice with 150 mM PBS and resuspended in 150 mM PBS. The samples were 
analyzed for fluorescence using spectrofluorimeter.
36
 
Measurement of reactive oxygen species (ROS) levels 
      Intracellular ROS levels were measured by using Carboxy-2’, 7’-dichlorofluorescin 
diacetate (Carboxy-DCFDA). U87MG cells were plated in 6 well plates at a density of 5x10
5
 
cells/mL and allowed to grow overnight. The cells were incubated with the IC50 
concentrations of the compounds 17, 23 and 29 for 24 h. After treatment, the medium was 
replaced with the culture medium containing DCFDA (10 µM) and further incubated for 30 
min at room temperature in dark. Cells were washed with 150 mM PBS, collected from the 
plate and resuspended in 150 mM PBS at 5x10
4 
cells/mL. The fluorescence intensity of the 
2’, 7’-dichlorofluorscein formed by the hydrolysis of Carboxy-DCFDA from each sample 
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was analyzed by spectrofluorimeter at an excitation and emission wavelength of 488 and 
525nm, respectively. Qualitative cellular fluorescence images were captured by using Nikon 
ECLIPSETE2000-S fluorescence microscope.
36
 
RT-PCR 
      U87MG Cells (1X10
6
 cells/well) in 6 well plates were exposed to the compounds 17, 23 
and 29 with their IC50 concentrations. After 24h incubation time, total RNA from the cells 
was extracted using TRIZOL reagent (Life Technologies, Carlsbad, CA, 12183-555) 
according to the manufacturer’s protocol. The obtained RNA was solubilized in 50 µL of 
DEPC water and stored at −80 °C. RNA concentration was determined using a Nano drop 
(Thermo Scientific, USA) by measuring the optical density at 260 nm and 280 nm. This 
method yielded an average of 30 µg total RNA from 10
6 
cells.  cDNA synthesis from RNA 
was performed in a total volume of 20 µL reaction mixture containing 1 µg of RNA in 10 µL 
nuclease free water along with 2 µL of 10X RT buffer, 0.8 µL of 25X dNTP Mix (100 mM), 
2 µL of 10X random primers in 3.2 µL of nuclease free water. The PCR cycles used for 
Reverse Transcription were: 25 
º
C for 10 min followed by 37 ºC for 2 h, 85 ºC for 5 min and 
finally hold at 4 ºC. The resulting cDNA was stored at −20 °C until use. Further, PCR was 
carried out in a volume of 10 µL reaction mixtures in PCR fast reaction tubes (Applied 
Biosystems), contained 2.5 µL of DI water, 5 µL of TaqMan Universal Master Mix (Applied 
Biosystems), 0.5 µL (300 nM) of assay primers (Eurofins, Germany) and 2 µL of cDNA. The 
specific gene primers (Bax,Bcl-2 and the internal control gene β-actin) were used to amplify 
the target genes. The sequences of the human genome based primers; probes used for RT-
PCR are  
β-actin (CCTTTGCCGATCCGCCGCCCGTCCA),  
Bax (CTGGTGCTCAAGGCCCTGTGCACCA),  
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Bcl-2 (CGGAGGCTGGGATGCCTTTGTGGAA),    
      The PCR cycles used were: 1 cycle of 95 
o
C for 3 min to activate the enzyme, followed 
by 40 cycles of 95 
o
C for 1 second (denaturation) and 60 
o
C for 20 seconds (annealing and 
extension). Fold change in mRNA expression levels were determined by the comparative CT 
method. CT of β-actin was used as an internal control. PCR products were run on a 1.5 % 
agarose gel containing ethidium bromide and viewed under UV light. Signal intensities for 
the PCR products were analyzed using Quantiscan software (Biosoft, Cambridge, MA, 
USA).
38
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NMR and Mass spectra of selected compounds 
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H NMR spectrum of compound 17 
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HRMS spectrum of compound 17 
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C NMR spectrum of compound 23 
 
ESI-MS spectrum of compound 23 
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H NMR spectrum of compound 29 
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Chapter-VI 
 
324 | P a g e  
 
 
HRMS spectrum of compound 29 
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Cancer is a global health problem, representing the second leading cause of deaths. Although 
current cancer treatments help to reduce or eliminate cancerous cells from the body, they are 
not always effective, efficient and often cause adverse effects. The currently useful 
chemotherapeutic drugs face several limitations such as drug resistance, high systemic 
toxicity, complex syntheses, and isolation procedures. This has encouraged scientists to 
develop new molecules as anti-cancer agents. 
The pharmacophore hybrid approach is an effective and proven method for exploration of 
novel and active compounds in modern medicinal chemistry.
1
 Previous reports have 
suggested that, several novel chemical molecules have been discovered from hybridization of 
two different bioactive molecules with complementary pharmacophoric functions resulting in 
more active and selective hybrids.
2,3 
This technique provides new scaffolds by connecting 
two pharmacophores which are of immense importance. Therefore, the design of hybrid 
molecules is a niche in the large field of drug discovery. It is one of the few possible 
approaches to create drugs via a rational drug design, and it has the potential to generate drug 
candidates with high scores in drug criteria and with maximum chances of success in clinical 
trials.  
 In this thesis, different series of new molecules of 4-aza podophyllotoxins, 
podophyllotoxin-benzimidazole, phenanthrene-triazole, pyrazole-benzimidazole and 
pyrazole-triazole based hybrids were synthesized for the first time by employing 
pharmacophore hybridization to produce promising chemotheraputic agents. 
 All these synthesized hybrid molecules were evaluated for their in vitro anticancer 
activity against different cancer cell lines. 
 Most of these newly synthesised hybrid molecules displayed potent in vitro anti-
proliferative activities against breast, cervical and brain cancer cell lines compared to 
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their parent individual molecules. Moreover, the structure activity relationship studies 
for each series of the compounds was established  
 From each series, the hybrid molecules which displayed potent activity on different 
cancer cells were further studied for their mechanism of cell growth inhibition using 
various cell based assays like cell cycle analysis, wound healing assay, colony 
formation inhibition assay, and different staining techniques such as Hoechst 33242, 
rhodamine 123 and Carboxy-DCFDA staining. 
 The obtained results imply that some of the hybrids reported in this thesis, colud be 
used as lead  compounds for further optimization towards development of anticancer 
agents against breast, cervical and brain cancers. 
 The overall results from thesis reveals that designing hybrid molecules by 
incorporating certain structural fragments that are bioactive by themselves, such as 
podophyllotoxin-benzimidazole, phenanthrene-triazole, pyrazole-benzimidazole, and 
pyrazole-triazole scaffolds, could lead to improved anticancer agents. 
Future Scope 
There are many elements of this investigation that could be subject of further investigation. 
Although these novel hybrid molecules showed promising in vitro anti-cancer activity, there 
is much more work ahead to understand the mechanisms of cell death induced by these drugs. 
Evaluation of their detailed cell growth inhibition mechanisms and in vivo antitumor 
efficacies of some of these novel agents in breast, cervical and brain tumor models could be 
explored. Additionally, other methods of improving the potency of the existing lead 
compounds could also be explored. 
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Overall, this research project has produced a number of significant outcomes that enhance 
research into the search for hybrid drug molecules based on podphyllotoxin, phenanthrene 
and pyrazole for the treatment of cancer. 
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